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Ahstract
The pulmonaiy circulation is a relatively dynamic environment in comparison to the 
systemic circulation. There is no easily applied sphygmomanometer for the 
pulmonary circulation and conventional methods of measurement have limitations 
which reduce their usefrilness. New treatments for pulmonary hypertension have 
improved considerably the prognosis for many patients and there is an emerging 
consensus that they are more effective if given earlier in the course of the disease. 
However these treatments are expensive and inconvenient to the patient and must be 
utilised in the context of high quality, objective assessment of the pulmonary 
circulation, both before and during treatment.
Ambulatory pulmonary artery pressure monitoring has been used in patients with 
heart disease to provide an indicator of left ventricular haemodynamics. It had not 
been used in patients with pulmonary vascular disease due to other causes before and 
has been shown to be safe and well tolerated in this group.
The hypothesis of this thesis was that ambulatory pulmonary artery pressure 
monitoring, by allowing assessment of the pulmonary circulation in a variety of real 
life situations in which patients commonly report symptoms, would pemiit the 
correlation of symptoms with haemodynamic changes in the pulmonary vasculature. 
These high fidelity pressure measurements in a low pressure system might pemiit a 
greater understanding of the total haemodynamic burden faced by these patients and 
(if abnormal pulmonary vascular responses to stress are indicative of the future 
development of pulmonaiy hypertension) may facilitate the early diagnosis of 
pulmonary hypertension.
In this thesis ambulatoiy pulmonary arteiy pressure monitoring has been used to 
assess changes in pulmonaiy artery pressure with posture in a group of patients with
XXIV
pulmonary hypertension secondary to connective tissue disease, during exercise and 
sleep in a group with chronic obstructive pulmonary disease compared with normal 
individuals and during exercise in a group with connective tissue disease where 
pulmonary artery pressure was correlated with non-invasively measured variables 
measured during cardiopulmonary exercise testing. These non-invasively measured 
variables were then used to assess the response to conventional treatment in a group 
of patients with pulmonary hypertension secondary to connective tissue disease.
These studies have shown that pulmonary artery pressure varies considerably in these 
circumstances and that rises in pulmonary artery pressure are not always predicted by 
resting pressure and can be correlated with symptoms. This work suggests that the 
contribution of secondary pulmonary hypertension to morbidity and mortality in 
patients with lung disease is considerable and underestimated.
The technique of ambulatory high fidelity pressure measurement obtains a more 
complete picture of the haemodynamic variations induced by normal daily activity 
and under stress and contributes to our appreciation of the morbidity of pulmonary 
hypertension. Abnormal pulmonary vascular responses in these circumstances in 
individuals with noimal resting pressure allows the identification of those at risk of 
resting pulmonary hypertension thus facilitating the early diagnosis of pulmonary 
vascular disease. The identification (during exercise) of non-invasive surrogates of 
pulmonary arteiy pressure is an area for future study since non-invasive, repeatable 
and reliable assessment of the pulmonary circulation is highly desirable.
XXV
Chapter 1
Introduction
1 General Introduction
Primary pulmonary hypertension (PPH) is a rare and devastating condition, but 
pulmonary hypertension (PHT) also occurs as a consequence of most heart and lung 
diseases where it is largely unrecognised and untreated and is therefore a major 
clinical challenge. The consequence of this failure to assess the pulmonary circulation 
is that the process may progress to the point where treatment is less likely to be 
beneficial. It is because the symptoms and signs of pulmonary hypertension are often 
rather vague and non-specific that it is important to be aware of methods of 
measurement in the pulmonary circulation and their sensitivity, specificity and 
relative merits. There is no easily applied sphygmomanometer for the pulmonary 
circulation, but there are a number of techniques -  both invasive and non-invasive -  
which can help us to make the diagnosis. Implicit in the desire to make an earlier 
diagnosis of pulmonary hypertension is the belief that there is some point in doing so 
-  that is, that the condition itself is of significance and that we may be able to offer 
some additional treatment to the patient. This thesis will describe the available 
methods of measurement in the pulmonary circulation and focus on the novel 
technique of ambulatory pulmonary artery pressure monitoring. This technique has 
not been used previously in patients with pulmonary hypertension secondary to lung 
disease. Ambulatory pulmonary artery pressure measurement allows the detection of 
pulmonary hypertension on exercise in patients with nomial resting pressure and thus 
offers an opportunity to detect the development of pulmonary hypertension in its 
earliest stages.
1.1 Structure and Function of the Normal Pulmonary Circulation
The human pulmonary circulation has been conventionally regarded as a lo'w - 
pressure conduit designed to facilitate gas exchange and subject to relatively little 
vaso-motor control. Despite this however, a variety of physiological and physical 
influences effect a balance between vasoconstriction and vasodilatation, growth 
promotion and growth inhibition and many of the complex relationships between 
these factors are not fully understood.
Thus the pulmonary circulation retains an element of “plasticity” when compared 
with the systemic circulation and in particular has the ability to react to changing 
pressures and consequently demonstrates the complex anatomy and physiology this 
entails. In order to assess the value of any new method of measurement of the 
pulmonary circulation it is important to first appreciate the normal responses of this 
system. The basic anatomical structure of the pulmonaiy circulation, aspects of 
pulmonary vascular function and regulatory mechanisms will be described here
1.1.1 Anatomy of the Pulmonary Circulation
In contrast to the systemic circulation where the eapillaiy system is configured to 
deliver the minimum nutritional requirement, in the pulmonary circulation the goal is 
gas exchange. At rest the pulmonary circulation is a low-pressure system ideally 
suited to facilitate gas exchange with the alveolar space and to minimise demand on 
the right heart. The normal pulmonary artery is about 30% less thick than the healthy 
aorta and the small pulmonary arterioles contain very little muscle. Small pulmonary 
arteries are lined by an initma consisting of endothelium and basement membrane. 
The medial layer is made up of vascular smooth muscle and the whole is lined by both 
an internal and external elastic lamina (double elastic lamina). The extracellular
matrix consists of the fibroblast layers. The precursors to vascular smooth muscle 
cells are the intermediate cells or pericytes. Pericytes are found in the non-muscular 
regions of the vessel wall and intermediate cells in the partially muscularised arteries. 
This muscle coat thins and eventually disappears, and the thickness of the adventitial 
compartment decreases, before the pulmonary capillary bed (Reid et al 1982). 
Generally, vessels with an external diameter of <80pm are non-muscularised while 
those with a diameter between 80 and 120pm are partially muscularised. Pericytes are 
found in non-muscular walls and intermediate cells (between pericytes and smooth 
muscle cells) are found in partially muscularised arteries. (Meyrick et al 1978) A 
variety of stimuli can cause all three layers of the pulmonary arteiy to proliferate, the 
process of pulmonary vascular remodelling (Chapter 1.2).
The complex nature of the pulmonaiy circulation has made its quantification difficult. 
Consequently an ordering system was developed (Strahler et al 1957) describing the 
circulation as being akin to the tributaries of a river, in which branching vessels are 
numbered, 1 being assigned to smallest peripheral vessel with the value inereasing 
backwards toward the hilum.
Pulmonary capillaries are large with frequent anastamoses, such that the alveoli are 
supported in a mesh of blood vessels, which have been described as alveolar and 
extra alveolar vessels (Howell et al 1961).
1.1.1.1 Extra Alveolar Vessels
Extra alveolar vessels are unique to the lung as are its conducting vessels. The arteries 
are of two types, axial or supernumerary (Hislop et al 1973). The fomier are so called 
because they run alongside the bronchi within the wedge shaped units which compose 
the lung. The latter (which greatly outnumber the former) leave the axial arteries at
90° and insert into the alveolar parenchyma where they branch and end by opening 
into the capillary networks at different locations. Thus, unlike their counterparts in the 
systemic circulation, the pulmonary capillaries are periodically fed and drained by 
arterioles and venules. These arteries, (axial or supernumerary) are never exposed 
directly to alveolar air but are always surrounded by a loose connective tissue sheath 
into which alveolar septae are inserted. Axial arteries share their connective tissue 
sheath with a bronchiole, whereas supernumerary arteries are in isolation. This 
conneetive tissue compartment is continuous throughout the lung parenchyma, all of 
its parts being in communication with each other. Consequently all these 
compartments, and the extra alveolar vessels they contain, are subject to the same, 
variable and negative air pressure.
1.1.1.2 Alveolar Vessels
The alveolar vessels constitute the pulmonary microcirculation. Unlike the situation in 
the systemic circulation (where the arterioles flow into capillaries which reform as 
venules) the pulmonary capillaries, as they enter the alveolar walls, are relatively 
disordered. Arterioles and venules feed and drain the capillary circulation at various 
points, and blood flows in different directions and into adjacent lung units. The 
alveolar wall is composed mainly of blood vessels separated from the air by a thin 
layer of cells. The alveoli can be considered to be virtually suiTounded by a meshwork 
of blood vessels and there is controversy over exactly how blood flows in these. 
Weibel (1963) first described the theory of eapillaiy blood flow while others describe 
the situation as blood flowing in sheets intermpted by “posts” of supporting tissue 
(Fung et al 1969). Re-oxygenated blood is then earned back to the left atrium in the
pulmonary veins. The conducting airways have an independent blood supply from the 
bronchial circulation. This carries a fraction of the blood volume of the pulmonary 
circulation and is much less important.
1.1.2 Function of the Pulmonary Circulation
This arrangement of alveolar and extra alveolar vessels is of great functional 
importance. The continuous, connective tissue compartment supporting the extra 
alveolar vessels is subject to a variable, negative pressure which increases during 
inspiration and is at its least on expiration. Thus the distensible, extra alveolar vessels 
become wider and longer on inspiration and the opposite on expiration. Alveolar 
vessels however are subject to the increased alveolar pressure during inspiration and 
may be collapsed with no flow: the exception to this are the “corner vessels” which 
are capillaries anatomically (situated in the alveolar microcirculation) but which 
behave like extra alveolar vessels in that they resist collapse on inspiration. This is 
because of their position in the connective tissue at the junctions of alveoli enabling 
them to resist collapse as alveolar pressure rises on inspiration; because of this ability 
to resist collapse with increased pressures, these vessels constitute an uninterrupted 
communication between the right and left sides of the heart, even when high pressures 
prevent flow in the rest of the system, and consequently are always available for gas 
exchange.
1.1.3 Passive Regulation of Pulmonary Haemodynamics
The vascular arrangement in the lung means that blood flow is exquisitely dependent 
on pressure, air, arterial or venous. The three zones of pulmonaiy blood flow have 
been described (West et al 1964) in which the different relationships of these 
pressures determine the prevailing conditions for gas exchange.
• Zone 1. Here air pressure exceeds arterial or venous pressure, and 
consequently blood can flow only through the comer vessels for the reasons 
discussed above. In vivo this state of affairs will not normally exist, except 
where air pressure is abnonnally high (e.g. in ventilated patients) or blood 
pressure is abnormally low (e.g. following haemorrhage).
• Zone 2. Arterial pressure exceeds air pressure and venous pressure. Here the 
arterial pressure increases the farther down the lung while the alveolar 
pressure remains constant throughout and venous pressure is veiy low. This 
gives rise to increasing flows down the zone, the so called “waterfall effect”. 
The pressure differences in this zone lead to the majority of capillaries being 
in a slit like state.
• Zone 3. Here arterial and venous pressures both exceed alveolar pressure. 
Unlike the other zones, these pressure relationships (i.e. venous pressure 
exceeds air pressure) mean that the capillaries bulge into the alveolar walls, 
which create very efficient conditions for gas exchange.
Other authors (Hughes et al 1975) have also described Zone 4 in which the increase in 
dependent blood flow is not seen and which cannot be explained in terms of arterial, 
venous or air pressures. Blood flow in zone 4 may be dependent on an increase in the
resistance of the extra alveolar vessels, although active control of the pulmonary 
circulation may be involved.
Thus gas exchange is variable throughout these zones with least favourable conditions 
existing in zone 1 and optimal conditions in zone 3.
1.1.4 Active Regulation of the Pulmonary Circulation
Because the pulmonary circulation is a low-pressure system it is very sensitive to 
mechanical influences as described above, and this can make measurements of 
pressure and flow very difficult. Active mechanisms of control (e.g. neuro-humoral) 
play a relatively small part in the regulation of the pulmonary circulation, with the 
notable exception of hypoxic pulmonary vasoconstriction (HPV).
1.1.4.1 Hypoxic Pulmonary Vasoconstriction
The pulmonaiy and systemic circulations differ fundamentally in their response to 
hypoxia. In the systemic circulation a drop in PO2 leads to vasodilatation and 
increased local blood flow to maintain tissue oxygenation. In the pulmonaiy 
circulation HPV occurs, where a similar fall in PO2 results in vasoconstriction to the 
affected lung unit, a drop in blood flow and hence the maintenance of arterial PO2 
(von-Euler and Liljestrand 1946). Since this initial observation on the arterial blood 
pressure in the cat, much progress has been achieved in the understanding of this 
phenomenon in animal models, but its exact nature in the human pulmonary 
circulation is still not fully understood.
HPV seems to exist in all mammalian species though varies considerably between 
species in its intensity. The response to hypoxia is initiated within 1-2 minutes and is
established between 3 and 5 minutes (Hughes 1975, Grover et al 1983, Fishman 
1985).
The essential components of HPV consist of an oxygen sensor linked by a chain of 
events to an effector. The effector in the human pulmonary circulation is the pre­
capillary smooth muscle cell: however there is still much debate over the nature and 
location of the oxygen sensor (Voelkel 1996).
The oxygen sensor may be a specific cell (or part of a cell) located in the airways. It 
seems likely that the stimulus to the oxygen sensor is delivered via the airways as 
isolated lung (i.e. perfused but not ventilated) demonstrates a very small HPV 
response when perfiised with deoxygenated blood (Naieje 1996).
This physiological mechanism of hypoxic pulmonary vasoconstriction protects 
ventilation perfusion matching in the healthy lung and is most effective in mild 
ventilation perfusion mismatch. It is responsible for the pulmonary hypertension seen 
in the foetal circulation, in clironic hypoxic lung disease and in individuals who live 
continuously at high altitude. The mediator of this response remains unknown and a 
number of candidates have been ruled out including catecholamines, histamine, 
serotonin prostaglandins. Angiotensin II and leukotrienes. Recent attention has 
focused on L-arginine nitric oxide pathway as a possible candidate (Dinh-Xuan 1992).
1.1.4.2 Neural control of pulmonary vascular tone
The effects of neural influences on pulmonary vascular regulation are not fully 
understood. The pulmonary vasculature has long been known to be well supplied with 
sympathetic and cholinergic nerve endings. There is extensive evidence of adrenergic 
influence on the pulmonary vascular tone where a  agonists produce vasoconstriction
and p agonists vasodilatation. The effects of sympathetic stimulation are less 
predictable however (Fishman 1985 and Grover et al 1983). Further work suggests 
that the sympathetic nervous system exerts a net vasodilator effect (Naieje et al 1989) 
although intense sympathetic stimulus is known to produce vasoconstriction (Fishman 
1985 and Grover et al 1983). The parasympathetic neiTous system is now thought not 
to influence normoxic or hypoxic pulmonary vascular tone (Lejeune et al 1989).
1.1.5 Humoral Control of Pulmonary Vascular Tone
A large number of mediators (Table 1.1) have been implicated in the humoral control 
of the pulmonaiy vasculature (Fishman 1985, Grover et al 1983 and Dinh-Xuan 
1992).
With the exceptions of Prostacyclin and nitric oxide (NO) - both of which have been 
shown to reduce pulmonary vasculature tone in several experimental models - none of 
the others have been shown to have consistent effects on the pulmonary circulation. 
From the foregoing it is clear that our understanding of the physiology and regulation 
of the pulmonary circulation is incomplete. It is on this basis that we must attempt to 
discuss the impact of disease on the pulmonary circulation.
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Table l A
Vasodilators V asoconstrictors
Acetylcholine Histamine
Bradykinin Serotonin
Prostacyclin Prostaglandin F series
Prostaglandin D2 Angiotensin II
Prostaglandin E series Vasopressin
Vasoactive intestinal peptide Thromboxane A2
Atrial naturelle peptide Endothelin
Nitric oxide Leukotrienes
Table 1.1 Vasoactive mediators in the pulmonary circulation
These substances are suspected mediators in the pulmonary circulation. With the 
exception of prostacyclin and nitric oxide (which are vasodilators) none of the others 
have been shown to have consistent effects.
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1.2 Pulmonary Circulation in Disease
1.2.1 Pulmonary Vascular Remodelling
The pulmonary circulation is sensitive to changes in pressure (air, arterial or venous). 
In the short-term this is manifest as change in pulmonary vascular resistance while, in 
the longer-tenn, pulmonary vascular remodelling can occur. Pulmonary vascular 
remodelling is an important process clinically because it adversely affects the 
pulmonary circulation’s response to therapy.
The pathological changes responsible for the clinical findings we associate with 
pulmonary hypertension are seen in the pre-capillary pulmonary arteries. These 
become muscularised and consequently there is interference with normal pressure and 
flow relationships in addition to functional changes in compliance and distensability 
(Hunter et al 1974, Reid et al 1982). In addition to increased muscle mass the 
pathological changes associated with pulmonary vascular remodelling may progress 
to include endothelial cell damage, inflammation, vessel wall destruction, 
intravascular thrombosis and intimai proliferation. (Wagenvoort et al 1979, Harris et 
al 1986) Changes also take place in the extra-cellular matrix and adventitia with 
synthesis and deposition of collagen and elastin and adventitial fibroblast proliferation 
(Welsh et al 1998), Figure 1.1. In the early stages these changes are reversible 
however in all models an irreversible element supervenes after a relatively short time.
1.2.1.1 Mechanisms of Remodelling
The mechanisms responsible for pulmonary vascular remodelling are complex and not 
yet fully understood, however they have been summarised as consisting of four 
separate events (Zhao and Winter 1996).
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Figure 1.1
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Figure 1.1 Pulmonary Vascular Remodelling
The left hand panel shows a normal small pulmonary artery from a chicken. In the 
pulmonary hypertensive panel vascular smooth muscle has extended into normally 
non-muscularised arteries with an increase in the intima and media which encroaches 
on the lumen. The adventitia is also affected by the synthesis and deposition of 
collagen and elastin and adventitial fibroblast proliferation (American Review of 
Respiratory Disease).
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1. the detection of altered physical and haemodynamic forces
2. the relay of the signals to the cells involved in the process of remodelling
3. the synthesis of the substances that may initiate and promote cell division and 
growth
4. alteration of the composition of both vessel wall and extracellular matrix 
Clinical and experimental models have been developed to investigate a variety of 
candidate substances and conditions and from these much greater understanding of 
the processes involved in remodelling has been gained.
Although vasoconstriction and pulmonary vascular remodelling lead to pulmonary 
hypertension they are not essential prerequisites of it (Jones et al 1985).
Vascular injury (McMurtry et al 1988) and high blood flow (Esterly et al 1968) can 
cause pulmonary vascular remodelling; platelets may be responsible for intimai 
proliferation by their adhesion to injured vessel walls and the production of a platelet 
derived growth factor (PDGF) (Schwartz et al 1987); the endothelial cell may also 
release substances implicated in remodelling with evidence for both detrimental (Zhao 
et al 1993) and beneficial (Peacock et al 1992) effects through the production of 
endothelin and endothelium-derived relaxing factor (EDRF).
In-vitro, a variety of blocking agents have been tested which offer some protection 
against these insults (Sugget et al 1988 and McMurtiy et al 1988) and it is possible 
that in the future agents which prevent or reverse pulmonary vascular remodelling 
will become available.
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1.2.1.2 Pulmonary Vascular Resistance
Measuring the effects of pathological processes in the pulmonary circulation requires
an understanding of the relative contributors to haemodynamic disturbance. In
addition to those pulmonary haemodynamic variables which are directly measured,
others are derived including Pulmonary Vascular Resistance (PVR) and Total
Pulmonaiy Resistance (TPR). The equations used to calculate these are shown below.
PVR = PAM-PAOP TPR = PAM
CO CO
PAPm= pulmonary artery mean pressure
PAOP= pulmonary artery occlusion pressure (left atrial pressure)
C0= cardiac output
PVR can be expressed either in Woods units or in dynes/s/cm^. The normal value of 
resting pulmonary vascular resistance is between 0.3 and 1.6 Woods units or 20 and 
130 dynes/s/cm^. Woods units are expressed as dynes by multiplying by 80. 
Haemodynamic assessment of the pulmonary circulation still relies heavily on the 
calculation of pulmonary vascular resistance (PVR). Measurements of 
haemodynamics in systems with constant flow calculate resistance as the drop in 
pressure from the inflow point to an outflow point, divided by the flow. In tubes with 
steady flow, Poiseuille’s law states that,
R =  (Pin-Pout)/Q  =  8 X 1 X T |/7t X r"^
Where 1 is the length of the tube, p is a co-efficient of viscosity, and r is the radius of 
the tube. When this equation is transposed to the pulmonary circulation inflow 
pressure becomes the pulmonary arterial pressure, outflow pressure the left atrial 
pressure, and flow, the cardiac output. Thus in the pulmonary circulation,
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PVR= PAP-PAOP/CO.
However a number of at least partially inaccurate assumptions have to be made about 
the pulmonaiy circulation for the application of Poiseuille’s law to be valid. The flow 
of blood through the pulmonary circulation is not steady but pulsatile. Pressure and 
flow measurement in the pulmonary vasculature is conventionally made with fluid 
filled, balloon tipped, pulmonaiy artery catheters which necessarily measure mean 
pressures over several cardiac cycles and cannot take this natural pulsatility into 
account. Blood is not a Newtonian fluid as foreseen by the equation but a complex 
substance of variable viscosity and the “tube” in which it flows is not laminar but a 
distensible, branching conduit (Mitzner and Chang 1989). The measurement of 
pressure and flow in the pulmonary circulation is relatively difficult because of its 
situation inside a pressure chamber (i.e. the thorax) and its sensitivity to these 
pressures. The resistance of the pulmonary circulation is, as mentioned above, very 
small thus allowing adequate perfusion of the lungs at minimum cost to the right 
heart. Further more it has the capacity to reduce its resistance even further by 
distension of functioning vessels, or by the recruitment of previously collapsed 
vessels.
Thus the calculation of PVR is unsatisfactory for a number of reasons but is the 
conventional “gold standard” measurement in the assessment of the pulmonary 
circulation. When left atrial pressure is not measured, TPR is sometimes substituted, 
expressed as TPR = PAP/CO.
It is clear from these calculated values that many variables interact to produce the 
clinical picture of pulmonary hypertension and that the pulmonary circulation has a 
large capacity to accommodate changes in pressure and flow without consequent 
increases in PVR.
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1.2.2 Definition of Pulmonary Hypertension
The pulmonary circulation differs from the systemic circulation in its greater potential 
to react to changing pressures (air, arterial or venous). It is a low-pressure system and, 
unlike the systemic circulation it reacts to hypoxia by vasoconstriction.
A practical definition of pulmonary hypertension is a mean pulmonary artery pressure 
(PAP) of 20 mmHg or greater at rest and at least 30 mmHg on exercise, with a normal 
pulmonary artery occlusion pressure (Weitzenblum et al 1996). It is common practice 
to consider a mean PAP of 40 mmHg to be inadequate to merit specific treatment, 
while a mean PAP of > 40 mmHg is likely to require therapy targeted at lowering the 
pressure itself. These statements assume that other contributing factors (e.g. airways 
disease) have been addressed.
Normal values for steady flow pulmonary haemodynamic measurements are given in 
Table 1.2.
1.2.2.1 Physiological Effects of Raised PAP
Irrespective of the aetiology of the pulmonary hypertension the sequence of events 
which follow its development is similar.
The noiTnal pulmonary circulation is uniquely adapted in a number of ways which 
make it capable of responding to considerable variations in pulmonary blood flow, 
without major rises in pulmonary arteiy pressure. At rest the pulmonary circulation is 
a high flow, low resistance system which reacts to the increased pulmonary blood 
flow of exercise by reducing its resistance and recruiting vessels which were not 
perfused at rest. The right ventricle is thin walled, with the capacity to react to large 
changes in venous return without any significant changes in filling pressures. Thus in
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Table 1.2
Variable Mean Normal limits
Q, L/min 6,5 4-8.3
HR, Beat/min 69 40-100
PAP, mmHg 13 8-20
PAOP, mmHg 9 5-14
RAP, mmHg 5 2-9
Table 1.2 Normal Values for Pulmonary Haemodynamic Measurements 
(Naeije 1983)
The mean and normal ranges for human pulmonary haemodynamics. These values 
were obtained at right heart catheterisation in 32 supine, healthy volunteers.
Q: pulmonary blood flow
HR: heart rate
PAP: pulmonary artery pressure
PAOP: pulmonary artery occlusion pressure
RAP: right atrial pressure
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the normal situation, the increased cardiac output of exercise can be accommodated 
by the pulmonary circulation without any major rise in pulmonary artery pressure, and 
hence no additional stress being placed on the right ventricle.
In the situation of raised pulmonary arteiy pressure, the right ventricle initially 
hypertrophies in response to the increased forward pressure and at this stage 
pulmonary hypertension may be present without any evidence of right heart failure, 
and with normal cardiac output. However with persistent pulmonary hypertension the 
cardiac output will initially fail to rise adequately on exercise and the patient will 
experience limitation of their exereise tolerance. As the right ventricle further 
hypertrophies its demands may exceed its myocardial blood flow leading to right 
ventricular ischaemia and chest pain.
Eventually the cardiac output becomes decreased at rest and right ventricular volume 
overload develops with the clinical signs of right ventricular failure. Advanced 
pulmonary hypertension (primary or secondary) is complicated by progressive right 
ventricular failure and sudden death. The latter may be due to a variety of causes 
including dysrhythmias, pulmonary emboli, pulmonaiy haemorrhage and right 
ventricular ischaemia.
1.2.2.2 Clinical Features of Pulmonary Hypertension
The presenting features of pulmonary hypertension are non-specific. Patients with 
PPH are usually young and appear well and therefore their complaints of dyspnoea, 
syncope or atypical chest pain will often be attributed to other causes.
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A detailed history may reveal past ingestion of anorexic agents or recreational drug 
use, or of an embolic event, while physical examination will elicit the signs listed 
above, or may reveal an underlying cause such as connective tissue disease.
Likewise in individuals with respiratory disease, the complaint of worsening 
breathlessness will usually be thought to be a reflection of deterioration in the 
underlying condition. Pulmonary hypertension should be suspected in individuals 
with persistent hypoxaemia (Pao2 <7.3kPa) who complain of decreasing exercise 
tolerance in the face of static spirometric values, or those who develop evidence of 
fluid retention.
Thromboembolic pulmonary hypertension should always be considered in a patient 
with a past history of deep venous thrombosis or pulmonary embolus who develops 
unexplained symptoms of breathlessness. This complication probably affects about
0.1% of all embolic patients and can present after months or years, though in about 
half of all such cases the initial event was unrecognised. (Moser et al 1990)
The commonest presenting feature of pulmonary hypertension is dyspnoea. This is 
present in 60% of patients initially and in almost all as the disease progresses. Chest 
pain is often present (in 47% of patients with PPH) and can be typically anginal in 
nature, or relatively non-specific. Other clinical features of more advanced pulmonary 
hypertension include dyspnoea at rest, poor peripheral perfusion, tachycardia and a 
low volume pulse.
On physical examination the jugular venous pressure is commonly raised and “a” and 
“v” waves may be seen. Peripheral oedema indicates advanced disease. The 
pulmonary component of the second heart sound is sometimes palpable, as is a left 
parasternal heave and a tapping cardiac impulse. On auscultation in addition to the
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loud second sound, third or fourth heart sounds may be heard, as may a systolic 
murmur, which is usually due to tricuspid regurgitation.
1.2.3 Classification of Pulmonary Hypertension
Previously pulmonary hypertension was classified as primary or secondary. There 
were a number of problems with this approach; in particular that Primary Pulmonary 
Hypertension (PPH) actually encompassed a number of aetiologies with various 
definitions in use in different countries. PPH is rare, but pulmonaiy hypertension also 
occurs as a consequence of a wide variety of conditions, including most heart and 
lung diseases, where it is largely unrecognised and untreated and is therefore a major 
clinieal challenge. The consequence of this failure to assess the pulmonary circulation 
is that the process may progress to the point where treatment is less likely to be 
beneficial.
Consequently in 1998 at an international symposium in Evian, sponsored by the 
World Health Organisation (WHO), a group of recognised international experts 
produced a consensus re-classification (Rich et al 1998). This new classification is 
intended for practical clinical use, including greater detail and providing fuller 
descriptions of clinical entities. Consequently it is more valuable in describing and 
following patients, than were previous classifications (Fishman 1998).
1.2.3.1 Primary Pulmonaiy Hypertension
PPH is a rare and progressive disorder, which usually affects the arterial side of the 
circulation. If left untreated (and where treatment is unsuccessful) right heart failure
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and death are inevitable. PPH has an incidence of one to two cases per million people 
per year in Western populations. Because of this and due to the fact that this disease is 
commoner in individuals in their mid 30s (female to male ratio of 1.7:1) there is often 
a delay in diagnosis of many months. During this time progressive and increasingly 
irreversible damage is done to the pulmonary circulation.
Previously the prognosis has been unifomily bleak with median survival of less than 2 
years, however significant advances in the diagnosis and treatment of PPH have been 
made in the last decade which constitute grounds for new optimism. Central to these 
was the observation that vasoconstriction is only part of the process by which 
pulmonary hypertension is generated and that marked histopathological changes are 
seen in PPH and in severe pulmonary hypertension associated with other disorders. In 
particular the introduction of continuous intravenous Prostacyclin has transformed the 
outlook for individuals with PPH.
The WHO classification suggests that the term PPH should be reserved for 
unexplained cases of pulmonary hypertension. There are a large number of 
associations with severe pulmonary hypertension (Table 1.3) and numerous risk 
factors associated with the development of severe pulmonary hypertension (Table 
1.4). The available treatments may have greater efficacy the earlier they are used, 
therefore the issue of screening becomes important (Peacock 1999).
1.2.3.2 Risk Factors for Pulmonary Hypertension
A risk factor for pulmonary hypertension may be necessaiy to cause the condition or a 
facilitator in the development of the disease. Consequently there are a variety of
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Table 1.3
WHO Classification of Pulmonary Hypertension (Rich S. ed.l998)
Diagnostic classification
1. P u lm onary  arterial hypertension
1.1 Primary pulmonary hypertension
(a) Sporadic
(b) Familial
1.2 Related to:
(a) Collagen vascular disease
(b) Congenital systemic to pnlmonaiy shunts
(c) Portal hypertension
(d) HIV infection
(e) Drugs/toxins
(1) Anorexigens
(2) Others
(f) Persistent pulmonary hypertension of the newborn
(g) Other
2. P u lm onary venous hypertension
2.1 Left sided ahial or ventricular heart disease
2.2 Left sided valvular heart disease
2.3 Extrinsic compression of the pulmonary veins
(a) Fibrosing mediastinitis
(b) Adenopathy/tumours
2.4 Pulmonary veno-occlusive disease
2.5 Other
3. P u lm onary hypertension  associated  w ith d isorders o f the resp iratory system  and/or  
hypoxaem ia
3.1 Chronic obstructive airways disease
3.2 Interstitial lung disease
3.3 Sleep disordered breathing
3.4 Alveolar hypoventilation disorders
3.5 Chronic exposure to high altitude
3.6 Neonatal lung disease
3.7 Alveolar-capillary hyperplasia
3.8 Other
4. P u lm onary hypertension  due to chronic throm botic and/or em bolic d isease
4.1 Thromboembolic obstruction of proximal pulmonary arteries
4.2 Obstruction of distal pnlmonaiy arteries
(a) Pulmonary embolism (thrombus, tumour, ova and/or parasites, foreign material)
(b) In situ tlirombosis
(c) Sickle cell disease
5. P u lm onary hypertension  due to disorders d irectly  affecting the pu lm onary vasculature
5.1 Inflammatory
(a) Schistosomiasis
(b) Sarcoidosis
(c) Other
5.2 Pnlmonaiy capillaiy haemangiomatosis
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Functional assessment
(A) Class I: Patients with pulmonary hypertension but without resulting 
limitation of physical activity. Ordinaiy physical activity does not cause 
undue dyspnoea or fatigue, chest pain or near syncope.
(B) Class II: Patients with pnlmonaiy hypertension resulting in slight limitation 
of physical activity. They are comfortable at rest. Ordinaiy physical activity 
causes undue dyspnoea or fatigue, chest pain or near syncope.
(C) Class III: Patients with pulmonary hypertension resulting in marked 
limitation of physical activity. They are comfortable at rest. Less than 
ordinary activity causes undue dyspnoea or fatigue, chest pain or near 
syncope.
(D) Class IV: Patients with pnlmonaiy hypertension with inability to cany out 
any physical activity without symptoms. These patients manifest signs of 
right heart failure. Dyspnoea and/or fatigue may even be present at rest. 
Discomfort is increased by any physical activity.
Table 1.3 WHO Classification of Pulmonary Hypertension
(Rich S. ed. 1998)
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Table 1.4
A, Drugs and Toxins
1. Definite
• Aminorex
• Fenfluaramine
• Toxic rapeseed oil
2. Very likely
• Amphetamines
• L-tryptophan
3. Possible
• Meta-amphetamines
• Cocaine
• Chemotherapeutic agents
4. Unlikely
• Antidepressants
• Oral contraceptives
• Oestrogen therapy
• Cigarette smoking
B. Demographic and Medical Conditions
1. Definite
• Sex
2. Possible
• Pregnancy
• Systemic hypertension
3. Unlikely
• Obesity
C. Diseases
1. Definite
• HIV infection
2. Very likely
• Portal hypertension/liver disease
• Collagen vascular diseases
• Congenital systemic-pulmonary vascular shunts
3. Possible
• Thyroid disorders
Table 1.4 WHO Classification of Risk Factors for Pulmonary Hypertension
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strengths of association and the WHO classification recognises this (Abenheim et al 
1998).
• Definite- indicates an association based on several observations and probably a 
major study.
• Very likely- indicates a similar series of observations or a consensus amongst 
experts.
• Possible- indicates a basis on the existence of case reports, registries or expert 
opinion.
• Unlikely- indicates risk factors which have aroused suspicion but for which no 
supporting evidence has been forthcoming.
The importance of early diagnosis and treatment in PPH is widely accepted but 
remains unproven. Furthermore the condition is very rare and the suggestive 
symptoms diffuse and vague. Hence it is important that screening programmes strike 
a balance between the risks of the invasive tests necessaiy to confirm the diagnosis, 
the likelihood of a good outcome from treatment, the use of scarce resources and cost.
1.2.3.3 Secondary Pulmonary Hypertension
Pulmonary hypertension can complicate a large number of conditions and may be a 
consequence of any cardiorespiratory disease. However a few conditions dominate 
clinical practice. The main causes of secondary pulmonary hypertension are:
• Chronic hypoxic lung disease including chronic airflow obstruction, fibrosing 
lung disease, and ventilatory failure due to primary chest wall dysfunction.
• Thromboembolic pulmonary hypertension.
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Connective tissue disease, especially CREST syndrome.
1.2.3.4 Chronic Hypoxic Lung Disease
The most commonly encountered cause of secondary pulmonary hypertension in 
clinical practice is chronic hypoxic lung disease. The extent of the problem is difficult 
to define and is further complicated by the debate about the term "cor- pulmonale" 
which is often used when patients with respiratory failure develop oedema. This 
expression implies dysfunction of the heart when, in fact, the fluid retention is 
probably renal in origin, though is associated with the pulmonary hypertension. For 
this reason many authors would prefer that the term be no longer used and that it 
should be replaced with "fluid retention in association with secondaiy pulmonary 
hypertension" (Weitzenblum et al 1996)
There is controversy about the contribution of secondary pulmonary hypertension to 
the mortality and morbidity of chronic hypoxic lung disease; however the important 
variations in PAP caused by exercise, sleep (due to alveolar hypoventilation) (Boysen 
et al 1979), and episodes of respiratory failure secondary to acute infection are now 
accepted. The latter have been shown to return to normal before becoming resistant to 
treatment as the disease progresses (Weitzenblum et al 1979). Clearly these variations 
in PAP are difficult to measure routinely because of the difficulty in making reliable 
measurements of pulmonary haemodynamics repeatedly. The signs and symptoms of 
pulmonary hypertension are usually overwhelmed by those of chronic obstmctive 
pulmonary disease (COPD), but pulmonary hypertension should be suspected in 
patients with persistent hypoxaemia (Pa02 <7.3 kPa) who complain of deteriorating
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exercise tolerance in the face of static spirometric values, or in those who develop 
evidence of fluid retention. This can be a difficult clinical diagnosis and one 
American study noted that up to 30% of admissions to hospital with a diagnosis of 
congestive cardiac failure actually had fluid retention associated with pulmonary 
hypertension (Intersociety Commission for Heart Disease Resources 1970).
There is little doubt that secondary pulmonary hypertension is an important factor in 
the morbidity and mortality of chronic hypoxic lung disease and other conditions. 
Quantifying pulmonary haemodynamics should be an important part of assessment of 
these patients and can assist us in future decisions about the success or otherwise of 
treatment directed both at the primary respiratoiy disease and at the pulmonary 
circulation itself. Clearly, the first therapeutic objective must be the treatment of the 
pulmonary condition (Peacock 1990), but we should be monitoring the effects of this 
treatment and the use of vasodilators, if appropriate, on the pulmonary circulation 
(Peacock 1993).
1.2.3.5 Thromboembolic Pulmonary Hypertension
This diagnosis should always be considered in a patient with a past history of deep 
venous thrombosis or pulmonary embolus who subsequently develops unexplained 
symptoms of breathlessness. Where the patient presents soon after the event the 
diagnosis may seem obvious, but Moser (1996) has described the "honeymoon 
period" after pulmonary embolism where the patient's symptoms can improve for a 
period of months or years before deteriorating again, sometimes rapidly. 
Significantly, his group estimated that between 0.1% and 1,0% of all embolic patients
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go on to develop thromboembolic pulmonary hypertension, and that in nearly half the 
initial event was unrecognised.
1.2.3.6 Connective Tissue Disease
Pulmonary arterial hypertension (PAH) has been described as a complication of every 
kind of collagen vascular disease (Hoeper 2002). PAH may occur as a result of 
interstitial lung disease in collagen vascular disease but can also be the sole 
pulmonary complication. Pulmonary veno-occlusive disease, pulmonary capillary 
haemangiomatosis and pulmonary vasculitis (<2% of patients with SLE) have also 
been reported in association with collagen vascular disease but are vei*y rare, though 
serious, complications (Deveraux et al 1998, Gugnani et al 2000, Morassut et al 1992, 
Gross 1972).
There is considerable variation in the frequency of PAH in collagen vascular disease 
being very rare in rheumatoid arthiitis yet complicating as many as 50% of cases of 
the Calcinosis, Raynaud’s phenomenon, oesophageal involvement, sclerodactyly and 
telangectasia (CREST) syndrome (Yousem 1990). PAH is the most important cause 
of mortality and morbidity in this condition.
PAH complicates Systemic Lupus Erythematosis (SLE) in between 5 and 10% of 
cases (Asherson et al 1990, Pan et al 2000, Shen et al 1999), 10-30% of cases of 
progressive systemic sclerosis (PSS) (Yamane et al 2000, Murata et al 1997) and in 
greater than 30% of cases of mixed connective tissue disease (MCTD) (Hoffman and 
Greidinger 2000).
29
In all cases the pathology of PAH associated with collagen vascular diseases is similar 
to that in PPH. Thus the predominant lesions are medial and intimai thickening of the 
small and medium sized pulmonary arteries. Plexiform lesions (previously thought to 
be the hallmark of PPH) have also been described in PAH associated with collagen 
vascular disease (Cool et al 1997).
Thrombosis in situ is an important feature of PPH and can also occur in pulmonary 
hypertension associated with collagen vascular disease (Welsh et al 1996, Hoeper et 
al 1998). In collagen vascular disease with a pro-coagulant tendency such as SLE it is 
very important therefore to exclude tliromboembolic disease.
Patients may present with minimal or no clinical respiratoiy signs other than 
breathlessness, but a clue is a low carbon monoxide gas transfer factor in the face of 
normal spirometric values. Patients at risk of developing PAH may exhibit abnormal 
PAP responses to exercise as a first sign as has been shown by stress exercise 
echocardiography (Grunig et al 2000) however at the present time this cannot be 
advocated as a routine screening tool. High-risk individuals (i.e. those with PSS, 
CREST and MCTD) should have annual echocardiography.
The contribution of PAH to morbidity and mortality may be subtle, overwhelmed by 
the symptoms of the underlying condition and its clinical significance may be 
negligible; alternatively pnlmonaiy hypertension may be the obvious problem. In 
some cases occult pulmonary hypertension may have caused irreparable damage 
before manifesting itself clinically. The ambulatory pulmonary artery pressure 
monitoring system permits the assessment of the pulmonary circulation during 
exercise and allows the detection of abnormal exercise responses in individuals with
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normal resting PAP. This may allow the early diagnosis of pulmonary hypertension, 
which is an important theme of this thesis.
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1.2.4 Treatment of Pulmonary Hypertension
Pulmonary hypertension may present as an incidental finding or be obviously the 
predominant cause of disability. In either case the importance of an individually 
tailored treatment plan in every patient with pulmonary hypertension of any aetiology 
cannot be overemphasised. In many cases the potential side effects (or harm) from 
treatment may greatly outweigh any therapeutic gain which might reasonably be 
expected. In the context of secondary pulmonary hypertension the importance of 
treating the underlying condition greatly exceeds the necessity to treat the pnlmonaiy 
artery pressure in the vast majority of instances. Table 1.5 lists some of the clinical 
mechanisms of pulmonary hypertension.
1.2.4.1 Treatment Models
Treatment philosophy can be summarised by considering a “pure” form of vascular 
disease (PPH) and COPD where the mechanism of injury is alveolar hypoxia.
The therapeutic goals of treatment should include improvement in symptoms and 
hence functional capability and prevention of progression. Ideally survival benefit 
would be conferred by a treatment.
These end points would be brought about by a decrease in cardiac work and an 
improvement in systemic oxygen transport (Weir et al 1992).
COPD appears akin to a “pure” example of vasoconstrictive pulmonary hypertension 
(provoked by hypoxia) but again the situation is more complex with long-term 
hypoxia producing changes in the small vessels veiy similar to those seen in PPH. 
This explains why oxygen does not entirely reverse the vasoconstriction seen in 
COPD.
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Table 1.5
Passive- increased left atrial pressure
• Hyperkinetic- increased pnlmonaiy blood flow
Obliterative- destruction of vessels or parenchyma
Vasoconstriction- increased vascular smooth muscle tone
Table 1.5 Clinical Mechanisms of Pulmonary Hypertension (Weir et al 1992)
Clinical mechanisms responsible for the genesis of pulmonary hypertension. These 
different mechanisms may co-exist.
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1.2.4.2 Treatment of Primaiy Pulmonary Hypertension
The majority of the advances seen in the treatment of pulmonary hypertension have 
been established in studies of patients with PPH. PPH is a “pure” foim of pulmonary 
vascular disease and while it is not always the case that conclusions from the study of 
patients with PPH will be readily generalisable to other patient groups some of the 
principles of treatment have been accepted. Consequently it is important to review the 
treatment of PPH before considering the treatment of pulmonary vascular disease of 
other aetiologies.
PPH is incurable and treatment is inevitably aimed at alleviating symptoms. The 
current consensus is that there is a place for vasodilator drugs and anticoagulation 
(Rich et al 1998). This is based on the concept that patients with PPH have increased 
vascular tone in the pulmonary circulation, and chronic, low-grade stimulation of their 
coagulation cascade (Rubin 1993). Table 1.6 lists some of the pathophysiological 
mechanisms of pulmonary hypertension in PPH.
Continuous intravenous prostacyclin can also be used in patients who do not seem to 
benefit from oral vasodilators. This is an expensive treatment, especially as 
tachyphylaxis seems to occur, but may offer a bridge to transplantation in patients 
with severe disease.
Both oral vasodilators and prostacyclin have been shown to improve function in 
patients with PPH and although it is not clear how long these improvements will last 
one study has shown benefit sustained for 5 years (Rich et al 1992).
PPH is the purest model of pulmonary hypertension and consequently by far the 
largest literature exists in this condition. It is useful therefore to consider the 
mechanisms involved in genesis of pulmonary hypertension in PPH prior to 
discussing treatment (Weir et al 1992).
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Table 1.6
Increased vascular smooth muscle tone
Abnormal cellular proliferation
Disordered endothelial cell function
Abnormalities of coagulation
Neurogenic and myogenic reflexes
Table 1.6 Pathophysiological Mechanisms of Pulmonary Hypertension (Weir et al 1992)
Pathophysiological entities involved in pulmonary hypertension. Some of these mechanisms are 
simultaneously a consequence of pnlmonaiy hypertension and promoters of its hirther development
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The pathogenesis of PPH remains obscure however intimai and medial proliferative 
changes in small pulmonary vessels with intravascular thrombosis or embolisation 
occurs.
Additionally there is a vasoconstrictive component with increased vascular tone in 
most patients. The cause or effect relationship of this with the anatomical changes 
described is unclear. Hence there is a therapeutic rationale for the use of vasodilators 
in PPH.
Vasoconstriction is the accepted predominant mechanism and this is based on 
histopathological studies and the favourable response many patients demonstrate to 
vasodilators (Rich et al 1992).
Although vasoconstriction is the important pathophysiological mechanism it may, or 
may not, be the primary event. It has been suggested that in susceptible individuals a 
number of triggers may be responsible for initiating a process of which it is a result 
(Weir et al 1992). These factors include
• hypoxia (normobaric or hypobaric)
• autoimmune disorders
• drugs and toxins (including HIV)
• increased pulmonary blood flow, + or -  increased pressure and shear stress.
• lung injuiy
• increased sympathetic tone and catecholamine induced injury.
In the susceptible individual these factors can damage the pulmonary vascular 
endothelium causing an imbalance in its production of mediators. Examples of this 
imbalance include an increase in the production of thromboxane v prostacyclin, which 
results in the promotion of a hypercoagulable state. This can initiate vasoconstriction
36
but will also lead to increased platelet activation. Consequently the damaged vascular 
endothelium is acted on by both cellular and humoral components of the blood which 
may result in pulmonary vascular remodelling and further vascular injury (Chapter 
1.2).
Additional factors at work include the release of an unidentified chemotactic agent, 
from pulmonary vascular endothelial cells, which stimulates the migration of smooth 
muscle cells in pulmonaiy arterioles (Gaiad et al 1993, Newby and George 1993). 
Thrombosis in situ can also occur as a result of pulmonary endothelial cell damage. 
The normal anticoagulant state of the pulmonary vascular bed is due to its production 
of prostacyclin and plasminogen activator inhibitors which is reduced in the 
pathological state as noted above. In PPH there are elevated levels of Fibrinopeptide 
A, suggesting in situ thrombosis. This theory is further supported by the survival 
benefit these patients obtain from anticoagulation (Rich et al 1992).
Despite the confusing array of treatments which have been used in pulmonary 
hypertension, in the last 10 years a consensus has begun to emerge particularly in 
PPH. Many treatments now have a sound scientific basis for their use (Peacock et al 
1999). These include,
• Anticoagulants
• Oral vasodilators
• Other vasodilators
• Inotropic agents
• Prostacyclin
• Surgical methods
• Transplantation
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1.2.4.3 Anticoagulants
Some of the earliest work in PPH addressed the problem of the chronic, low -grade 
pro-thrombotic state endured by patients with significant pulmonary hypertension 
(Rubin et al 1993).
It has been shown that anticoagulants double survival in patients who are non­
responders to vasodilators from 31% to 62% at three years (Rich et al 1992). It is now 
therefore standard practice to use warfarin to achieve an internationalised normalised 
ratio (INR) of 2 in patients with a mean resting PAP of > 30 mniHg in the absence of 
a contraindication (Gaine and Rubin 1998).
1.2.4.4 Oral Vasodilators
Approximately 30% of PPH patients will respond positively to vasodilators though it 
is not possible to predict which. However, about 25% of patients may be adversely 
affected by these drugs, reinforcing the need to provide individually tailored therapy 
regimens for all patients with PPH.
It has now been shown that high dose oral vasodilators are beneficial in patients with 
a positive vasodilator response (Rich and Brundidge 1987, Rich and Kaufman 1991) 
and the dihydropyridine dmgs are the group with which there is most experience in 
PPH.
Patients who demonstrate a potentially beneficial response to a trial of an acute 
vasodilator drug at cardiac catheterisation should be given an oral calcium channel
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blocker, titrated to the highest tolerated dose up to a maximum of for example 
Diltiazem 720mg. per day or Nifedipine 240mg. per day.
The principle problem with the administration of these drugs at such high doses is 
their potential to depress the myocardium. They can be dangerous in patients who do 
not have an acute vasodilator response and consequently must not be used prior to a 
formal vasodilator study. Dose titration is best carried out in specialist units where 
patients must also be closely followed in case side effects develop. These include 
systemic hypotension, worsening of ventilation-perfusion mismatching, right 
ventricular dysfunction, cardiac arrhythmias and death. The most serious of these is 
heart failure which can progress quickly with grave consequences.
From the foregoing it is clear that the presumed mechanism of action is vasodilatation 
of the pulmonary vascular bed; however there are other possible mechanisms for the 
beneficial action of oral vasodilators in pulmonary hypertension including inhibition 
of growth of smooth muscle or other pulmonary vascular cells.
Combined with oral anticoagulants in suitable patients oral vasodilators can produce 
survival figures of the order of 90% at five years (Peacock et al 1999) and are 
beginning to constitute a challenge to transplantation as the most effective treatment 
for such individuals.
1.2.4.5 Other Vasodilators
A number of other vasodilators have been tried in pulmonaiy hypertension, mostly 
without success or with unacceptable side effects. These include captopril (Ilcam et al 
1982), diazoxide (Honey et al 1980) and hydralazine (Packer et al 1982).
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Nitric oxide is an attractive candidate as a specific pnlmonaiy vasodilator but delivery 
problems restrict its use to specialist units. Oxygen is a non-specific vasodilator of the 
pulmonaiy circulation but its role relates to the correction of hypoxic lung disease 
complicated by pulmonary hypertension. Presently the calcium channel blockers 
remain the vasodilators of choice in PPH.
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1.2.4.6 Inotropic Agents
There is very little data to support the use of inotropes in PPH. Their rationale is 
nonetheless sound in that in the context of right ventricular failure (in severe 
pulmonaiy hypertension) where maximum vasodilatation has been obtained using 
substances which are themselves negative inotropes (calcium channel blockers) it 
would seem logical to use a drug which might improve right ventricular function. At 
present the use of inotropes in severe pulmonary hypertension should be restricted to 
specialist units.
1.2.4.7 Prostacyclin
Perhaps one of the most important advances in our understanding of pulmonary 
hypertension has been the observation that prostacyclin confers benefits over and 
above those which might be expected from a vasodilator alone and is sometimes 
beneficial in individuals in whom no acute vasodilator response has been 
demonstrated (McLaughlin et al 1998). This led to a sea change in the way that 
vasodilators were used in the treatment of severe pulmonaiy hypertension.
Initial observations had suggested that prostacyclin acted as a vasodilator in patients 
with PPH (Rubin et al 1982) and initially its place was felt to lie in providing a 
therapeutic bridge to transplantation (Higgenbottam et al 1984). Subsequent studies 
have shown additional benefit in a large group of patients with PPH receiving 
conventional treatment (Rubin et al 1990) and since then continuous intravenous 
prostacyclin has been shown to be superior to conventional treatment both in the short 
term over 12 weeks (Barst et al 1996) and over a longer period (McLaughlin et al 
1998).
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The observation that prostacyclin may reverse the disease process has led to a review 
of its place in the treatment of primary pulmonary hypertension and the realisation 
that it may offer an alternative to transplantation. There are problems associated with 
its long-term use however.
Prostacyclin has a half-life of three minutes meaning that infusion pumps must be 
reloaded quickly. It must be stored at between 2 and 8 °C and used within 24 hours of 
reconstitution. The drug, at present, must be administered by continuous intra-venous 
infusion by a pump via a Hickman line. This exposes an individual to the risks of 
indwelling central venous catheters such as infection, catheter clot, breakage and 
migration. Patients must be taught to make up the drug using aseptic technique. The 
possibility of life threatening rebound pulmonary hypertension means that a back up 
system must be in place.
Side effects of prostacyclin include nausea, diarrhoea, headache, flushing, sweating, 
postural hypotension, palpitations, skin rashes and jaw pain. Almost all patients will 
experience some side effect and while some relate to the drugs vasodilator action, 
others (such as jaw pain) are unexplained.
There is no general agreement about the correct starting dose and practices have 
varied. Patients described in this thesis were commenced at two nanograms per 
kilogram per minute and increased in similar increments until side effects limited 
further increases. Tachyphylaxis is a problem and necessitates continuous review of 
the dose with attendant increases in cost.
Cost is a major issue with the averaging between £50,000 -£60,000 per patient in the 
UK. This necessitates that prostacyclin must be administered under the supervision of 
one of the specialist pulmonaiy vascular units in the UK.
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Prostacyclin is contraindicated in pulmonary veno-occlusive disease (Rubin et al
1990) and pulmonary capillary haemangiomatosis (Humbert et al 1998).
Clearly, while prostacyclin has vastly improved the outlook for many patients with 
PPH, its impact on quality of life and cost implications are considerable. An 
alternative would be highly desirable and these are discussed later.
1.2.4.8 Surgical Treatment
1.2.4.8.1 Atrial Septostomy
In severe pre-capillary pulmonary hypertension the creation of an atrial septal defect 
can effectively reduce the load faced by the right ventricle while simultaneously 
improving pre-load to the left heart. This will result in a reduction in the oxygen 
content of arterial blood however this will be offset by the anticipated increase in 
cardiac output and an overall increase in tissue oxygen delivery.
There are no large-scale trials of this technique in pulmonary hypertension but some 
units have gained considerable experience with encouraging results (Rich and Lamb 
1983, Kerstein et al 1995, Rich et al 1997).
The technique of atrial septostomy is essentially palliative and should be restricted to 
experienced units, however it is a useful adjunct to the other available treatments.
1.2.4.8.2 Transplantation
Prior to improvements in medical therapy, transplantation was the best option for 
individuals with severe intractable pulmonary hypertension and considerable 
experience has accumulated. Transplantation offers suiwival benefits to patients with
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favourable vasodilator responses which are slightly inferior to those obtained with 
modern medical therapy; one year survival of 70% and tliree year survival of 50-60% 
(Peacock 1999).
The principal problem with transplantation remains the supply of donor organs; this is 
complicated further by the donor lung’s fragility and the matching of suitable donors 
to recipients. The outcome for patients with severe pulmonaiy hypertension seems 
comparable to those transplanted for other indications and no procedure confers 
additional benefit, though single lung transplantation seems to be associated with a 
slightly worse outcome in pulmonary hypertension (Peacock et al 1999).
With improved medical treatment it is now more difficult to decide when to refer for 
transplant assessment. The essential message must be that it is preferable to refer too 
early than too late and there is extensive guidance available in the literature 
(D’Alonzo et al 1991, Nootens et al 1994 and Rubin 1997).
1.2.4.8.3 Pulmonary tluomboendarterectomy
This operation is specific to the clinical situation of chronic thromboembolic 
pulmonaiy hypertension (CTEPH) but merits mention, as it is potentially curative. 
The first operation was carried out in 1957 however the teclmique has evolved 
considerably in recent years. The most experienced units now quote operative 
mortality rates of 7% and demonstrate improvements in NYHA functional class and 
in haemodynamics (Dunning and McNeil 1999). Patients with CTEPH who have a 
mean PAP in excess of 50mmHg have a five-year survival of 10%. Thus a corrective 
surgical procedure with a mortality rate of 7% (which compares favourably with 
transplantation) is an attractive therapeutic option.
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1.2.4.9 Treatment of Secondary Pulmonary Hypertension
The treatment of secondary pulmonary hypertension remains a much more 
contentious area than in PPH and initially treatment should be directed primarily at 
the underlying condition (Peacock 1990). In the absence of contraindications all 
patients with significant pulmonary hypertension should be anticoagulated, long-term 
oxygen therapy (LTOT) prescribed for those who are hypoxic and venesection 
considered where chronic hypoxia causes polycythaemia.
1.2.4.9.1 Chronic Hypoxic Lung Disease
In contrast to the situation in PPH, in pulmonary hypertension secondary to COPD 
(by far the commonest cause of secondary pulmonary hypertension) any reduction 
seen in pulmonary artery pressure will not usually translate to an improvement in 
function. Pulmonary hypertension progresses slowly in COPD rising by only 3mmHg 
per year in one group of patients followed over 5 years (MRC Council Working Party 
1981) but nonetheless has been shown to imply a poor prognosis (Weitzenblum et al 
1996). Furthermore in certain situations transient pressure rises can be much greater, 
e.g. during infective exacerbations, on exercise or when asleep (due to alveolar 
hypoxia).
Oxygen (a selective pulmonary vasodilator) remains the mainstay of treatment and 
although levels of pulmonaiy hypertension may not be reduced, further progression is 
prevented (MRC Council Working Party 1981). It remains unclear whether calcium 
channel blockers are helpful in this situation (Peacock 1996, Sajkov et al 1997) and 
there have been no studies of prostacyclin.
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Hypoxia is the most important functional factor affecting pulmonary vascular tone 
and in the context of COPD there are two mechanisms responsible for this. The first is 
the pulmonary vasoconstriction seen caused by acute hypoxia and the second the 
structural changes induced in the pulmonaiy vascular bed by cluonic hypoxia.
Acute hypoxia was first noted to cause a rise in PVR in the cat by Von-Euler and 
Liljestrand (1946). Since then the human response to hypoxia has been described 
(Motley et al 1947, Fishman et al 1952) and a rise in PAP demonstrated. There is 
inter-individual variation in this response (Grover 1990) which has also been 
demonstrated in individuals with COPD (Weitzenblum et al 1988). COPD patients 
have been characterised as “responders” or “poor responders” to hypoxia 
(Weitzenblum et al 1996) though the significance of this has not been clear. Patients 
with COPD are subject to variations in their baseline values of oxygen saturation for a 
variety of reasons as described above. Ambulatory pulmonary artery pressure 
monitoring offers the opportunity to correlate symptoms with the fluctuations in PAP 
caused by these changes and may lead to an improved understanding of their 
importance. Chapter 4 describes the measurement of PAP during exercise and sleep 
in a group of patients with severe COPD compared with normal individuals and found 
elevations in PAP during sleep (breathing air) similar to those seen on exercise in the 
COPD subjects.
Further to the acute effects of hypoxia on the pulmonary circulation, chronic 
reductions in oxygen levels leads to remodelling of the pulmonary vascular bed. In the 
circumstance of mild hypoxia (as is the case for a majority of individuals with COPD) 
the rationale for this assumption has been based on studies of people living at high 
altitude. Such populations tend to have mild elevations of PAP (20-30mmHg) and 
have been shown to have pulmonary vascular remodelling (Harris and Heath 1986).
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The situation in COPD is probably more complex with mechanical factors playing a 
part (Wilkinson et al 1988). This is supported by the observation that while the 
elevated PAP of high altitude dwellers is potentially reversible, this is rarely fully the 
case in COPD (Timms et al 1985).
Pulmonary hypertension in COPD is rarely severe with normal resting levels of 20 
and 35 mmHg (Weitzenblum et al 1981) and non-invasive investigations unhelpful in 
this group. In particular Doppler echocardiography can be very difficult in patients 
with COPD and hyperinflation (Tramarin et al 1991). The signs of pulmonary 
hypertension may also be masked by the underlying lung disease and for these 
reasons pulmonary hypertension -  or its contribution to morbidity- is probably 
underestimated in patients with mild to moderate COPD. ambulatory pulmonary 
artery pressure monitoring (in the research setting) can add useful information to the 
assessment of such patients by allowing accurate pressure measurement in a variety of 
clinical situations which can be compared with symptoms.
1.2.4.9.2 Connective Tissue Disease
The situation in pulmonary hypertension secondary to comiective tissue disease is 
similar to that in PPH where oral vasodilators (Sanchez et al 1999 and Alpert et al
1991) and warfarin probably have a beneficial effect in “responders”.
Patients should not be given oral vasodilators unless they have been shown to have a 
favourable acute vasodilator study (Chapter 2.4.3.1) as these drugs may have a 
deleterious haemodynamic effect in patients who are non-responders to acute 
vasodilators and the proportion of responders is smaller in patients with connective 
tissue disease than in PPH (Raffy et al 1996, Sitbon et al 1998).
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Continuous intravenous prostacyclin has also been shown to be beneficial for some 
patients with connective tissue disease (Humbert et al 1999, McLaughlin et al 1999, 
Badesch et al 2000, Robbins et al 2000). Because of the inconvenience and 
complications of permanent central venous catheters alternative methods of 
prostacyclin delivery have been explored and a stable prostacyclin analogue 
(Treprostinil) has been shown to be effective given subcutaneously in large 
randomised studies in patients with PPH (Barst et al 2000, Bailey et al 2001). It is 
likely that this therapy will be considered for patients with PAH and connective tissue 
disease in the future.
There is some evidence that controlling the underlying disease process may improve 
PAH associated with other pulmonary complications (Davas et al 1999) however 
where PAH develops in isolation there is no evidence for benefit from 
immunosuppression. Conversely it has been observed that prostacyelin has improved 
some of the extra-pulmonaiy manifestations of collagen vascular diseases (Hoeper 
2002).
Transplantation should be considered for patients with collagen vascular disease in 
whom the extra-pulmonary manifestations are not severe. There is considerable 
evidence that the survival of such patients after transplantation is comparable with 
other groups (Pigula et al 1997, Rosas et al 2000, Levy et al 1993).
With growing interest in the treatment of pulmonary hypertension in patients with 
collagen vascular diseases and with increasing treatment options, accurate and 
objective measurement of treatment responses is important. In Chapter 3 the utility of 
ambulatoiy pulmonary artery pressure monitoring was assessed in a group of patients 
with connective tissue disease and the effects of posture were observed; in Chapter 5 
the technique was used to measure PAP responses to exercise in a similar patient
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group and non-invasively measured correlates of PAP were obtained from 
cardiopulmonary exercise testing variables. In Chapter 6 these non-invasive eorrelates 
of PAP were used to assess response to treatment with oral vasodilators in a group of 
patients with connective tissue disease. If patients with connective tissue disease are 
to be offered prostacyclin or its analogues where oral vasodilators have not benefited 
them then it is essential to assess response adequately. Ambulatory pulmonary artery 
pressure monitoring is useful in the research setting to measure haemodynamics 
during treatment and has led to the identification of non-invasively obtained correlates 
of PAP measured on exercise.
1.2.4.9.3 Pulmonary Tliromboembolic Disease
Oral vasodilators have not been studied in pulmonary tluomboembolic disease (PTE). 
There is evidence of benefit from prostacyclin in pulmonary hypertension secondary 
to distal thrombosis (McLaughlin et al 1999).
Surgical treatment (Chapter 1.2.4.6) should be considered where proximal clot is 
demonstrated. Patient selection is very important but in experienced units the outcome 
is good with the potential to improve haemodynamics, extend survival and improve 
quality of life (Mayer et al 1996).
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1.2.4.10 Future Management
1.2.4.10.1 Vasodilators
Calcium channel blockers with effects specific to the pulmonary circulation seem 
unlikely to be forthcoming in the near future. A more realistic hope might be the 
refinement of those drugs which exert fewer adverse effects on the myocardium. 
Pulmonary vascular smooth muscle cells have potassium channels which are thought 
to be involved in sensing flow changes and interacting with the endothelium to 
activate pulmonary vascular remodelling (Olesen et al 1988). Drugs which interact 
with these channels exist, but have not yet been assessed in pulmonary hypertension. 
Nitric oxide in the form of oral NO donors is another therapeutic aim and it is possible 
that such compounds will be available for inhalational use also.
1.2.4.10.2 Prostacyclin Alternatives
Iloprost is an alternative to prostacyclin with a longer half-life and similar effects 
when given intravenously (Higgenbottam et al 1998). The longer half-life offers for 
potential for different routes of administration and in particular there is interest in 
nebulised iloprost. Nebulised prostacyclin has also been assessed and found superior 
to inhaled nitric oxide in one study (Mikhail et al 1997)
An oral form of prostacyclin (Beraprost) has been developed but is not yet available 
for clinical use (Miyata et al 1996 and Saji et al 1996). Bosentan, an orally 
administered endothelin receptor antagonist has been found to improve exercise 
capacity in patients with pulmonary hypertension (Rubin et al 2002).
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Currently large scale randomised trials of nebulised Iloprost are in progress and a 
subcutaneous prostacyclin analogue, Treprostinil has recently been shown to be an 
effective treatment for pulmonary arterial hypertension (Simonneau et al 2002).
1.2.4.10.3 Genetics of Primaiy Pulmonary Hypertension
Familial PPH accounts for 6% of all cases and has been shown to be an autosomal 
dominant inheritance with markedly reduced penetrance (Massague et al 2000). The 
gene for familial primary pulmonary hypertension was localised to chromosome 
2q31-32 in 1997 (Nichols et al 1997) and recently the genetic mutation underlying 
this condition has been reported (Deng et al 2000, The International PPH Consortium, 
Lane et al 2000).
These discoveries have led to speculation that targeted gene therapy may become 
possible in primary pulmonary hypertension (Rudarakanchana et al 2001)
1.2.4.11 Conclusions
PPH is a rare but serious condition whose early diagnosis is desirable in order that 
patients can be fully assessed and offered appropriate treatment. Advanees in medical 
therapy in the last ten years have greatly improved the prognosis and rendered 
transplantation a treatment of last resort.
Secondary pulmonary hypertension is an important complication of many 
cardiorespiratory diseases and its recognition is important. Patients whose histoiy, 
signs or symptoms suggest pulmonary hypertension should be sereened non- 
invasively (Section 1.3.1) and refeiTcd to a specialist centre for further investigations 
if necessary.
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While there is an emerging consensus for the treatment of PPH the situation in 
secondary pulmonary hypertension remains much less clear-cut. Undoubtedly the 
underlying condition should be aggressively managed; the risk/benefit ratio of the 
other available treatments can then be considered in each individual case.
In the future new treatments may become available, including new delivery systems 
for existing treatments (such as oral or nebulised forms of prostacyclin) or new 
classes of drugs acting on the pulmonary circulation.
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1,3 Methods of Measurement in the Pulmonary Circulation
Because the symptoms and signs of pulmonary hypertension are often rather vague 
and non-specific, it is important to be aware of methods of measurement in the 
pulmonary circulation and their sensitivity, specificity, and relative merits. There is no 
easily applied sphygmomanometer for the pulmonary cireulation, but there are a 
number of techniques - both invasive and non-invasive - which can help us to make 
the diagnosis. Implicit in the desire to make an earlier diagnosis of pulmonaiy 
hypertension is the belief that there is some point in doing so - that is, that the 
condition is itself of significance and that we may be able to offer some additional 
treatment to the patient.
1.3.1 Non-invasive Methods of Measurement
Traditional methods of assessment include tests which suggest the presence of 
pulmonary hypertension (clinical examination, electrocardiography, chest 
radiography, and conventional echocardiography) and those which suggest a cause 
(pulmonary function tests, ventilation perfusion scanning, and arterial blood gas 
tensions).
The clinical features of raised PAP are non-specific. Patients with isolated pulmonary 
vascular disease (PPH or pulmonary hypertension secondary to connective tissue 
disease) are often young and appear otherwise well and dyspnoea, syncope and 
atypical chest pain are often attributed to other causes. A detailed history is essential 
as it may reveal past ingestion of anorectic agents, recreational drug use or an embolic 
event.
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The commonest presenting feature of pulmonary hypertension is dyspnoea. This is 
present in 60% of cases rising to 100% as the disease progresses and (in patients with 
respiratory disease) is often attributed to the underlying condition, pulmonary 
hypertension should be suspected in those with persistent hypoxaemia (PaOi < 7.3 
kPa) or in those who develop oedema.
Thromboembolic pulmonary hypertension should be considered in patients with a past 
history of deep venous thrombosis or pulmonary embolism who develop unexplained 
breathlessness. This complication can develop many years after the initial event, 
affects approximately 0.1% of individuals with venous thromboembolism and in 
about 50% of cases the initial event was unrecognised (Moser et al 1990).
Chest pain (often relatively non-specific) is a feature of pulmonaiy hypertension and 
is most common in PPH affecting 47% of patients. As pulmonary hypertension from 
any cause advances other clinical features include dyspnoea at rest, poor peripheral 
perfusion, tachycardia and a low volume pulse.
Physical examination in early pulmonaiy hypertension can be completely normal 
however as the pressure increases the signs of right heart strain predominate. The 
jugular venous pressure is commonly raised and “a” and “v” waves may be seen. The 
pulmonary component of the second heart sound is sometimes palpable, as is a left 
parasternal heave and a tapping cardiac impulse. Third or fourth heart sounds may 
also be heard as might a systolic murmur due to pulmonary regurgitation. The 
development of peripheral oedema is a late development and usually indicates 
advanced disease.
The electrocardiogram (EGG) may indicate right axis deviation, right atrial 
hypertrophy or right ventricular hypertrophy, but will often be noimal, particularly in 
secondary pulmonary hypertension.
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The chest X-ray in established pulmonary hypertension may show prominence of the 
pulmonary arteries and sometimes pruning of the peripheral vessels. Radiological 
assessment of pulmonaiy artery diameter, M mode echocardiography, and 
electrocardiography were compared in one study (Algeo et al 1984) and each was 
found to have a high specificity for detection of pulmonary hypertension (particularly 
at higher levels of pulmonary hypertension) but were individually too insensitive to be 
useful for routine clinical screening; a normal test does not exclude pulmonaiy 
hypertension. More recent work (Bishop & Csukas 1989) has employed complex data 
analyses to assess the combined value of these tests, ineluding forced expiratory 
volume in one second (FEVi), arterial blood gas tensions, electrocardiography, 
pulmonary arterial dimension on chest radiography, M mode echocardiography, and 
myocardial thallium scanning, and confiimed that this approach allows the prediction 
of the presence of pulmonary hypertension but gives no indication of the actual value 
of the pulmonary artery pressure.
Ventilation / perfusion lung scanning is widely used in the evaluation of patients with 
pulmonary hypertension, primarily to exclude tliromboembolic disease and to assess 
the need for pulmonary angiography. Where clinieal suspicion of pulmonary 
embolism is high and the V/Q scan is non-diagnostic, further imaging (such as 
pulmonary angiography or CT angiography) is essential.
Pulmonary function tests may likewise point to an underlying cause for suspected 
pulmonary hypertension such as COPD. Furthermore, an isolated reduction in 
diffusing capacity may be a pointer to pulmonary hypertension in a breathless patient 
with normal spirometric values.
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These have recently been augmented by techniques which tell us about the severity of 
pulmonary hypertension, such as Magnetic Resonance Imaging (MRI) and Doppler 
echocardiography which will be considered in more detail.
However, the traditional methods are still of value. From the above it is clear that the 
signs and symptoms of early pulmonary hypertension may be very subtle. One of the 
principal advantages of ambulatory pulmonary artery pressure monitoring is that it 
permits the assessment of the pulmonary circulation during exercise in individuals 
with normal resting pressures in whom the clinical suspicion of pulmonary 
hypertension is high.
1.3.1.1 Doppler Echocardiography
The techniques described above, most of which remain in routine clinical use, can 
detect pulmonary hypertension but give no assessment of its severity. Hence, they 
cannot be used to follow the clinical course of patients with pulmonary hypertension 
or assess the benefits of intervention.
In 1984, Yock and Popp described a teclinique which allowed estimation of 
pulmonary arterial pressure from the measurement of the maximum velocity of the 
regurgitant jet in patients with tricuspid regurgitation (TR). When TR is present the 
velocity of the regurgitant jet is determined solely by the pressure difference between 
the right ventricle (RV) and the right atrium (RA) and not by the geometry of the 
orifice. To make this estimate the TR jet is identified and located using pulsed or 
colour Doppler before continuous wave Doppler recordings are made to determine 
peak TR jet velocity. Providing that the angle between the ultrasound beam and the
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direction of flow is less than 20 degrees, velocity of flow can be caleulated accurately. 
This maximum velocity can then be used in a modified form of the Bemouilli 
Equation which states that: RV to RA pressure gradient -  4 x (maximum velocity of 
TRjet)^
The ealculated gradient is added to the right atrial pressure (which can be estimated 
clinically) to give an estimated value of right ventricular systolic pressure. Assuming 
there is no pulmonary stenosis, which can be excluded by echocardiography, this 
value will be equal to pulmonaiy arterial pressure (Figure 1.2). The authors have 
shown these values to correlate closely with those found at right heart catheterisation 
even when not measured simultaneously. Figure 1.3 illustrates a comparison of PAP 
measured non-simultaneously by Doppler echocardiography and fluid filled 
pulmonary artery catheter.
This technique confers a number of advantages. The values obtained are accurate over 
a wide range of pressures and are not affected by ehanges in cardiac output. Inter­
observer variability is <3%, though clearly the technique is, to some extent, operator 
dependent (Berger et al 1985, Currie et al 1985, Chan et al 1987) Continuous Doppler 
echocardiography has attained widespread use and recent data suggest that the error 
limits for Doppler TR derived pressure calculations are only 5-9 mmHg (Naeije et al 
1995). The technique is well tolerated, safe, and repeatable, but there are some 
disadvantages. In particular, it is difficult to recover a TR signal of sufficient quality 
in patients with COPD where success rates may be as low as 30% (Torbicki et al 
1989). There is no such difficulty in examining flow characteristics in the right 
ventricular outflow tract. The pulsed Doppler signal is directed at the pulmonary 
valve and two important measurements are made - namely, aceeleration time (AT) 
and right ventricular ejection time (ET) (Kitabatake et al 1983). AT is defined as the
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time from the onset of ventricular ejection to the attainment of maximum flow 
velocity through the pulmonary valve, and ET is defined as the interval between the 
beginning and end of flow in the right ventricular outflow tract. These flows have 
characteristic pulsed wave Doppler velocity envelopes. Normal subjects have a 
smooth dome-shaped envelope while patients with pulmonary hypertension show a 
notched pattern caused by a shortened AT followed by a second slower rise during 
deceleration. AT and ET can therefore be used to demonstrate the presence of 
pulmonaiy hypertension but, unlike continuous wave Doppler assessment of TR jet 
velocity, the calculation of underlying values of pulmonary arteiy pressure is poor 
(Tramarin et al 1991). Intra and inter-observer variability is slightly worse than with 
continuous wave Doppler and the technique is less sensitive to factors which induce 
acute changes in pulmonary artery pressure (Torbicki et al 1990). However, compared 
with the success rate for continuous wave Doppler in COPD of approximately 30%, 
pulsed wave Doppler can detect pulmonary hypertension in over 90% of cases.
1.3.1.2 Magnetic Resonance Imaging
Magnetic resonance imaging (MRI) can provide accurate anatomical information 
about the cardiac ventricles and normal ranges for ventricular volumes and masses 
have been established (Lorenz et al 1999). It has been used to estimate pulmonary 
artery blood flow and distensability (Paz et al 1993) as well as cardiac output and 
stroke volume (Tarvidon et al 1994) and has been shown to be more accurate than 
echo in monitoring left ventricular mass (Bellenger et al 2000). Recent work has 
attempted to correlate the Ventricular Mass Index (ratio of right ventricular mass to 
left ventricular mass) with mean PAP and found this to be superior to the correlation
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of Doppler echocardiography with the same variable (Saba et al 2002). The authors 
suggest that this might be because MRI reflects the right ventricle’s response to 
sustained pulmonary hypertension and is less susceptible to short-term variables -  
such as posture and heart rate - which affect Doppler echocardiography. MRI is not 
yet widely available and again provides an estimate of PAP.
1.3.2 Invasive Methods of Measurement
Conventionally, fluid filled thermodilution catheters have been taken as the gold 
standard against which other techniques have been compared, though this view is not 
accepted by some authors (Naieje et al 1996). Right heart catheterisation is usually 
carried out using a fluid filled thermodilution catheter of the Swan Ganz type (Swan 
et al 1970). The procedure can be used to answer a number of questions and is very 
fully described elsewhere (Groves et al 1996) but essentially, the catheter is inserted 
via a central vein and advanced until the tip is placed in the pulmonary arteiy. 
Position can be determined either from the pressure trace or by direct screening with 
fluoroscopy. The catheter has two fluid filled lumina from which pressure traces of 
right atrial and pulmonary artery pressures are recorded simultaneously by external 
transducers, and a thermistor for measurement of pulmonaiy blood flow by the 
thermodilution technique. Pressure measurements are conventionally made in the 
right atrium, right ventricle, pulmonary artery, and in the wedge position to record 
pulmonary artery occlusion pressure, which is an estimate of left atrial pressure. 
Pressure and flow measurements can be repeated following interventions such as the 
administration of vasodilators or oxygen, or after exercise. Thus, in addition to the 
direct measurement of pressures, a number of variables are derived which can be used
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to calculate further information such as pulmonary vascular resistance (PVR) which is 
calculated by subtracting the pulmonary artery occlusion pressure (estimated left atrial 
pressure) from the mean pulmonary artery pressure and dividing by the cardiac 
output. Changes in PVR (expressed in Wood's units) give a measure of the 
vasoreaetivity of the pulmonary circulation.
1.3.3 Risks and Complications of Invasive Assessment of the Pulmonaiy Circulation 
Using Fluid Filled Cardiac Catheters
1.3.3.2 Risks and Complications of the Procedure
Cardiac catheterisation is generally a safe and well-tolerated procedure. 
Complications of pulmonary artery catheters are traditionally divided into those 
related to catheter insertion and those related to the presence of the catheter itself 
(Mansfield 1999). The overall mortality is 0.4% (Shah et al 1984)
1.3.3.2.1 Procedure related complications
There are a number of minor complications such as bleeding at the catheter insertion 
site and trivial arrhythmias during the procedure. There are risks associated with the 
placement of the venous sheath but these can be minimised by using the appropriate 
approach. The subclavian approach is associated with a 1-6% risk of pneumothorax 
and when unintentional arterial cannulation occurs, bleeding is difficult to control 
(Matthey and Chatterjee 1988). For these reasons access via the internal jugular vein 
is preferred. The peripheral veins (antecubital or femoral) were not appropriate for the 
passage of the relatively stiff micromanometer tipped pulmonary artery catheter and 
were not used.
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AiTyhthmias provoked during the passage of the catheter are usually benign and 
sustained ventricular tachycardia is rare (3%) (Weidemann et al 1984).
1.3.3.2.2 Catheter Related Complications
1.3.3.2.2.1 Infection
Indwelling pulmonaiy artery catheters (>24 hours) are associated with vaiying risks 
of infection from 0.7% to 11.4% (ASA task force on Pulmonary artery Catheterisation 
1993) and the incidence of bacterial endocarditis can be as high as 7% (Rowley et al 
1984). Higher infection rates are associated with the right internal jugular route for 
venous access, catheter repositioning and prolonged catheter insertion times (>96 
hours) (McGrath 1986).
1.3.3.2.2.2 Thrombosis
The incidence of mural thiombi found at post mortem in the right ventricle of patients 
with a pulmonary artery catheter has been estimated at 30%, however this was not 
associated with an increased risk of pulmonary thromboembolism (Weidemann et al 
1984).
1.3.3.2.2.3 Balloon Rupture
Balloon rupture (releasing air into the circulation) complicates 3% of procedures and 
is not usually associated with serious consequences (Sise et al 1981).
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1.3.3.2.2.4 Pulmonary Artery Rupture
This is an extremely rare complication of right heart catheterisation occurring during 
1 in every 3000 procedures (Kearney and Shabot. 1995). Possible causes are thought 
to include prolonged balloon inflation or catheter manipulation. Pulmonary artery 
rupture is more likely in older subjects, in the presence of pulmonary hypertension 
and in the anticoagulated. This complication did happen during conventional right 
heart catheterisation while studying a subject for this thesis and the patient survived. 
Other complications are particularly relevant to patients with relatively low and fixed 
cardiac output and these are detailed below (Groves and Badesch 1996).
• Vasovagal reactions with systemic hypotension and bradycardia
• Supraventricular tachycardia may occur as a direct consequence of catheter 
passage tlirough the right heart. These can be significantly disabling to patients in 
whom the contribution of atrial contraction to cardiac output is important.
• Systemic hypotension as a consequence of vasodilator administration.
1.3.3.3 Advantages, Disadvantages and Limitations of Conventional Cardiac 
Catheterisation
Cardiac catheterisation in the catheter laboratory is conventionally regarded as the 
“gold standard” against which other techniques must be compared. It is a safe 
procedure in a controlled environment which, when performed correctly will produce 
high quality, reliable data which is suitable for comparison with that produced by the 
many centres using very similar techniques. Patients do not require prolonged hospital 
admissions and in some centres are managed as out patients. During the procedure the 
opportunity exists to collect additional data as seems appropriate e.g. angiography
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(Chapter 2.4.4.1) a saturation run (Chapter 2.4.4.2) or vasodilator studies (Chapter 
2.4.3) may be performed provided that consent is adequate.
The most important disadvantages of conventional cardiac catheterisation are the 
limitations placed on the circumstances in which data can be collected. Because of the 
external transducer and the need for accurate levelling with the catheter tip, 
measurements must be made in supine patients usually at rest. Such circumstances 
may bear little relation to the pulmonary haemodynamics actually experienced by 
patients when they complain of symptoms.
Finally there are technical problems with fluid filled, pulmonary arteiy catheters, 
which may be subject to catheter whip, catheter impact and end pressure (Ellis et al 
1951, Grossman 1986) and have a tendency to damp the signal making them 
unreliable for the measurement of instantaneous pressures.
Thus conventional cardiac catheterisation with fluid filled, pulmonary artery catheters 
makes limited measurements in unrepresentative surroundings in an unrepresentative 
position and in an unrepresentative state.
Apart from the risks of cardiae catheterisation, hospital admission is usual which may 
be inconvenient for patients. There are also problems inherent in the teclinique. The 
fluid filled catheter acts as a damper of the signal and is incapable of measuring 
instantaneous pressures. Furthermore, these catheters rely on an external transducer, 
which is levelled with the right atrium making it impossible for the patient to change 
position and allowing limited manoeuvres on the catheter table. Hence the results 
obtained, though of value, bear little relation to the pulmonary haemodynamics 
actually experienced by patients.
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In conclusion, there is now a formidable array of tools available for the investigation 
of a patient with suspected pulmonary vascular abnormalities. Though the more 
traditional methods have been shown to be too insensitive to be valuable in isolation, 
collectively they remain important screening techniques by which patients who 
require further investigation can be identified.
Pulmonary hypertension is an important complication of many cardiorespiratory 
diseases and its recognition is important. When it is suspected, usually on the basis of 
the patient's signs and symptoms and the traditional screening tests, referral should be 
made, in the first instance, for echocardiography. This should include assessment by 
both continuous wave and pulsed wave Doppler. When pulmonary hypertension is 
confirmed, or where there continues to be any doubt, the patient should be referred to 
a pulmonary vascular centre for further assessment.
66
1.4 Evolution of Systems of Measurement in the Systemic Circulation and 
Parallels with the Pulmonary Circulation
It has been loiown for some time that blood pressure measured by physicians in 
clinical surroundings are different from those obtained at home (Ayman and 
Goldshine 1940) and that placebo effects on blood pressure are only seen in the 
clinical setting (Goul et al 1981).
Thus there has been a move towards ambulatory blood pressure monitoring in the 
systemic circulation based on the belief that this provides more accurate infomiation 
about blood pressure and consequently better prognostic inforaiation. This is 
important in pathology where small changes in recommended blood pressure targets 
for populations might translate into major epidemiological benefits. This observation 
seems likely to hold true for the pulmonary circulation (albeit on a mueh smaller 
scale) and indeed in a low-pressure system small reductions are even more significant. 
Hence there are implications for the measurement of the pulmonary circulation in the 
way that ambulatory blood pressure monitoring has developed.
The conclusions of a number of investigators in the late 1980’s was that ambulatory 
blood pressure measurement offered signifieant advantages over conventional 
measurement. Studies suggested that measurements made by attending physicians 
(office blood pressure measurements) were not predictive of ambulatory blood 
pressure measurements and that the latter offered a better assessment of individual 
cardiovascular risk and a more accurate evaluation of therapy (Brunner et al 1985). 
Others had previously shown that ambulatory blood pressure differed from office 
pressures and that this correlated with a significant increase in fatal and non fatal 
adverse events; the benefits of ambulatory blood pressure measurement were shown 
to be greatest in those individuals with borderline hypertension (Perloff et al 1983).
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The technique also allowed the distinction between pseudo and true hypertension and 
because ambulatory blood pressure measurements correlate even more strongly with 
future disease than casual pressures and because of the large number of readings 
obtained, clinician confidence improved (Sleight 1985).
Another important advantage of ambulatory blood pressure measurement is that it 
measures not only mean pressure but also blood pressure variability which is 
important in mortality and morbidity (Mancia et al 1985) and has been subsequently 
shown to correlate with target organ damage (Parati et al 1987, Palatini et al 1992).
In conclusion, it is now understood that office hypertension is not associated with the 
same degree of cardiovascular risk as sustained hypertension revealed by ambulatory 
monitoring. Ambulatory blood pressure measurement can be used to define those at 
risk either due to sub optimal blood pressure control or because of patterns of 
hypertension associated with a poor outcome such as nocturnal hypertension. The 
technique allows the more rigorous assessment of antihypertensive agents (Prasad et 
al 1996).
In the assessment of the pulmonary circulation pressure measurements are usually 
made in unrepresentative surroundings, position and state (Raeside and Peacock 
1997). The importance of early recognition of pulmonaiy hypertension is widely 
accepted if not yet scientifieally proven and the efficacy and cost benefit ratios of 
treatment very hard to balance. For these reasons it seems logical that investigators 
into the pulmonary circulation might see some parallels in the development of 
ambulatory measurement systems in the systemic circulation.
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1.5 Measurement Of The Pulmonary Circulation Using Micro Manometer 
Tipped Pulmonary Artery Catheters
1.5.1 Previous Work to Develop an Integrated System for the Measurement, 
Recording and Analysis of PAP
In 1941 Cournand & Ranges performed the first right heart catheterisation in man 
using the technique to sample blood and measure cardiac output before demonstrating 
in 1945 that measurement of pressure was also possible.
The realisation that “pulmonary capillary blood” could be obtained by taking samples 
with the catheter in the wedge position (Dexter et al 1946, Hellems et al 1949) led to 
right heart catheterisation being used to investigate cardiovascular physiology and 
assess the effects of treatment (Lenegre and Maurice 1944, McMichael and Sharpey- 
Schafer 1944, Stead and Warren 1947). Subsequently it has been shown that pressure 
measured in the wedge position can be an accurate approximation of pressure in the 
left atrium (Werko et al 1953, Nathan et al 1983, Levy et al 1987).
Right heart catheterisation was shown to be a useful technique in the management of 
critically ill patients (Bradley 1964, Fife and Lee 1965) and in 1970 Swan and Ganz 
described a simple method for catheterlsing the pulmonary circulation without the 
need for fluoroscopy.
There are disadvantages inherent in fluid filled catheters however, which lead to 
problems of signal damping, catheter whip and inadequate frequency response 
(Grossman 1980). This led to interest in solid, micromanometer tipped pulmonary 
artery catheters which can overcome these problems and the development of systems 
for clinical use which allow the high fidelity recording of pulmonaiy artery pressure 
(Ellis et al 1951). Solid pulmonary artery catheters permit high fidelity pressure
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recordings and accurate measurement of rate of pressure change (Gould et al 1973). 
Gauer and Gienapp (1950) reported the development of a miniature pressure 
recording device designed for insertion into the circulation and based on original work 
by Wetterer (1943). This device deployed the transducer at the catheter tip and 
allowed high fidelity tracings of the pulmonary artery pressure wave to be made. The 
advantages of such a system were that it allowed measurement in active subjects and 
eliminated the artefacts generated by the transmission of a pressure signal by a fluid 
filled tube sueh as a conventional pulmonary artery catheter. Furthermore 
micromanometer tipped catheters eliminate the need for levelling with an external 
transducer and allow subjects to be fully ambulant.
Such systems have been investigated in cardiac disease (Chapter 1.5.3). One of the 
priiieiple disadvantages of such catheters is their tendency to baseline or zero drift and 
the catheter described in this thesis incorporates a novel method of in vivo calibration 
to counteract this phenomenon (Chapter 1.5.2).
The subsequent development of transducer tipped systems with no need for levelling 
with an external transducer meant that high quality pressure recordings could be made 
in ambulant patients. The system described above also allows the in vivo correction of 
zero drift.
The system used in this thesis was then developed by Gibbs et al (1992) in order to 
produce a complete system for the measurement, recording and analysis of 
ambulatory pulmonary artery pressure.
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1.5.2 The PAP Recording System
1.5.2.1 The Catheter
The ambulatory pulmonary artery catheter described here is a 7F NIH, double lumen 
catheter (Gaeltech Ltd UK), Figure 2.1.
A pressure transducer is located at the catheter tip, which eliminates the necessity for 
levelling with an external transducer. Because the catheter tip incorporates its own 
zero reference point patients are able to be fully ambulant with no disruption to the 
reeording. This catheter is designed for multiple use and is gas sterilised in ethylene 
oxide for 48 hours. The prineipal advantage of this system is that the catheter 
incorporates an in vivo calibration system, which allows correction for "zero drift".
1.5.2.2 The Ambulatoiy Recorder
The data are recorded by a portable battery powered recorder (Type MPR/2, Gaeltech 
Ltd, Isle of Skye, UK). The recorder dimensions are 188 by 135 by 45mm and its 
weight 850 g including four AA size batteries. Figure 2.2.
The recorder incorporates two buttons which have start/stop and event marker 
functions. The latter, pushed by the patient or investigator, marks an event and time 
on the trace, which can then be compared with an activity diary kept by the patient or 
investigator. This permits direct comparison of the pressure trace with activity. The 
recorder ineorporates a liquid crystal display showing the amount of memory used 
and a clock allowing annotation of the trace in real time. The memory incorporates a 
2 MB expansion card giving more than 24 hours continuous recording and is protected 
by an internal power source during battery changes.
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The catheter is connected to the recoding box tlnongh a port at its rear and a socket on 
its side is used to attaeh a serial link to a desktop computer for storage and analysis 
(Mitsubishi Apricot Pentium 100). This linlc can also be used to interrogate the 
recording box and alter its parameters at any time (including during recording) and 
permits the pulmonary artery pressure tracing to be displayed on the computer screen 
in real time. Pulmonary arteiy pressure can be recorded in the range of -30 to 223 
mmHg. The analogue pressure signal from the catheter is amplified and filtered to 
limit the highest frequency to 16 Hz and compressed.
1.5.2.3 Data Compression
Mean pressures are derived from the recorded pressure waveform. Point values are 
taken from the pressure trace every 0.03 seconds and then divided by the total time for 
which a mean pressure is required.
In order to allow studies to be performed without interruption the recorder compresses 
the data it receives. This is a particular problem in the pulmonaiy circulation because 
of the inegularity of the pressure wave. Large swings in intrathoracic pressure can 
occur with respiration and the system must accommodate these. This is achieved by 
applying an algoritlim to the pressure trace which selects representative data points at 
a rate of 32 per second. These samples are at inflection points to reduce subsequent 
enors in pressure calculation (<lmmHg) and are linked by straight lines in order to 
minimise deviation of other points. Because of inter-individual variations in 
pulmonary arteiy pressure waveform this system has been validated against real time, 
non-compressed data (Gibbs et al 1992).
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1.5.3 Technical Characteristics and Validation of this System
1.5.3.1 Zero-drift
Micro manometer tipped pulmonary artery catheters are prone to zero-drift; this refers 
to a change in the baseline voltage at which the catheter output has heen set when the 
transducer was exposed to atmospheric pressure (Gibbs et al 1989). Provided that the 
sensitivity and gain stability of the recording equipment remain unchanged, zero-drift 
will result in a similar alteration in output voltage to the same applied pressure.
The principle of calibrating a pressure transducer by applying equal pressure above 
atmospheric to both of its surfaces has previously been described (Eversden 1970). 
This technique was exploited in the development of the catheter described in this 
thesis to allow the correction of zero-drift while the catheter was in the circulation 
(Gaeltech UK Ltd). The transducer lies in the stainless steel tip of the catheter 
between the two catheter lumina (both of which are exposed to the atmosphere); on 
one side a 2 mm^ window exposes it to the circulation from which it is protected by a 
silicone elastomere membrane. The two lumina are in communication with a luer 
fitting on the catheter into which 0.4 ml air is injected using a one ml syringe. This 
action results in a pressure of 124 mmHg being applied via the catheter lumina to both 
sides of the transducer causing the membrane to be temporarily lifted off its surface 
before springing back into place. While the membrane is lifted off the transducer 
surface the pressure on both of its sides is high and equal, allowing calibration to be 
performed.
Gibbs (1989) has shown that this reference calibration is a valid function of zero and 
confirmed that the zero drift observed during bench testing can be used to predict how 
much zero drift will occur in ambulant patients.
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1.5.3.2 Validation equipment and experiments
A series of experiments were perfonned in the laboratory followed by clinical 
evaluation (Gibbs et al 1989).
Prior to testing the catheter tip was soaked in normal saline for at least two hours to 
stabilise the elastomere membrane. Measurements of zero were made with the tip 
exposed to atmospheric pressure and measurements of catheter voltage output made 
when the membrane was under inflation were referred to as reference calibrations. 
These measurements were all performed on at least two catheters.
Static pressure testing dem onstrated an accuracy o f ±0.1% o f the applied pressure 
m ass at 20°C and a tem perature eiTor o f ±0.07% betw een 20-25°C.
Dynamic pressure testing was carried by subjecting the catheter tip to 
morphologically accurate pulmonary artery pressure waveforms using a blood 
pressure systems calibrator (Bio-Tek Instruments Inc.). The frequency response of the 
catheter generated waveforms was flat from 0-150Hz and the pressure range was -20- 
200mmHg with an accuracy of ±2% of the reading.
When performing reference calibrations the pressure applied is unimportant provided 
that it is greater than atmospheric and the pressure being measured. The volume of air 
required to achieve this varied from 0 . 1 -0 .6 ml and was compared with the catheter 
output in milli-volts. The pressure within the catheter during reference calibrations 
was determined by applying a known pressure to the catheter using a dead weight 
pressure balance; the pressure immediately prior to a sharp rise in the catheter’s 
output was taken to be that at which the known applied pressure and the catheter 
pressure were balanced.
The relationship between reference calibration and zero was determined. During 
bench testing, transducers are subject to very little zero-drift and therefore this had to
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be induced using by subjecting the catheter to temperature variations (4-50°C). This 
resulted in the zero reading drifting by 7.4mmHg (10% of full scale). Measurements 
were made during static and dynamic testing.
Further experiments were perfomied to ascertain that the catheter output altered by 
the same amount as the zero-drift measured and to determine the influences of the 
pressure being measured the morphology of its waveform and heart rate on the 
reference calibration. Temperature changes at the catheter tip did alter the pressure 
volume relationship under the elastomere membrane and the effect of these was 
assessed over a range of temperatures (20-43 °C).
Dynamic testing was achieved by subjecting the catheters to pressure changes 
generated by the blood pressure calibrator for five days. Zero measurements were 
made every 2 0  minutes for the first 1 2  hours and randomly thereafter.
No difference was found between the two catheters. The optimum volume of air for a 
reference calibration was found to be 0.4ml as that which was sufficient to exert the 
required pressure and unlikely to damage the membrane.
The relationship between the reference calibration and zero was shown to be linear 
with no important changes at extremes of zero-drift. The change in zero was seen to 
be similar to the changes seen in other pressures.
The influence of the pressure being measured on the reference calibration was greater 
during static than dynamic testing (1.45% of full scale v 0.7%) and the morphology of 
the pressure waveform affected the reference calibration by 0.0005% of full scale. 
Catheter tip temperature differences altered the reference calibration by 0.004% of 
full scale per °C.
The zero-drift seen during dynamic testing was 5.2mmHg for catheter one and
0.37mmHg for catheter two.
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1.5.3.3 Clinical evaluation
Ambulatory pulmonary artery pressure measurement was carried out in eight patients 
for between eight and 48 hours. Catheter drift was seen to vary in amount and 
direction and was a function of time with the most rapid period of drift occurring in 
the first four hours of recording. Again calibration lines did not alter significantly 
before and after periods of pressure recording.
Gibbs (1989) concluded that that zero-drift is likely to occur during ambulatory 
pulmonaiy artery pressure measurement with micromanometer tipped pulmonary 
artery catheters and is not predictable. The differences observed between laboratory 
and in vivo testing probably relate to the stresses the catheter endures passing through 
the right side of the heart and with each heartbeat. The design modifications made by 
Gibbs (1989) to the catheter used in this thesis allow for in vivo correction of zero- 
drift and minimise the effects of artefactual pressure changes.
1.5.3.4 Risks And Complications Of Cardiac Catheterisation Using Micro Manometer 
Tipped Pulmonary Artery Catheters
The procedure carries the same general risks and complications as those described for 
conventional cardiac catheterisation (Chapter 1.3.3). Specific risks related to the use 
of the micromanometer tipped pulmonary artery catheter are that it is stiffer than a 
fluid filled catheter which may cause difficulties in placement and increase the risk of 
ventricular mpture. Complications specific to the micromanometer tipped pulmonary 
artery catheter were not encountered in the procedures described here.
1.5.3.5 Advantages, Disadvantages And Limitations Of Micromanometer Tipped 
Pulmonary Artery Catheter PAP Monitoring
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The principal advantage of this system is its ability to provide high quality recordings 
of PAP in fully ambulant patients as described in Chapter 2.3.
There is no facility to measure cardiac output or pulmonary artery occlusion pressure, 
which limits the haemodynamic obtained with this system. There are theoretical risks 
of infection, catheter migration, arrhythmia and bleeding from the insertion site 
associated with long term indwelling pulmonary artery catheters, but these were not 
observed in the studies described in this thesis.
When used with the relevant recording and information storage systems, these 
catheters allow the accurate recording of long term (>24 hours) pulmonary pressures 
(Gibbs et al 1992). These, when analysed in conjunction with a simple patient diary, 
reveal changes in pulmonary artery pressure with everyday activity such as sleeping, 
standing, walking, or exercising (Chalmers et al 1996). More formal exercise testing 
can also be carried out with the catheter in situ. However, though superior to fluid 
filled catheters in many respects, micromanometer tipped catheters are expensive, less 
flexible, and lack a flotation balloon, which can lead to difficulties in placement. 
Since the patient should be ambulant to gain maximum infonnation, the femoral route 
is not possible and the internal jugular or subclavian route must be used.
Despite their advantages, neither type of pulmonary artery catheter takes into account 
all the complex forces which constitute pulmonary haemodynamics. However, when 
combined with Doppler echocardiography a much more complete picture is obtained.
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1.5.4 Previous Work Measuring Ambulatoiy PAP in Heart Disease
Initial interest in ambulatory pulmonary artery pressure monitoring followed from the 
observation that that left ventricular end diastolic pressure (LVEDP) is related to 
indices of physical performance (Sarnoff and Mitchell 1962). In the absence of mitral 
valve disease or raised pulmonary vascular resistance pulmonary artery diastolic 
pressure is an accurate estimate of left ventricular end diastolic pressure in man 
(Hodges et al 1969, Russell et al 1969, Falicov and Resnekov 1970) and consequently 
a number of authors have utilised ambulatory pulmonary arteiy pressure measurement 
in the investigation of heart disease.
Jenkins et al (1970) studied this relationship in patients with acute and chronic cardiac 
disease and found that it only held true where PVR was normal. Later work utilised 
ambulatoiy pulmonary artery pressure measurement to demonstrate the relationship 
between ST segment changes and rises in PAP in patients with ischaemic heart 
disease subjected to stress (Levy et al 1986). The same authors also observed that a 
similar relationship existed between chest pain and haemodynamic changes in patients 
with variant angina and asymptomatic ST segment changes but not in the situation of 
chest pain and normal coronary angiography (Syndrome X). In this sequence of 
papers Levy and co-authors (1986) concluded that ambulatory pulmonary artery 
pressure monitoring provided a useful surrogate for changes in left ventricular 
haemodynamic function in patients with coronaiy artery disease.
Gibbs et al (1989) studied the assumed ehanges in PAP in chronic heart failure due to 
posture and sleep. Measuring ambulatory pulmonary artery pressure they 
demonstrated that these variations were not wholly explained by posture as the 
observed changes were gradual and absent in two subjects. Again the advantages of 
real time comparison between activity and PAP changes were important in the
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conclusions of this study. Richards et al (1989) studied variations in PAP using an 
ambulatoiy pulmonary artery pressure measurement system in patients with PPH 
compared with a control group during activities of daily living. They observed that 
these changes were more variable and had greater magnitude in the PPH group.
Gibbs et al (1990 and 1991) again studied subjects with chronic heart failure 
comparing rises in PAP during activities of daily living with those seen during 
maximal exercise tests. They observed that neither symptoms nor PAP variations 
during nonnal activity are the same as those experienced during exercise and 
questioned the validity of maximal exercise tests in the assessment of patients with 
chronic heart failure.
Further work assessed the neuroendocrine response to cardiac catheterisation in 
patients with chronic heart failure. The authors found no relationship and therefore 
questioned the accepted practice of delaying haemodynamic measurements following 
cardiac catheterisation.
The use of ambulatory pulmonary artery pressure measurement in heart disease 
evolved from a physiological observation that it offered a useful surrogate for LVEDP 
to the realisation that the technique permitted real time comparisons between applied 
stress and haemodynamic responses.
1.5.5 The Re-Evaluation of Ambulatory PAP Monitoring in Patients with Pulmonary 
Hypertension Secondary to Lung Disease
This thesis examines the utility of ambulatory pulmonary artery pressure monitoring 
in patients with pulmonary hypertension secondary to lung disease. Such patients 
usually complain of symptoms when active while haemodynamic monitoring of the 
pulmonary circulation is conventionally carried out at rest. The benefits of ambulatory
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pulmonary artery pressure monitoring described in Chapter 1.5.4 therefore seemed 
equally applicable to the pulmonary circulation and the measurement of PAP even
more so.
• Postural changes in a model of PPH.
PPH offers the “purest” elinical presentation of pulmonary hypertension but is 
very rare. The pulmonary hypertension associated with connective tissue disease 
is very similar clinically and pathologically to PPH and connective tissue disease a 
much commoner condition. This therefore provides a useful model of PPH which 
was used in Chapter 3 to study the effects of posture on the pulmonary circulation 
using ambulatory pulmonary artery pressure monitoring.
• Changes in PAP with sleep in COPD.
COPD is as common as PPH is rare and is the predominant clinical situation in 
which most clinicians will encounter pulmonary hypertension. Important changes 
in PAP are known to occur due to a variety of stresses including exercise and 
sleep. The accurate assessment of these changes in the pulmonary circulation may 
have implications for treatment in COPD, particularly with reference to oxygen 
treatment. In Chapter 4 ambulatory pulmonary artery pressure monitoring was 
carried out during sleep and exercise in a group of patients with COPD and a 
control group and the effects of oxygen treatment in the COPD group was 
assessed.
• Surrogate markers for PPH.
Invasive haemodynamic monitoring is safe and well tolerated, however carries a 
small risk and is inconvenient and expensive. Ideally reliable surrogates of PAP 
will be identified to avoid the need for invasive procedures and to widen the kinds 
of patients studied. The ambulatory pulmonary artery pressure monitoring system
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has advantages which make it particularly suitable for identifying these surrogates
i.e. the capacity to make accurate measurements of PAP during exercise. In 
Chapter 5 a group of patients with connective tissue disease were studied (again as 
a model of PPH). The ambulatory pulmonary artery pressure monitoring system 
was used to measure changes in PAP simultaneously with variables measured 
during cardiopulmonary exercise testing and conelations sought.
• Treatment of pulmonary hypertension.
The physiological variability of the pulmonary circulation makes the assessment 
of treatment a particular challenge. In Chapter 6  the surrogates of PAP identified 
using the ambulatory pulmonary artery pressure monitoring system were used to 
assess the responses to treatment with oral vasodilators of a group of patients with 
connective tissue disease (again as a model of PPH).
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1.6 Hypothesis and Aims of this Thesis
1.6.1 Hypothesis
The hypothesis of this thesis is that variations in pulmonary artery pressure in man 
during activities of daily living, sleep and exercise secondary to respiratory disease 
can be measured using an ambulatory pulmonary arteiy pressure measurement 
system.
Conventional methods of assessment of the pulmonary circulation have disadvantages 
in these settings while it is likely that the ambulatory pulmonary artery pressure 
monitoring system has particular strengths in allowing the measurement of pulmonary 
artery pressure in fully ambulant patients.
1.6.2 Aims
The primary aim of this thesis was to prove that ambulatory pulmonary artery
pressure monitoring is safe and well tolerated in patients with respiratory disease.
Secondaiy aims were:
• To evaluate ambulatory pulmonary artery pressure monitoring in pulmonaiy 
hypertension secondary to pulmonary vascular disease. Specifically to assess 
changes in pulmonary haemodynamics related to posture, sleep and exercise.
• To assess the relationship of ambulatoiy pulmonaiy artery pressure monitoring to 
the other available methods of measurement in the pulmonary circulation.
• To determine the relationship between pulmonary artery pressure measured during 
exercise and other variables measured non-invasively during cardiopulmonary 
exercise testing.
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To assess the effect of treatment of secondary pulmonary hypertension using the 
ambulatory pulmonary artery pressure monitoring system.
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Chapter 2
Materials and Methods
2.1 Patient Recruitment
The patients studied in the course of this thesis were recruited from the respiratory 
clinies of the West Glasgow Hospitals University NHS Trust, and via referral from 
respiratory physicians from other trusts across Scotland.
Ethical approval for all studies was obtained from the West Glasgow Hospitals 
University NHS Trust’s West Ethics Committee. All patients gave written, informed 
consent prior to participation in all studies (Figure 2.1).
2.2 Routine Work Up
Routine investigations performed on every patient included routine blood tests, 
electrocardiogram, chest radiograph, ventilation/ perfusion lung scan, CT scan of 
thorax, conventional, cardiac catheterisation, and cardiopulmonary exercise testing. 
All these investigations were earned out using the facilities of the Western Infirmary 
(Glasgow).
2.2.1 Doppler Echocardiography
Echo Doppler measurements (Acuson 128 XP/IOC, Acuson Ltd, Mount View, 
California, USA) (Fig 2.2) were made in the semi-recumbent position. The jet of 
tricuspid regurgitation was identified, its maximum velocity measured, and pressure 
gradient calculated. This gradient was added to an assumed right atrial pressure 
(10 mm Hg) to give an estimate of pulmonary artery systolic pressure. Echo 
measurements were made by the same operator in almost all cases and at least 
24 hours in advance of cardiac catheterisation, so the operator was ignorant of the 
"true" PAP.
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Figure 2.1 Consent Form For Ambulatory Pulmonary Artery Pressure
Monitoring
GREATER GLASGOW HEALTH BOARD 
THE WEST ETHICAL COMMITTEE
FORM OF CONSENT FOR PATIENTS / VOLUNTEERS IN CLINICAL 
RESEARCH PROJECT
RIGHT HEART CATHETERISATION WITH 24 HOUR MONITORING 
PatienFs Summary
We invite you to participate in a trial of measurement of the pressures in the lung 
circulation. We believe that you have high pressures in the heart as a consequence of 
problems either with your lungs or the vessels leading from your heart to the lung. 
Since these pressures may be the cause of your breathlessness, we would like to make 
measurements of these pressures both at rest and while you exercise quietly. Exercise 
will be gentle on a tieadmill at a fixed work rate within your capacity, which will be 
estimated beforehand. We will stop the exercise if you become breathless. We aim to 
measure the difference in pressure from rest to exercise because we believe that arise 
in pressure with exercise may be a major cause of breathlessness experienced with 
exercise. The order of measurements, i.e. measurements at rest and measurements on 
exercise will be randomised so that some subjects will have resting measurements 
made before exercise and some after exercise. This will not affect the character of the 
study nor the length of time it takes.
To measure these pressure we will insert a thin catheter via a neck vein into your heart 
and attach this to a tape recorder which will allow us to continually measure the 
pressure and should provide useful information as to how this varies as you go about 
your daily activities. There are slight risks associated with the insertion of the 
catheter. These include; damage to the blood vessels, leakage of air into the lining of 
the lung and irregular heart beat. However the catheter will be placed either by or 
under the supervision of Dr Peacock who has experience of placing himdreds of these 
catheters and has had no serious problems to date.
You should not take part if you are pregnant and can refuse to participate or withdraw 
at any time without detriment to youi current or future medical care. The results may 
not prove of any direct benefit to you. Your general Practitioner will be notified of 
your involvement.
Consent
I , ................................................. o f .......................................................................................
give my consent to the research procedures described above, the nature, purpose and 
possible consequences of which have been described to me b y ......................................
S igned...................................................  Date
W itness.................................................
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2 .2 . 2  Cardiopulmonaiy Exercise Testing
Cardiopulmonary exercise testing in this thesis was carried out using the 
SensorMedics V Max System (Sensormedics, Yorba Linda, California) (Fig 2.3) 
wearing an adult facemask (Hans Rudolph, inc.7200, Kansas City, Mo. 64114 USA). 
This is a breath by breath measurement system the main components of which are 
described below.
2.2.2.1 Components of the Sensormedics V Max System
The Mass Flow Sensor™ makes volume measurements by exposing laminarised 
streams of gas to a pair of heated, stainless steel wires. The principal of measurement 
involves the assumption that the rate at which heat is lost from the wires is directly 
proportional to the mass of the individual gas molecules flowing across them.
Gases are measured by the Multi-gas Analyser using a Non-Dispersive Infrared 
(NDIR) technique which peimits real time measurement of carbon dioxide (CO2) and 
methane (CH4). Specifically the system measures gas concentrations by directing the 
infrared beam through the relevant gas and measuring how much of it is absorbed. 
Particular gases are selected by adjusting the wavelength of the band.
The Paramagnetic Oxygen Analyser is a fast response oxygen analyser which works 
on the principal of the high paramagnetic susceptibility of oxygen. This allows 
sufficiently fast response times to provide real time breath by breath analyses.
The Carbon Dioxide Analyser utilises the same NIDR measurement technique as 
described above for the multi-gas analyser. The sample chamber size has been 
minimised to enhance response characteristics as with the oxygen analyser.
The One-way Breathing Valve exhibits low flow resistance and is used for mixing 
gases during exercise.
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The mixing chamber has a capacity of 2.6 litres and is used for mixing expired gas 
during exercise.
2.2.3 Exercise protocols
The exercise protocol described in Chapter 3 required subjects to exercise at 30% of 
their V 02 max achieved in a previous maximal test; because some of these subjects 
found a maximal test relatively difficult it was subsequently decided to change this 
protocol. Furthermore whereas the comparisons of exercise data in Chapter 3 were 
within subjects, subsequent studies would require a repeatable and reliable exercise 
protocol which permitted valid comparisons between subjects. Thus with the 
exception of the data presented in Chapter 3 exercise data was obtained during steady 
state exercise testing. Exercise was perfonned on the electromagnetic, cycle 
ergometer and consisted of a steady state exercise test at a workload of 30 Watts for a 
maximum of 8  minutes or at a percentage of Vo2max predetermined during a maximal 
exercise test. Constant work rate testing was chosen because it is particularly suitable 
for measuring cardiovascular, ventilatory and gas exchange kinetics (Neiy et al 1982). 
The electromagnetic ally braked cycle ergometer was chosen over the treadmill 
because it is safer and can maintain a given work-rate despite fluctuations in the 
frequency of pedalling. This relatively low workload for steady state testing was 
chosen as manageable, and likely to be below the anaerobic threshold, for patients 
with expected limited exercise capacity.
2.2.4 Cardiopulmonary Exercise Testing Data
In each case breath by breath measurements of gas exchange were made. These 
included ventilation, tidal volume, respiratory rate, end tidal oxygen and carbon
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dioxide concentrations, oxygen saturations, oxygen uptake (VO2) and carbon dioxide 
production (VCO2). From these measurements other variables were derived including 
oxygen pulse (oxygen uptake / heart rate), and the ventilatory equivalents for oxygen 
(VE/VO2) and carbon dioxide (VE/VCO2) i.e. the ratios of ventilation to oxygen 
uptake and carbon dioxide output respectively. During exercise the PAP was recorded 
continuously with the micro-manometer tipped pulmonary artery catheter. 
The exercise data presented in this thesis are the mean pressures recorded at the onset 
of the fourth minute of steady state exercise.
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2.3 Treatment and Follow Up
Where indicated, subsequent treatment and follow up was performed in the out patient 
clinics and wards of the Western Infirmary or Gartnavel General Hospital. Patients 
who demonstrated a positive vasodilator response were readmitted for the initiation 
and dose titration of an oral vasodilator: those in whom the vasodilator study was 
negative were transferred to the respiratoiy unit for the initiation of intravenous 
prostacyclin.
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2.4 Cardiac Catheterisation
2.4.1 Technical Considerations and Equipment Tolerances
Cardiac catheterisation was carried out in the laboratory at the Western Infirmaiy in 
Glasgow (Fig 2.4). All patients were admitted for the procedure; diuretics and calcium 
channel blockers were stopped on the night prior to cardiac catheterisation. Sedation 
was not routinely given; very anxious patients were occasionally pre-medicated with a 
short acting benzodiazepine prior to the placement of the introducer.
An 8 F introducer was placed in the right internal jugular vein, using a high anterior 
approach, not less than tlnee hours prior to the procedure. Right heart catheterisation 
was performed using a triple channel thermodilution Swan Ganz catheter (Swan Ganz 
7 F Thermodilution Catheter, Baxter Healthcare, Irvine, California, USA). The 
transducer was levelled with the right atrium with the patient lying supine. Pressure 
measurements for comparison with the other systems were made in the right atrium 
(RA), right ventricle (RV) pulmonary artery (PA) and in the wedge position to 
measure pulmonaiy artery occlusion pressure (PAOP). Pressure values were recorded 
while patients breath held at functional residual capacity (to eliminate the effects of 
respiration on PAP). A mean of six beats was recorded and systolic and diastolic 
pressures were averaged. Pressures were recorded in the right atrium, right ventricle 
and proximal pulmonary artery, and an estimate of pulmonary artery occlusion 
pressure was made with the catheter in the wedge position. Cardiac output was 
averaged over a minimum of three measurements using the thermodilution technique.
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2.4.2 Exercise
111 all patients the effects of exercise on pulmonary artery pressure was assessed by 
asking them to perform 3 minutes of straight leg raising. The subject was asked to lift 
each leg alternately to a measured height of 60 seconds as many times as possible in 3  
minutes. This method of exercise assessment is dependant on patient effort and much 
encouragement was given however it is clearly not reproducible; while the use of a 
metronome might improve repeatability it will still be difficult to determine 
retrospectively the extent to which an individual was cooperative and made good 
effort. Nonetheless this weakness in data collection means that direct comparisons 
between catheter laboratory exercise pressures and those obtained with the 
micromanometer tipped pulmonaiy artery catheter must be interpreted with caution. 
This demonstrates an advantage of the micromanometer tipped pulmonary artery 
catheter in that it allows standardised exercise protocols to be employed in ambulant 
patients. In the last 30 seconds of exercise measurements of pulmonary artery 
pressure, and cardiac output were repeated. Pulmonary artery occlusion pressure was 
not re-measured if the resting value had been normal. This is our standard practice, as 
we believe that repeat measurement after exercise slightly increases the risk to the 
patient.
2.4.3 Assessment of the Pulmonaiy Circulation
Early in the disease process pulmonary vasoconstriction is likely to be prominent and 
its identification and magnitude serve as a guide to subsequent vasodilator treatment. 
Patients may have relatively fixed & low cardiac outputs with high RAP. Hence drugs 
which cause systemic, but not pulmonaiy, vasodilatation can cause catastrophic 
systemic hypotension and even death (Reeves et al 1991).
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There are alternative sti'ategies to the assessment of the pulmonary circulation; accept 
the risk of systemic hypotension, using a drug with a short duration of action, such as 
prostacyclin given intravenously so that any systemic hypotensive effect can be 
reversed within seconds by stopping the drug.
Use a substance with an even shorter duration of action such that its effects cease 
before it reaches the systemic circulation (Morgan et al 1991). Acetylcholine, 
Adenosine and NO are such drugs. Acetylcholine has not found general use because 
of its potential to slow conduction tlirough the SA node. NO requires cumbersome 
delivery systems which has limited its widespread use.
2.4.3.1 Acute Vasodilator Studies
Acute vasodilator drugs are used to detennine reversibility in the pulmonary 
circulation. Most drugs in common usage result in simultaneous systemic hypotension 
which limits their usefulness. A vasodilator with effects limited to the pulmonary 
circulation would have advantages.
Adenosine is a purine nucleoside with a variety of effects including systemic 
vasodilation, inhibition of platelet aggregation and of Irpolysis, and in vitro has a 
relaxant effect on human pulmonary vessels.
All patients in whom pulmonary hypertension was confirmed at cardiac 
catheterisation had an acute vasodilator trial using Adenosine. Adenosine at a 
concentration of Img per ml for patients < 55kg or 1.5 mg per ml for patients > 55kg, 
was infused via a small-bore peripheral IV line. The starting dose was 100 
micrograms per kg per min rising in increments of 50 micrograms per kg per min 
every 2 minutes until either side effects appeared, or the maximum dose of 300 
micrograms per kg per min was reached.
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Adenosine has actions on both circulations however has been shown to decrease the 
ratio of pulmonary vascular resistance (PVR) to systemic vascular resistance (SVR) 
indicating that adenosine has a preferential vasodilator effect on the pulmonary 
circulation.
The indications for a study should be reconsidered if the mean right atrial pressure is 
> 15mmHg as the procedure caiTies greater risk in this circumstance. Severe asthma 
or a history of reaction to contrast media was also considered a contraindication. In 
this thesis all acute vasodilator studies were carried out using adenosine as detailed 
below.
During the last 2 minutes of the infusion haemodynamic variables were re-measured 
i.e. either as the patient began to complain of side effects or as the maximum dose was 
being reached. Adenosine was mixed with N. saline to a total volume of lOOmls and 
run through an intravenous infusion pump (Graseby UK) set to run at hourly flow 
rates. These volumes and flow rates allowed an adenosine study to be completed in 
about 1 0  minutes.
2.4.3.2 Oxygen Therapy
In patients with significant resting hypoxaemia 100% oxygen was administered for 10 
minutes and haemodynamic variables re-measured. In individuals receiving long term 
oxygen therapy supplemental oxygen was administered at the usual flow rate.
2.4.4 Determining Pulmonary Vasoreactivity
In this thesis a positive vasodilator study has been defined as a fall in pulmonary 
vascular resistance (PVR) or total pulmonaiy resistance (TPR) of >30%. This value 
was originally described by Rubins et al (1982) who defined it arbitrarily on the basis
97
of a study of prostaglandin as an acute vasodilator in patients with PPH. 30% of these 
patients demonstrated such a reduction in PVR hence its choice as a reasonable 
measure of pulmonary vasoreactivity. Because of the manner in which these variables 
are calculated it is possible for the PVR or TPR to have fallen without any reduction 
in PAP. Where PAP is shown to have fallen with a concomitant rise in cardiac output 
this combination carries the most positive prognostic value.
2.4.4.1 Pulmonary Angiography
If the ventilation/perfusion (V/Q) scan is low probability and/or the patient had had a 
negative spiral CT angiogram, or if the mean right atrial pressure is >15 mmHg, we 
did not perform pulmonary angiography.
2.4.4.2 Saturation Run
A saturation run was only perfonned if a left to right shunt could not otheiwise be 
excluded. When necessaiy this was performed by the withdrawal of one ml of whole 
blood from multiple sites including PA, high RA, mid RA, low RA, high superior 
vena cava (SVC), low SVC, high inferior vena cava (IVC) and low JVC.
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2.5 24 Hour Ambulatory Pulmonary Artery Pressure Monitoring
The pulmonary artery pressure monitoring system described in this thesis consists of a 
7 F catheter supplied by Gaeltech Ltd (Dunvegan, Isle of Skye, UK) (Fig 2.5), the 
ambulatory recorder (Fig 2.6) and a personal computer with the analysis software.
2.5.1 Catheterisation Procedures
The catheter is designed for multiple uses and is gas sterilised in ethylene oxide for a 
minimum of five days.
Central venous access was acquired on the morning of the cardiac catheterisation not 
less than three hours prior to the procedure. An 8 F sheath was inserted in the right 
internal jugular vein using local anaesthetic and secured with tape.
The computer and recorder were taken to the cardiac catheterisation laboratory with 
the patient. The placement of the ambulatory pulmonary artery catheter immediately 
followed the right heart catheterisation. The ambulatory catheter was removed from 
its sterile packaging and coiled and placed in sterile saline. 0.4 millilitres (mis.) of air 
were injected into a port on the side of the catheter using an insulin syringe with the 
needle removed and the transducer membrane observed immersed in the sterile saline 
to check that there is no air leakage. The catheter then remained under the saline for a 
minimum of 2  minutes to allow the catheter insulation to absorb some of this fluid. 
The catheter was then connected to the recording box, which was switched on, and the 
programme started. On the monitor the set up menu was entered and the legend 
“calibrate pressure transducers” selected.
This offered a positive or negative pressure calibration and a negative pressure 
calibration was always used in the studies in this thesis. When this was selected the 
menu required the recorder to be stopped. At this stage non-sterile rubber tubing was
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Figure 2.5
Fig 2.4 The M icromanometer Tipped Pulmonary Artery Catheter
The external luer fitting allows injection of air for calibration. The stainless steel tip 
houses the transducer.
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Figure 2.6
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Figure 2.5 The Ambulatory Recorder
The recorder weighs 650g and is carried over the patient’s shoulder. The 
liquid
crystal display reads real time and available memory. The event button
marks the trace.
101
connected to the port on the catheter and, via a 3-way tap, to the port on the rear of the 
recording box. The 3-way tap was opened to air and return pressed on the computer 
keyboard. The instruction menu then specified that the system should be open to air 
before the pressure calibration was continued, return was pressed again and a pressure 
of zero was established. The programme then required the negative pressure 
calibration to be perfonned in which a 20 millilitre (ml) syringe was connected to a 3- 
way tap in communication with the recording box and the catheter. The syringe 
plunger was then withdrawn until the programme read “calibration complete”. This 
instruction also appeared on the display of the recording box. At this stage the 
catheter was ready for insertion into the patient.
This was placed in the usual way in the proximal pulmonary artery. Care was taken 
not to advance the tip too far into the pulmonary circulation (i.e. no further distal than 
the transverse processes, preferably on the right) as wedging led to loss of trace as 
well as complications.
Once the catheter was satisfactorily positioned it was re-connected to the recording 
box and on the computer screen the “record” menu selected and “start new real time 
recording” option selected. This displayed a real time pressure tracing (Fig 2.7). 
0.4mls of air was again injected into the port in the catheter to check that the pre-set 
zero was satisfactory. So long as the value lay between plus or minus 32 the eiTor 
could be corrected later.
With the catheter in a satisfactory position the sheath was pulled back over the 
catheter to its end and left in this position. This tended to displace the catheter further 
forward into the pulmonary circulation, therefore a further fluoroscopy screening 
check was made before finally securing the catheter with a suture at the point of 
insertion.
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the patient was then returned to the general ward (Fig 2.8). At the end of the study the 
ambulatoiy recorder was stopped and the data processed as described in Chapter 
2.3.4.
The ambulatory catheter was removed and hand washed in warm soapy water. The 
transducer membrane was re-checked by the injection of 0.4mls of air into the 
catheter port during repeat immersion. The catheter was then dried and re-connected 
to the recording box and a “new real time recording” started under the Record menu. 
The end of the catheter was then placed in a sealed pressure chamber (Gaeltech UK 
Ltd.) and plastic tubing connected to the end of this chamber and, via a 3-way tap, to a 
conventional sphygmomanometer. A syringe was then connected to the 3-way tap 
and a pressure (measured by the sphygmomanometer) applied to the pressure chamber 
and hence the catheter. This pressure appeared on screen as a square wave trace 
with a given value at the side of the screen for the pressure being measured by the 
catheter. Thus for an applied pressure of 50 mmHg. ideally the pressure wave on 
screen also recorded 50 mm but where error was observed, the recorded value was 
noted and the whole test trace saved to the hard disc as a real time record.
2.5.2 Data Recording, Handling and Analysis
2.5.2.1 The Programme
The ambulatory pulmonary artery pressure monitoring programme is Windows based 
and is accessed in DOS via the “C” prompt by typing “PAP return, AMB return”.
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2.5.2.2 Making a 24 hour Pulmonary Artery Pressure Recording
On return to the ward area the “record” menu was opened and “start real time 
recording” selected. This displayed the pulmonary artery pressure tracing on screen 
and confirmed that the catheter was continuing to record satisfactorily. The recorder 
battery voltage was checked at this stage using the selection from the same menu and 
if this was adequate a new recording was started.
A two-megabyte RAM card was inserted in the slot in the base of the recording box 
and “start recorder” selected from the record menu. This cleared the memory card 
for a new recording and gave the time on the liquid crystal display at which the new 
recording was being started. At this point, this recording was being recorded on the 
memory card and on the hard disc of the computer.
At any time during recording the actual trace could be viewed on screen using the 
“start new real time” record option in the record display and early in the trace this was 
done on a number of occasions to check that zero calibrations were adequate.
2.5.2.3 Troubleshooting
When this was not the case i.e. injection of 0.4mls of air into the catheter port resulted 
in the trace recording a figure beyond the limits of plus or minus 32, an in vivo 
calibration was performed. To carry this out, under the “record” menu, the recorder 
was stopped, the balloon on the catheter inflated with 0.4 mis of air and kept inflated 
and the “enter terminal mode” selection made from the record menu. This took the 
programme back into DOS where at the C prompt the instruction PZERO in 
continuous upper case was entered and return pressed.
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The programme then inserted a new zero into the catheter and at this stage the 
ambulatory PAP programme was re-entered. “Start new real time recording” was 
then selected from the record menu and zero rechecked viewing the screen trace. If 
this procedure had been successful, the zero calibration should now result in an 
adequate trace, which records close to the actual zero line when calibrated.
If the tracing was still not satisfactory, the above procedure was repeated (several 
times if necessary).
Zero calibrations were performed every half-hour at the beginning of a trace and 
ideally at this frequency tliroughout the recording, and hourly throughout the night. 
However, where this was difficult, a minimum of hourly zero calibrations were 
performed until midnight, after which, the next were done at 8  a.m. by either the 
nursing staff or the patient.
The liquid Crystal display on the recording box indicated the time and the percentage 
of memory which had been used. If the patient was tachycardie, sufficient memory 
may not have been available to record a full 24 hour trace in which case the recorder 
was stopped, the trace downloaded to the hard disc of the computer and the trace re­
started for the remaining required recording.
2.5.2.4 Postural Manoeuvres and Exercise Testing
Study subjects were put tlirough a series of postures which were done in the same 
order of lying awake, sitting legs down, standing and the “event” button on the 
recording box was pressed at the beginning and end of these manoeuvres and the 
patient diary marked accordingly. Where possible, particularly in the lying awake 
position, patients did not speak or make any unnecessary movements and were in the
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same position i.e. in terms of number of pillows etc., as they would be at night when 
asleep. The nursing staff in the ward were asked to note times at which the patient 
was definitely asleep.
Exercise testing was canied out at between two and three p.m. on the second study 
day. At the beginning and end of each segment of exercise, the traee was annotated 
using the event button and frequent calibrations were performed at these points.
2.5.2.5 Completing a Trace
At the end of a 24-hour ambulatoiy recording, from the record menu the “stop 
recorder” option was selected. The two-megabyte RAM card was then removed from 
the recording box and inserted in a card reader device, which was connected to the 
computer via the printer port.
On the “record” menu the “read data from PC card slot” was then selected and the 
patient file was then transferred from the RAM card to the hard disc of the PC. This 
was then saved to the hard drive and patient details entered as appropriate. Under 
“comments”, the catheter used for this catheterisation was always recorded as 
subsequent problems which might have occurred during recordings, and which were 
specific to individual catheters, could be identified.
To check that satisfactoiy data transfer had been achieved the “review menu” was 
opened, “list load recordings” selected, followed by, “load from disc C” when the 
trace should have appeared as the most recent recording. If the data had not 
transferred satisfactorily then the data remained on the RAM card and could be loaded 
again to the hard disc.
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2.5.2. 6  Analysing a Trace
The original pressure trace was viewed on screen by selecting the “review” option. 
“Review” menu - “list load recordings”, “list load from Disc C” commands are 
sequenced, and the patient trace was selected and loaded. Changing the time scale 
could then open out the pressure trace. Traces could be viewed in segments of just 
over one second to just over 33 hours. Figures 2.9, 2.10 and 2.11 show traces of 
approximately one minute, 2 hours and 21 hours respectively. The trace was then 
corrected for any zero drift.
Using the “Select page” option at the foot of the screen, the cursor was dragged to the 
beginning of the trace where the time should have corresponded with that noted as the 
start time in the patient diary.
At this point the trace was opened out to 1.03 minutes per page and using the page 
scrolling facilities the first of the in vivo calibrations was brought onto the screen. 
The cursor was then placed on the middle of the zero calibration and the value to the 
right of the screen read the actual measurement which was made at that time (Fig 
2.12). At this stage, if there was any error inherent in the catheter’s calibration 
revealed against the tiue pressure applied in the pressure chamber with the 
sphygmomanometer, then this should now be corrected for.
The CTRL F9 keys were pressed simultaneously and a window appeared on screen, 
showing “Channel normalising procedure”. “Enter value at cursor” appeared and zero 
was entered. Return is then pressed and the menu requested the “Enter the output 
observed output observed for a thousand unit step”.
The error noted against the measured pressure of 50 was then calculated for a unit 
step of 1000 (e.g. a reading of 40 mm against a measured pressure of 50 would have 
required 800 to be entered). Return was then pressed and the “continue” option on the
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bottom line selected and the channel was “normalised”, i.e. corrected for the 
calculated error. The trace was then re-checked at the first and last zero points which 
should have been on the baseline. If this was not the case, then in addition to the 
correction having been inserted, the trace also required to be levelled. The cursor 
was once again placed on the first zero calibration, and the F9 key pressed. The box 
on screen indicated that the channel levelling procedure was being used and that the 
cursor indicated the first point to be included. Return was then pressed and the cursor 
moved to the next zero point, F9 pressed again and so on until the end of the trace. 
Once the last zero had been selected using F9, Shift F9 was pressed and the entire 
trace levelled. At this stage the trace had been coiTected and levelled and was ready 
for analysis (Fig 12.13).
2.5.2.7 Data Analysis
The “analyse” option was selected and from the review menu and “make beat by 
beat” file selected. The programme then analysed the entire trace beat by beat 
removing any artefacts. At the end of this procedure a “beat file” had been created 
and this was stored on the hard drive (Fig 2.14). Once the beat-by-beat file had been 
created the next option “Start new average file” was selected and the procedure 
repeated. In this case the programme selected every 16 beats of information and 
created a new “average file” (Fig 2.15). This was again stored on the hard disc. 
Further analysis was earned out using the “use average data file” option. Where more 
than one recording was made, the second was added to the first using the command in 
the review menu “Add to Average File”.
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2.5.2 . 8  Creating an ASCII File
To create data files for further statistical analysis the “average data file” was 
converted to the ASCII format.
The “use average data” file was selected and this trace appeared on screen. The trace 
was opened out to 1 min. per page and using the “select page” option the cursor 
dragged to the beginning of the trace. Using the mouse the trace was then marked as 
close to the beginning as possible. Using the “select page” option the cursor was then 
dragged to the end of the file and the 2nd point marked at the end of the trace. Under 
the “analyse” option “Create ASCII file” appeared and this was selected. The 
programme then created an ASCII file for the entire average trace and this was stored 
to the hard drive. Figure 2.16 shows the selection of approximately 2 hours of a 
standard trace and the creation of an ASCII file from this segment.
For statistical analysis the ASCII files were imported into an Excel file.
2.5.2.9 Creating an Excel ASCII File
The ambulatory PAP programme was exited and a Microsoft Excel file opened. 
Under the command “Open” the C drive prompt in DOS was highlighted and the PAP 
menu selected. A sub heading of the average file in PAP contained the ASCII files 
which were highlighted. At this stage the file which had just been stored was not in 
the form of an Excel file but a text tabbed delimited file and therefore under the 
“Select files” command was accessed via the “all files” option. The Microsoft 
wizard text import appeared and the commands followed. Once the file had been 
imported it was saved as a Microsoft Excel file and saved to disc.
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At this stage the raw data tracing was stored on the computer hard drive. The “beat by 
beat” file, “average file” and ASCII files were stored in the computer hard drive. The 
ASCII file was also stored as a Microsoft Excel file on the hard drive, and the original 
raw date trace was stored on floppy disc as a ZIP file as was the Excel ASCII.
2.5.2.10 Analysing ASCII Files
The data, which appeared in the ASCII file, was in four columns. The first was an 
indicator of time i.e. 0.664 of a day. The second column was the diastolic pulmonary 
artery pressure - the third column the mean pulmonaiy artery pressure - the 4th the 
systolic pulmonary artery pressure and the 5th indicates whether the event button had 
been pressed by marking one instead of zero.
Conversion to real time from the ASCII file was carried out as follows: the time was 
expressed as a total number of minutes, which was then divided by 1440 minutes 
(i.e. the number of minutes in a day). This gave the time as a decimal representation 
of a day. Therefore, e.g., 14.38 was expressed as 14 x 60 x 24 (+ 38) -f- 1440. Thus 
the timings from the patient recording box could be selected very accurately on the 
ASCII trace. The ASCII traces were then analysed in total or in segments as required.
2.5.2.11 Common Problems Encountered With The Ambulatory Pulmonary Artery 
Pressure Measurement System
Few insunnountable problems were encountered using this system. A recording was 
lost due to transducer failure and another due to phase shift. On one occasion the 
catheter could not be negotiated through the right heart, probably because it was too 
stiff.
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One catheter was found to have a ruptured transducer membrane prior to insertion and 
a second sterile catheter was always available for this eventuality.
Otheiwise most problems occurred during recording and were usually correctable in- 
vivo or (following completion of recording) by manipulation of the trace. Patients 
with COPD occasionally had pressure variation imposed on the waveform by the 
changes in intra-thoracic pressure with respiration caused by their lung disease (Fig 
2.17). This did not interfere with the waveform analysis because of the facility to 
derive average traces.
Phase shift refers to delays in the output signal of the recording system relative to the 
input signal. Relatively small delays in output will lead to significant phase shifts and 
recording errors because of the relationship between phase and frequency. Thus 
certain frequency components of the system must not be delayed in order for the 
signal to be accurately represented. The Gaeltech catheter incorporates a method of 
measurement of the phase response and playback systems which ascertains that signal 
output delay is constant (Levy et al 1986). This permits high fidelity recording 
without significant phase shift. It is not anticipated that phase shift should be a 
significant problem with this recording system based on our experience.
Zero-drift (Chapter 1.5.3.1) occurs most commonly at the beginning of a trace. For 
this reason it is advisable to perform as many in-vivo calibrations as possible at the 
start of a period of recording, as these facilitate accurate coiTcction of the trace at the 
immediate pre-analysis stage. While the majority of these calibrations are performed 
by the investigator while viewing the trace in real time on the computer screen, the 
subject also often did them. This could lead to a greater sense of involvement for 
some of the patients and (because of the sheer number of calibrations achieved by
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motivated individuals) made such traces easier to analyse. During periods of sleep the 
ward nursing staff could calibrate the trace without disturbing the patient.
Zero-drift was rarely significant and never sufficient to require the cessation of a 
record. Where the error exceeded the limit con'ectable by an in vivo calibration 
(>30mmHg) a correction could be applied by interrogating the catheter with the 
computer programme via the recorder. In DOS mode the command PZERO was 
entered followed by the required correction. This was then applied to the catheter and 
the trace could be reviewed on screen; if necessary this procedure could be repeated 
until a satisfactory trace was obtained.
The recording system had sufficient memory to complete 24 hours of recording 
without inteiTuption. Where this was not possible (e.g. in patients with tachycardia) 
the recording box display indicated that the memory usage was approaching 1 0 0 % 
and the recording had to be stopped. The data was then downloaded and then 
recording recommenced. This caused no inconvenience to the patient other than the 
need to increase the frequency of in-vivo calibrations at the start of the new recording. 
Exercise testing was carried out towards the end of the recording period and was 
relatively demanding of memory. Where any doubt existed about sufficient remaining 
capacity it was essential that a new recording be started to avoid data loss.
The correction of traces prior to analysis is described in Chapter 2.5.2.6. Using these 
procedures it was possible to achieve accurate analysis of all traces. Each catheter had 
an individual serial number, which was recorded with each 24 hour trace. This would 
have allowed the identification of any recuiTing faults with a particular device though 
no such problems were found in the work in this thesis.
In conclusion the ambulatory pulmonary artery pressure measurement system used in 
this thesis proved robust and reliable and did not lead to data loss. This was
123
particularly important when the technique required patients to be subjected to invasive 
procedures.
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Chapter 3
Changes in Pulmonary Artery Pressure with Posture in a Group of 
Patients with Connective Tissue Disease
3.1 Introduction
In Chapter 1.5.4 it was shown that interest in ambulatory pulmonary artery pressure 
monitoring in cardiac disease developed because of a desire to relate symptoms and 
haemodynamic changes. Pulmonary hypertension can complicate many diseases of 
the heart or lungs but there has been debate about its role in the mortality and 
morbidity of patients with primary lung disease. We have little understanding of the 
epidemiology of pulmonary hypertension in these conditions because, unlike the 
systemic circulation, there is no easily applied sphygmomanometer for the pulmonary 
circulation. Consequently the development of pulmonary hypertension can be missed 
in the early stages and its progression can be difficult to monitor. The currently 
available methods of measurement in the pulmonary circulation have some 
disadvantages. Echocardiography may be non-invasive, accurate and repeatable, but 
gives only an estimate of systolic pressure at rest or on limited exercise and can be 
technically difficult in some patients, especially those with COPD. Cardiac 
catheterisation with fluid filled eatheters has long been considered to be the gold 
standard but the position (lying supine on the catheter table) and the circumstances (at 
rest) during which the measurements are made may not reflect the situation in which 
an individual experiences symptoms.
In an attempt to overcome this difficulty, some authors have exercised patients while 
catheterised to reveal changes in pulmonary haemodynamics apparent only with 
increased cardiac output. However, even when measurements are made on exercise, 
the catheterisation procedure allows measurements to be made only over a short 
period of time and may not give information which represents accurately the pressures 
experienced during normal activities such as exercise and change in posture. 
Furthermore, cardiac catheters of the Swan Ganz type do not measure instantaneous
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pressures, the signal obtained may be damped by the fluid filled lumen (Grossman 
1980), and it is difficult to maintain the necessary fixed relationship between the 
position of the external transducer and the right atrium.
This thesis attempts to address some of these difficulties by using (for the first time in 
this group of patients) a micromanometer tipped pulmonary artery catheter which can 
continuously record PAP in various postures and during different activities without 
loss of accuracy, and can make recordings for 24 hours. This allows collection of data 
of possibly greater relevance to the circumstances in which patients are likely to 
experience symptoms such as on exercise.
This chapter addresses whether there are significant variations in PAP with changes in 
posture and exercise in patients with pulmonary hypertension. To examine this 
hypothesis, the variations in PAP over 24 hours were studied, both at rest and on 
exercise, in a group of patients with connective tissue disease.
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3.2 Methods
3.2.1 Patient Group
All 6  patients described in this chapter had connective tissue disease, as defined by 
imniunopathological patterns, with antibody profiles suggestive of the categories 
stated in Table 3.1. 5 had progressive systemic sclerosis (3 with CREST variant - 
calcinosis, Raynaud's phenomenon, oesophageal dysmotility, sclerodactyly, 
telangectasia-), and one had systemic lupus erythematosis. There were 2 men and 4 
women of mean age 58 years (range 31-68). This study did not include a control 
group as the invasive nature of the investigation would have made this ethically 
difficult.
Written informed consent was obtained for all patients. The study was approved by 
the West Glasgow Hospitals University NHS Trust Ethics Committee.
3.2.2 Measurements
All patients underwent pre-catheterisation investigations as described in Chapter 
2.1.2. These included a chest radiograph, electrocardiogram, pulmonaiy function 
tests, echocardiography, and a CT scan of the thorax to exclude other causes of 
secondary pulmonary hypertension. Parenchymal lung disease was excluded using 
high resolution CT scanning. Pulmonary artery systolic pressure was estimated from 
Doppler measurements. A symptom limited exercise test was also performed.
3.2.3 Cardiac Catheterisation
Conventional cardiac catheterisation described in this chapter was carried out as 
described in Chapter 2.4. Pressure measurements for comparison with the other
128
I
î
0
1fVi
yII
p .
0
1SIIII8
HI
w
I
0
10
1
w to
s
t - r j
a\oo ONO N
'T l
m
Md0000
hd0000 I 0000
oo
O N
1 ?
to
O N O N
' OO O
O N
LA
' Obo
H *
yiCl
wCl 00
U\
wNO
4L^A
L Ao
O N
to >
LJ - t ^L A - O
gI
s
o
gL• 3 :
I .K
îi
R.
H&cT
u >
toMD
systems were made in the proximal pulmonary artery. Pressure values were recorded 
while patients breath held at functional residual capacity (to eliminate the effects of 
respiration on PAP). A mean of 6  beats was recorded and systolic and diastolic 
pressures were averaged.
3.2.4 Ambulatory PAP Monitoring
Ambulatory pulmonary artery pressure monitoring was carried out using a 7 F  
catheter supplied by Gaeltech Ltd (Dunvegan, Isle of Skye, UK) as described in 
Chapter 2.5.
The micromanometer tipped pulmonary artery catheter was left in situ for 24 hours. 
During this period the patient carried out normal daily activities in addition to a 
number of pre-set postural manoeuvres performed according to instructions from the 
investigator. These consisted of periods of 10 minutes each of lying awake, sitting, 
and standing in that order, perfomied 2-4 hours after returning from the cardiac 
catheterisation laboratory. During the final hour of data recording, on the second day, 
a second exercise test was carried out with the catheter in situ.
3.2.5 Echocardiography
Echocardiography data were obtained as described in Chapter 2.2.1. The same 
operator made echo measurements in all cases 24 hours in advance of cardiac 
catheterisation, so the operator was ignorant of the "true" PAP. It was not possible 
logistically to make simultaneous measurements with echo Doppler and the 
micromanometer tipped pulmonary artery catheter.
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3.2.6 Cardiopulmonary Exercise Testing
Exercise testing was performed as described in Chapter 2.2.2. An exercise test was 
carried out before cardiac catheterisation and repeated with the micromanometer 
tipped pulmonary artery catheter in situ. Initially patients perfoiined a maximal 
exercise test on the cycle ergometer. During the repeat exercise test patients were 
exercised under steady state conditions at 30% of the maximum oxygen uptake 
(VOzmax) achieved in the initial test. This workload was chosen as likely to be 
manageable for sustained exercise in this patient group as constant work rate testing is 
preferable to maximal testing for the measurement of cardiovascular, ventilatory and 
gas exchange kinetics (Chapter 2.2.3). This workload was not used in subsequent 
studies because it was felt that reproducibility and repeatability, in addition to 
comparisons between patients, would be improved by steady state exercise at the 
same defined workload for each patient (i.e. 30 watts). The exercise data presented 
are the mean pressures recorded at the onset of the fourth minute of steady state 
exercise. Figure 3.1 shows an exercise trace recorded with the micromanometer 
tipped pulmonary artery catheter.
3.2.7 Data Recording, Handling and Analysis
Data were recorded and processed as described in Chapter 2.5.1.
3.2.8 Patient Diary
An important component of the recording system described in the present chapter is 
the patient diary. This consisted of a simple paper record of time and current activity 
plus a note of when calibrations were made and the event button pressed. This diaiy
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was compared with the pulmonary artery pressure trace to relate patient activity or 
posture with haemodynamic changes,
3.2.9 Statistics
All results reported in this chapters are presented as mean (±SD) unless otherwise 
stated. Differences between grouped mean pulmonary artery pressures measured in 
different postures were examined by analysis of variance (ANOVA) calculations, a p 
value of 0.05 being regarded as statistically significant.
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3.3 Results
3.3.1 Baseline Investigations
Baseline investigations are shown in Table 3.1. Pulmonaiy function tests revealed 
virtually normal spirometric values with a mean forced expiratory volume in 1 second 
(FEVi) of 86.9% predicted but marked impairment in gas transfer, carbon monoxide 
transfer coefficient (KCO) 0.93 (0.4) mmol/min/kPa/1, 57.8% predicted (range 11.8- 
80.6). All of the 5 patients who were able to complete a cardiopulmonary exercise test 
demonstrated impaired exercise responses (mean VOimax^ 50.6% predicted, range 
17-58).
3.3.2 Measurement of Resting PAP by Three Methods
A comparison of values obtained using three methods of measurement of PAP is 
shown in Table 3.2. Systolic PAP measured by echocardiography and 
micromanometer tipped pulmonary artery catheter is compared with systolic PAP 
obtained using the fluid filled catheter in Figure 3.2. There was no significant 
difference between the values obtained for systolic PAP using these tlnee methods.
3.3.3 Heart Rates
Heart rates were obtained from the 24-hour recordings and are shown in Table 3.3. 
The expected increase with exercise and fall during sleeping was observed.
3.3.4 Ambulatoiy PAP Recording
Ambulatory PAP was measured over 24 hours in all subjects and the results are 
shown in Table 3.3 and Figure 3.3. Changes in PAP on exercise were not predicted by
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Table 3.2
Patient no. Echo systolic PAP 
(mmHg)
Catheter 
laboratory systolic 
PAP (mmHg)
Ambulatory 
catheter systolic 
PAP (mmHg)
1 40 34 37
2 70 65 59
3 6 8 90 1 0 1
4 8 8 90 117
5 1 0 0 85 98
6 70 90 99
Mean (±SD) 72.7 (20.4) 75.8 (22.6) 85.2 (30.4)
Table 3.2 Individual Values of Systolic PAP Measured by Three Techniques
Values shown are systolic PAP for each patient while lying awake measured by three 
techniques
• Doppler echocardiography (Echo)
• Cardiac catheterisation with fluid filled catheter (Catheter laboratory)
• Micromanometer tipped pulmonaiy artery catheter (Ambulatory catheter)
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Figure 3.2
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Figure 3.2 Comparison of Three Methods of Measurement
Differences in the values obtained for systolic PAP by Doppler 
echocardiography and micromanometer tipped pulmonary artery catheter 
from the values obtained by the fluid filled catheter. The differences 
between the three techniques are not significant.
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Figure 3.3 PAP by Posture for each Subject
The mean PAP recorded by the micromanometer tipped pulmonary artery 
catheter, for each subject, for a period of 24 hours. Pressures were recorded for 
each posture for a period of 10 minutes. The exercise values were obtained at 
the beginning of the 4^*^ minute of steady state exercise.
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resting values of PAP. A higher PAP occurred while lying awake than when sitting or 
standing. There were significant variations in mean PAP for the group between 
different postures compared with lying awake (Figure 3.4). Lying awake was chosen 
for this comparison because it is the position in which conventional measurements are 
made.
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Figure 3.4
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Figure 3.4 GroupMean PAP by Posture
Mean PAP recorded with the micromanometer tipped pulmonary artery catheter for 
the group of subjects averaged over 24 hours and for each posture over 10 minutes. 
The exercise values were obtained at the onset of the 4'^  minute of steady state 
exercise. The asterisks indicate that the values are significantly different from the 
measurement lying awake. 140
3.4 Discussion
This chapter has shown that ambulatory 24 hour PAP monitoring in patients with 
connective tissue disease is feasible in the clinical setting. The data indicate that PAP 
varied with different postures and activities and that mean PAP in these patients fell 
on sitting up or standing compared with lying awake. Only five patients were able to 
complete exercise tests; this small number makes it virtually impossible to draw 
meaningful statistical conclusions and the results must be interpreted with caution as 
the possibility of type II errors arises. However trends in the exercise results may be 
observed.
While it may not be surprising that a physiological variable such as pulmonary artery 
pressure changed over 24 hours, these variations have not been measured previously 
in such patients.
In mild pulmonary hypertension (such as in the group studied) PAP measured lying 
awake equalled exercise pulmonary artery pressure and exceeded the mean total 
pulmonary artery pressure over 24 hours. Within the limitations of the 
micromanometer tipped pulmonary artery catheter measurement system we were not 
able to explain this phenomenon. It was consistently observed in all subjects therefore 
seemed to be real.
"Lying awake" was chosen as the baseline measurement for comparison with the 
other postures because it is the position in which conventional pressure measurements 
are usually made. It was observed that the change in PAP seen on exercise was not 
predicted by the resting PAP (measured lying awake) in this group of patients with 
varying levels of pulmonary hypertension. The patient group in this chapter had 
reduced exercise tolerance compared with that predicted (Table 3.1). A number of 
explanations have been proposed for this.
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Previous work in patients with connective tissue disease using Doppler 
echocardiography has shown reduced exercise capacity, thought to be due in part to a 
rise in pulmonary vascular resistance on exercise (Winslow et al 1993). Other authors 
have highlighted the importance of pulmonary artery haemodynamics during exercise 
and the consequent increase in right ventricular workload in patients with primary 
pulmonary hypertension (Laskey et al 1993). The data presented in this chapter 
suggest that, not only are there significant variations in pressure with exercise, even in 
patients with only mild resting pulmonary hypertension, but there are also pressure 
variations during normal daily activity. This may indicate that the stresses faced by 
the right ventricle over a 24 hour period may also vary considerably and that 
conventional methods of measurement of PAP may underestimate this variation. A 
number of issues arise from these observations;
(1) PAP while lying awake is higher than when measured sleeping in the same 
position.
(2) PAP falls on adopting a sitting or standing posture.
(3) PAP variation appears to be due to changes mainly in systolic, and hence pulse, 
pressure.
(4) PAP at rest does not predict the change in PAP on exercise.
3.4.1 PAP Lying Awake
The higher values of PAP when lying awake compared with lying asleep suggest that 
the former may not truly reflect the basal state. Values when lying awake were always 
measured after at least 1 0  minutes at rest and this position was the first of the series of 
postures in which measurements were made after return to the main ward from the 
cardiac catheterisation laboratory. During the lying awake manoeuvre patients were
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observed continuously and were discouraged from moving or speaking. At night they 
were asked to lie flat with the identical number of pillows as had been in place when 
lying awake, and were cheeked hourly by the nursing staff (when performing in vivo 
calibration of the catheter) who noted whether the patients were asleep or not. Despite 
these precautions, in the absence of continuous EEG monitoring it is not possible to 
say that these patients were asleep throughout the night.
3.4.2 Change in PAP with Posture
Micromanometer tipped catheter values also show a fall in PAP on sitting or standing. 
Doppler echo values (obtained in the semi-recumbent position) were also lower than 
the fluid filled catheter baseline values, but the Doppler measurements were not 
repeated in the lying position. This observation has been reported previously by 
Brecker et al (1994) who found that, in patients with severe pulmonary hypertension, 
Doppler echocardiography consistently underestimated systolic PAP by 20% when 
compared with high fidelity pulmonary artery catheters. Though Doppler values were 
lower in the results presented in this chapter, they were not significantly so, possibly 
because this patient group had milder pulmonary hypertension.
These differences may be explained by the fact that these two techniques are 
measuring different things; however, the lower values measured with Doppler 
echocardiography may be due to decreased venous return on sitting or standing, with a 
subsequent fall in right ventricular filling pressure, cardiac output and hence PAP. 
Systolic pressure measured lying awake with the micromanometer tipped pulmonary 
artery catheter compared with the fluid filled pulmonary artery catheter in the same 
position was not significantly different. The values with the solid catheter were 
slightly higher; while this may be due to differences in the way these systems actually
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measured pressure these measurements were not simultaneous. In all cases the 
micromanometer tipped pulmonary artery catheter measurements were made towards 
the end of the cardiae catheterisation by which time the patient had undergone a 
number of measurements and manoeuvres (e.g. exercise) and it is possible that the 
pressure measurement was affected by this.
3.4.3 Change in PAP with Exercise
PAP at rest did not predict changes in PAP with exercise in this group of patients. 
This is unlike the situation in patients with moderate or severe pulmonary 
hypertension in whom such a relationship is described (Reeves 1984). This anomaly 
may be due to the fact that the exercise workload at which pressures were measured 
differed between the subjects presented here.
Patients with similar lung function often have markedly dissimilar exercise tolerance 
and it may be that these differences exist because of variation in the response of the 
pulmonary circulation to increased cardiac output.
If the pulmonary circulation cannot accommodate the increased cardiac output of 
exercise by vasodilating or by recruiting additional vessels then the right side of the 
circulation is unable to transmit the additional venous return to the left side. This 
effectively places a brake on the increase in cardiac output required to respond 
adequately to the exercise stimulus. This leads to a slowing in the rate of rise of VO2 
and (because heart rate continues to increase despite this) a failure of O2 pulse to rise 
on exercise. Patients with pulmonary vascular disease have a high physiological dead 
space to tidal volume ratio (V d /V t )  and a positive value for arterial -  end-tidal PCO2 
difference (P(a-Er) CO2) suggesting poor perfusion of ventilated air spaces. Other 
abnormalities present where the main abnormality lies in the pulmonary circulation
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include shortening of the red cell transit time due to loss of the pulmonary capillary 
bed, and the development of metabolic acidosis on exercise rather than the respiratory 
acidosis which accompanies respiratory disease on exercise. For these reasons 
limitations in exercise tolerance in patients with pulmonaiy vascular disease cannot be 
reliably predicted from resting measurements (Wasserman et al 1999).
Resting pulmonary artery pressures in patients with mild pulmonary hypertension may 
not be predictive of exercise induced changes in PAP; if so then earlier diagnosis of 
the development of changes in the pulmonary vasculature may be possible using the 
micromanometer tipped catheter than is the case with conventional methods of 
measurement.
In the 1980s there was a move away from single "office" readings of systemic blood 
pressure to the development of simple non-invasive systems for the measurement of 
24-hour ambulatory systemic blood pressure as described in Chapter 1.4. The 
technique described in this chapter is not likely to gain widespread acceptance in the 
investigation of the pulmonaiy circulation because of its cost and invasiveness. 
However as a research tool it does offer a similar advantage to ambulatory blood 
pressure monitoring in the systemic circulation in that it can provide data about 
pressure in relation to daily activity and symptoms. The mean PAP over 24 hours can 
be accurately calculated and some additional insight gained into the chronic 
haemodynamic load faced by the right ventricle. This may allow the earlier 
identification of individuals at greater risk of subsequent right ventrieular failure and 
consequently those with a poorer prognosis.
The advantages of ambulatory PAP measurement may also be relevant in the 
assessment of response to treatment. At present there is no completely selective 
pulmonary vasodilator and there continues to be debate about the appropriateness of
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treatment in secondary pulmonary hypertension. There is, however, considerable 
evidence to support the use of vasodilators in primary pulmonary hypertension (Rubin 
et al 1993). Objective assessment of responses to these treatments will be required 
and, in addition to the information which may be gained by conventional catheter 
laboratoiy measurements of the pulmonary circulation, the micromanometer tipped 
pulmonary artery catheter described in this chapter can add measurements of 24 hour 
variations in PAP and the changes seen on exercise, and so possibly present a friller 
picture of the continuing stresses faced by the right ventricle as well as responses to 
treatment. Furthermore, it is likely that treatment may be more effective early in the 
development of pulmonary vascular changes when single resting measurements may 
be normal (Salvaterra et al 1992) and the PAP response to exercise may reveal that 
these changes are taking place.
This chapter demonstrates some of the strengths and weaknesses of this technique in 
the assessment of the pulmonary circulation in patients with connective tissue disease. 
Although ambulatory monitoring of PAP has been extensively used in patients with 
heart failure and coronary artery disease (Chapter 1.5.4) it had not been used 
previously in patients with pulmonary vascular disease secondary to connective tissue 
disease and larger numbers of patients are required to assess its future role. However, 
ambulatory pulmonary artery pressure monitoring may have additional advantages 
alongside conventional systems in the assessment of the pulmonary circulation.
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Chapter 4
Ambulatory PAP Monitoring During Sleep and Exercise in Normal 
Individuals and Patients with COPD
4.1 Introduction
In Chapter 3 it was shown that ambulatory pulmonary artery pressure monitoring 
provides useful data which is not obtainable using conventional methods of assessment of 
the pulmonary circulation. Furthermore it was suggested that conventional cardiac 
catheterisation has limitations which restrict its usehdness in certain patient groups. This 
is particularly tme of COPD when, furthermore, echocardiography can be technically 
difficult. Pulmonary hypertension is a common complication of COPD and when severe 
implies a poor prognosis (Weitzenblum et al 1981). The signs and symptoms of COPD 
can be overwhelming and accurate measurement of pulmonary hypertension requires a 
cardiac catheter. Hence it is often difficult to diagnose and quantify secondary pulmonary 
hypertension and its role in morbidity of COPD is poorly understood. PAP may rise 
during sleep or exercise in patients with COPD (Riley et al 1948 and Boysen et al 1979). 
When this rise on exercise is excessive the future development of resting pulmonary 
hypertension is likely (Weitzenblum et al 1996). It has been shown that other routine 
daily activities are associated with a reduction in oxygen saturation in patients with 
COPD but nonnal resting saturations (Soguel Schenkel et al 1996) but the 
haemodynamic significance of this is more difficult to quantify. Conventional 
measurement of PAP is difficult during sleep, exercise or in ambulant patients, because 
of the nature of conventional fluid filled pulmonary arteiy catheters and in particular their 
dependence on external transducers. Chapter 3 described the use of a micromanometer 
tipped pulmonary artery catheter and data recording system to make continuous 
pulmonary artery pressure recordings in patients with pulmonary hypertension secondary 
to connective tissue disease.
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In this chapter the use of this system to provide accurate measurements of PAP during 
daily activity, sleep or exercise in patients with COPD is described, thus providing 
information about the total haemodynamic burden faced by these individuals.
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4.2 Methods
4.2.1 Patient Group
10 subjects were studied (5 male, 5 female) with a mean (±SD) age of 61 (±8 ) and an age 
range of 43-69 years. 5 patients had COPD defined as irreversible airflow obstruction as 
determined by their lung function testing (Table 4.1) and were receiving long-tenn 
oxygen therapy (LTOT) and 5 were normal. The latter group was referred with suspected 
pulmonaiy hypertension, usually because of misleading screening investigations (such as 
overestimation of PAP by echocardiography in 4 cases) or because of a strong clinical 
suspicion of pulmonary hypertension despite normal non-invasive tests of PAP. All of 
these patients had had alternative cardiac or pulmonary causes for their symptoms 
excluded by the referring hospital. In this group, where repeat screening investigations 
were normal, ambulatory pulmonary artery pressure measurement was performed to 
exclude exercise induced pulmonary hypertension.
Noimal subjects were defined as those in whom there was no evidence of COPD or of 
pulmonary hypertension, neither in the cardiac catheterisation laboratory nor after 24 
hours of ambulatory pulmonary arteiy pressure monitoring. All patients in the noimal 
group had normal lung function and oxygen saturation. No alternative end diagnosis was 
reached in any of these patients.
Written informed consent was obtained for all patients. The study was approved by the 
West Glasgow Hospitals University NHS Trust Ethics Committee.
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4.2.2 Measurements
All patients were referred for further investigation of suspected pulmonary hypertension 
and all underwent pre-catheterisation investigations as described in Chapter 2.2. These
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Table 4.1
COPD Normals
A^e 62 (3.9) 60 (11.4)
PAP 
(Cath. Lab.)
44.4 (5.5) 16.2 (4.3)
PVR 
(Woods Units)
5.5 (1.8) 1 . 6  (0 .6 )
PAP
(mmH^)
Mean total 50 (5.0) 13.8 (6.0)
Rest 55.9 (10.2) 14.8 (3.8)
FEVi
(Litres)
0.99 (0.31)
FVC
(Litres)
2.24 (0.90)
Sp02%  
(on air)
79 (3.44)
Table 4.1 Patient Demographics and Resting Haemodynamics.
Patients were breathing oxygen during the first period of sleep and air during the 
second period. Normals were breathing air throughout. Rest refers to sitting at rest. 
Normals had normal lung function. All values are means.
PVR- pulmonary vascular resistance (Wood’s Units)
PAP-pulmonary artery pressure 
Sp02-oxygen saturation
Cath. Lab.-mean PAP measured supine in the cardiac catheterisation laboratory. 
(±SD)- values in parentheses are standard deviations
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included a chest radiograph, electrocardiogram, echocardiography and pulmonary 
function tests. A steady state exercise test was performed.
4.2.3 Cardiac Catheterisation
Conventional cardiac catheterisation was carried out as described in Chapter 2.4. Pressure 
values were recorded while patients breath held at functional residual capacity (to 
eliminate the effects of respiration on PAP). A mean of 6  beats was recorded and systolic 
and diastolic pressures were averaged.
4.2.4 Ambulatory PAP Monitoring
Ambulatory pulmonary artery pressure monitoring was carried out as described in 
Chapter 2.5. The catheter was left in situ for 24 hours.
Both groups had pulmonary artery pressure continuously measured during sleep in two 4 
hour periods, from midnight to 4 am and from 4 am till 8  am. The COPD group was 
given continuous oxygen at their usual flow rate for the first period and remained off 
oxygen for the second period. Ward nursing staff were asked to confirm that the patients 
were asleep at the stated times.
4.2.5 Echocardiography
Echocardiography was carried out as described in Chapter 2.2.1. Data was obtained 
between 24 and 36 hours prior to cardiac catheterisation. Where echo measurements did 
not confirm pulmonary hypertension, ambulatory pulmonary artery pressure monitoring
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was carried out to confirm normal resting PAP and to exclude exercise induced 
pulmonary hypertension.
4.2.6 Exercise Testing
All patients were exercised breathing air as described in Chapter 2.2.2.
A steady state workload of 30 watts was chosen because this was believed to be 
manageable for the patients with COPD and likely to allow reproducible and repeatable 
exercise data to be obtained by standardizing exercise protocols at this achievable 
workload.
4.2.7 Data Recording, Handling and Analysis
Data was recorded and processed as described in Chapter 2.5.1. Mean PAP during sleep 
was measured for the middle 2 hours of each nocturnal period. Exercise PAP 
measurements are the average, mean pressure recorded over 1 minute from the onset of 
the 4‘*' minute of steady state exercise.
4.2.8 Statistics
All data are expressed as mean ± standard deviation (SD) with 95% confidence intervals 
(Cl) for all significant differences, unless otherwise stated. Statistieal testing was by 
paired t-test. A p value of < 0.05 was considered to be statistically significant.
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4.3 Results
4.3.1 Baseline Investigations
Baseline investigations for the control group were normal and are not shown. Pulmonary 
function tests for the COPD group were abnormal. Table 4.1.
The mean FEVi was markedly reduced, 0.99L (±0.31) as was resting oxygen saturation 
(Sp0 2 ) breathing air, SpOz 79% (±3.44). These results reflected severe airflow obstmction 
in a group of patients receiving LTOT. Mean oxygen saturation measured asleep 
breathing air was 79% for the COPD group (Table 4.1) and remained above 92% for the 
normal group. Mean oxygen saturation measured asleep breathing oxygen was 90% for 
the COPD group and remained above 92% for the normal group. These results were 
recorded by nursing staff.
4.3.2 Mean PAP Measured in the Catheter Laboratory
• Group mean PAP in inmHg was 44.4 (±5.5) for the COPD group and 16.2 (±4.3) 
for the normal group. Table 4.1.
4.3.3 Mean PAP over 24 hours
• Group mean PAP in mmHg for the 24 hour period of pressure recording was 50.0 
(±5.0) for the COPD group and 13.8 (±6.0) for the normal group. Table 4.1
4.3.4 Mean PAP at Rest
• Group mean PAP in mmHg sitting at rest was 55.9 (±10.2) for the COPD group and
14.8 (±3.8) for the normal group. Table 4.2.
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4.3.5 Mean PAP During Sleep
• Group mean PAP in mmHg for the COPD group was 59.8 (±8.1) asleep off oxygen 
and 50.8 (±5.5) asleep breathing oxygen. Table 4.2.
• Group mean PAP in mmHg for the normal group was 14.6 (±5.9) for the first 
nocturnal period and 14.6 (±7.0) for the second nocturnal period. Table 4.2.
4.3.6 Mean PAP During Exercise
• Group mean PAP in mmHg for the COPD group during exercise was 59.0 (±10.7).
• Group mean PAP in mmHg for the normal group during exercise was 17.0 (±4.0).
4.3.7 Within Group Comparison - COPD Group
• PAP asleep on oxygen is significantly lower than PAP asleep breathing air: mean 
difference (±SD) = 9.6 mmHg (5.32) (95% Cl 4.9-14.3) p= 0.016 (Table 4.2) (Fig
4.1).
• PAP asleep breathing air remained significantly greater than 24 hour mean PAP: 
difference 9.8 mmHg (95% Cl 0.2-19.4) (p<0.05). Figure 4.1.
• PAP during exercise is not significantly different from PAP asleep breathing air: 
mean difference (±SD) = 0.8 mmHg (8.9) (95% Cl -7.0-8.6 ) p= 0.851 (Table 
4.2.) (Fig 4.1).
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Figure 4.1
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Figure 4.1 Mean PAP in Normals and Patients with COPD
Mean PAP for the COPD group and the normal group is shown during each activity. 
For the COPD group PAP was significantly lower breathing oxygen compared with 
air (* = p< 0.05)
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4.3.8 Within Group Comparison -  Normal Group
• PAP asleep breathing air for period 1 was not different from PAP asleep breathing 
air for period 2: mean difference 0.0 (2.4) (95% Cl -2.1-2.1) p= 1.000, (Table 4.2) 
(Fig 4.1).
• PAP during exercise is not significantly different from PAP asleep breathing air; 
mean difference (±SD) = 3.3 mmHg (2.2) (95% Cl 1.1-5.5) p= 0.061. (Table 4.2) 
(Fig 4.1).
4.3.9 Comparison between COPD and Noimal groups
• Asleep on oxygen versus asleep on air for the COPD group compared with asleep 
on air for the noimal group is significantly different: mean difference (±SD) = 7.6 
mmHg (5.6) 95% Cl 2.7-12.5) p= 0.039.
• Exercise versus asleep on air for both groups is significantly different: mean 
difference (±SD) = 5.0 mmHg (2.71) (95% Cl 2.3-7.7) p= 0.034.
The PAP trace obtained from a patient with COPD during sleep is shown (Fig 4.2). This 
demonstrates the rise in PAP during sleep breathing air, which is abolished by breathing 
oxygen.
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4.4 Discussion
This chapter has shown that patients with COPD receiving LTOT tolerate invasive 
haemodynamic assessment, including ambulatory pulmonary artery pressure monitoring 
and can safely perform cardiopulmonary exercise testing at a low workload. The number 
of patients discussed is small due to the difficulties encountered in recruiting frail patients 
in respiratory failure for invasive haemodynamic monitoring but nevertheless significant 
changes in haemodynamics were observed.
Previous studies of PAP in COPD have demonstrated that values are modestly elevated 
and progression slow (Weitzenblum et al 1979). However most of these measurements 
have been of resting pressure which has been shown to be of relatively poor prognostic 
value (Report of the Medical Research Council Working Party 1981). Furthermore it has 
also been shown that even routine daily activities in patients with mild COPD and noimal 
resting oxygen saturations are associated with reductions in oxygen saturation (Soguel 
Schenkel et al 1996).
This chapter reports the measurement of PAP in a variety of situations in patients with 
respiratory failure receiving long-term oxygen therapy and the higher levels of PAP 
observed are therefore not surprising. These results demonstrate that patients with COPD 
receiving long-term oxygen therapy have levels of PAP, which are significantly higher 
than those of a control group when measured over 24 hours. These patients also have 
significantly higher PAP when the periods of sleep or exercise are excluded i.e. when 
performing normal daily activity breathing supplementary oxygen. Specific activities of 
daily living were not defined prior to these studies therefore this data is not presented. 
When studied during sleep without oxygen, the COPD group has a further rise in PAP,
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which is greater than that measured on exercise and which is abolished by breathing 
oxygen during sleep. Others have previously reported increased pulmonary vascular 
resistance during REM sleep and the beneficial effects of oxygen in patients with 
moderate pulmonaiy hypertension and severe COPD (Fletcher and Levin 1984). 
However the extent of these rises compared to those seen during other activity has not 
been studied.
The normal group did not show any change in PAP during sleep (which is not surprising) 
nor did they demonstrate a significant rise during exercise as others have predicted (Riley 
et al 1948). This is probably because the workload chosen for the exercise test (30 watts) 
was too low to sufficiently stress the pulmonary circulation of normal individuals. 
Furthermore there was no variation in this group’s PAP during normal daily activity. 
There is no increase in pulmonaiy artery pressure on exercise compared with asleep 
breathing air in either within group comparison (section 4.3.7 and section 4.3.8 and table
4.2). In the COPD group this may have been due to restricted exercise capacity limiting 
the rise in pulmonary artery pressure combined with higher than expected pulmonary 
artery pressure asleep breathing air: in the normal group there was trivial rise in 
pulmonary artery pressure on exercise which was not significantly different from the 
pulmonary artery pressure measured during sleep.
The number of patients with COPD in this chapter is small and therefore it is difficult to 
reach firm conclusions. However, for these individuals, the rise in PAP seen during sleep 
may be an important contribution to the overall work facing the right heart and 
constitutes at least as great a haemodynamic burden as low level exercise.
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This chapter has shown considerable variations in PAP during 24-hour ambulatory 
monitoring with normal daily activity, on exercise and during sleep and this may have 
implications for the way COPD is assessed. Measurement of PAP is difficult in ambulant 
patients because of the restrictions inherent in conventional cardiac catheterisation and 
may be unrepresentative because of the circumstanees in which these are made i.e. at rest 
in the laboratory. Furthermore non-invasive measurement with echocardiography in 
COPD patients is often limited by the poor signal obtained.
The technique of ambulatory pulmonary artery pressure monitoring described in this 
chapter allows the time eourse and extent of rises in PAP to be measured and correlated 
with symptoms in patients with severe COPD cariying out normal daily activities.
Such knowledge of the pulmonary circulation under stress or during sleep in patients with 
COPD may be useful in assessing the contribution of pulmonary hypertension to overall 
morbidity and mortality. Transient rises in PAP have been observed and quantified 
during sleep and exercise during ambulatory monitoring in the hospital environment in 
patients treated with LTOT. It is possible that similar elevations in PAP may also be 
important in patients with milder COPD, which might have implications for future 
interventions.
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Chapter 5
PAP Measurement During Exercise in Patients with Suspected 
Pulmonary Hypertension
5.1 Introduction
Chapter 4 has shown the usefulness of ambulatory pulmonary artery pressure 
monitoring to the study of sick patients with COPD and allowed measurement of PAP 
during sleep and exercise. In both cases this data about PAP would not have been easy 
to obtain using conventional methods of assessment.
Conventional methods of measurement in the pulmonary circulation may be invasive 
or non-invasive. Cardiac catheterisation with fluid filled, pulmonary artery catheters 
remains the gold standard method of haemodynamic measurement and is usually 
performed in supine patients at rest.
In the past secondary pulmonary hypertension has not been regarded as an important 
target for therapy and therefore few patients required multiple haemodynamic 
measurements. It is now realised that secondaiy pulmonary hypertension is relatively 
common and is a particular problem in connective tissue disease (Battle et al 1996). 
Furthermore, new treatment options are available and Prostacyclin and its derivatives 
have been shown to be beneficial long-term therapy for some patients (McLaughlin et 
al 1998), including those with severe pulmonary hypertension in association with 
connective tissue disease (De La Mata et al 1994 and Humbert et al 1998). Thus 
many more patients now require repeated haemodynamic assessment.
While cardiac catheterisation remains the assessment of ehoice, the increased demand 
on existing facilities suggests that additional methods of measurement might be 
useful.
Of particular interest in the study of the vasoreactivity of the pulmonary circulation is 
its response to the demands of exercise, when patients often report symptoms, and 
when abnormal levels of PAP may predict the subsequent development of pulmonary
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hypertension (Weitzenblum et al 1996). Exercise testing of the pulmonary circulation 
can be performed with fluid filled, pulmonary artery catheters in the cardiac 
catheterisation laboratory (Ikram et al 1984), or alternatively by Doppler 
echocardiography (Winslow et al 1993) but there are technical difficulties inherent in 
both techniques.
Patients with pulmonary vascular disease often have limited exercise tolerance. This 
may be partly due to their prolonged adaptation to, and recovery from, exercise 
because of the limitations to blood flow imposed by the central circulation. This 
results in a reduction in oxygen uptake (VO2) despite a greater than normal increase in 
ventilation (VE). Such patients have an oxygen deficit (i.e. require to perform work 
using preformed energy sources) and therefore perform exercise at a biological 
disadvantage (Sietsma 1992).
Ambulatory pulmonary artery pressure monitoring allowed measurement of gas 
exchange variables and PAP simultaneously during cardiopulmonary exercise testing 
in a group of patients with suspected pulmonary hypertension.
Correlations were sought between gas exchange variables and pulmonary artery 
pressure, measured simultaneously during cardiopulmonary exercise testing to assess 
whether these variables might then merit further study as potential non-invasive 
surrogate markers of the PAP response to exercise.
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5.2 Methods and Equipment
5.2.1 Patient Group
This investigation was approved by West Glasgow Hospitals University NHS Trust 
Ethics Committee and all patients gave written, informed consent.
10 patients were studied of whom 7 had eonnective tissue disease, as defined by 
immunopathological patterns. (2 with CREST syndrome, 3 with positive 
autoantibodies and an undefined connective tissue disease, 1 with rheumatoid arthritis 
and 1 with features suggestive of a Scleroderma / Systemic Lupus Erythematosis 
overlap syndrome). Three had presumed PPH according to NIH criteria. There were 7 
female and 3 male patients with mean age of 49 years (range 25-69 years). Table 5.1. 
All patients were considered capable of exercise at low workload on the cycle 
ergometer.
5.2.2 Measurements
Baseline investigations were carried out prior to cardiac catheterisation as described 
in Chapter 2.2. These routine investigations included electrocardiogram, pulmonary 
function testing, chest radiograph and Doppler echocardiography. High resolution CT 
scanning of thorax was performed to exclude interstitial lung disease.
5.2.3 Cardiac Catheterisation
Conventional cardiac catheterisation was performed as described in Chapter 2.4. 
Pressures were recorded in the right atrium, right ventricle and proximal pulmonary 
artery and an estimate of pulmonary artery occlusion pressure was made with the 
catheter in the wedge position. Cardiac output was averaged over a minimum of tln-ee
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Table 5.1
Patient
No.
Age Sex Diagnosis FEVi (L),
(% predicted)
FVC (L),
(% predicted)
KCO
(mol/min/kpa 
(% predicted)
1 36 F CTD 4.5 , (145%) 4.9, (123%) 1 .2 , (6 8 %)
2 62 F CREST 2.2, (105%) 2.7, (92%) 1.2, (72%)
3 67 F CREST 1.4, (83%) 2.0, (84%) 1 .0 , (62%)
4 69 F CTD 1.4, (80%) 2 .1 , (80%) 0.9, (56%)
5 40 F SLE/SCL 2 .8 , ( 1 0 0 %) 3.6, (102%) 1.8, (76%)
6 56 M RA 3.7, (93%) 5.0, (94%) 0.6, (43%)
7 25 M PPH 3.9, (95%) 5.1, (107%) 1.5, (77%)
8 54 F PPH 2.6, (119%) 3.2, (113%) 1 .1 , (6 6 %)
9 39 M PPH 3.5, (99%) 4.4, (104%) 1.4, (80%)
1 0 41 F CTD 2.6, (92%) 3.3, (93%) 0.7, (39%)
Mean
(±SD)
48
range
25-69
2 .8 , ( 1 0 1 . 1 %) 
(1.1), (±18.9)
3.2, (99.2%) 
(1.2), (±13.2)
1.1, (63.9%) 
(0.4), (±14.1)
Table 5.1 Patient Demographics, Diagnoses and Baseline Pulm onary Function 
CTD; Connective tissue disease.
CREST; Calcinosis, Raynaud’s phenomenon, oEsophageal dysmotility, 
Sclerodactyly, Telangectasia.
RA; Rheumatoid arthritis.
SLE/SCL; Systemic Lupus Erythematosis/ Scleroderma overlap syndrome.
PPH; Primary Pulmonary Hypertension.
FEVi; Forced expiratory volume in one second.
FVC; Forced vital capacity.
KCO; Carbon monoxide transfer factor.
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measurements using the thermodilution technique. In all patients the effects of 
exercise on pulmonary artery pressure was assessed by asking them to perform 3 
minutes of straight leg raising. In the last 30 seconds of exercise measurements of 
pulmonary artery pressure, and cardiac output were repeated. Pulmonaiy artery 
occlusion pressure was not re-measured if the resting value had been normal, as was 
standard practice, as repeat measurement after exercise slightly increases the risk to 
the patient.
5.2.4 Ambulatory PAP monitoring
Ambulatory pulmonary artery pressure monitoring was carried out as described in 
Chapter 2.5.
5.2.5 Exercise testing
All patients were exercised breathing air as described in Chapter 2.2.2.
Formal exercise testing was performed after the micro-manometer tipped pulmonary 
artery catheter had been in place for almost 24 hours.
All the exercise variables presented are the mean of the values recorded for one 
minute from the onset of the 4^  ^minute of exercise. This was based on the assumption 
that three minutes of constant workload exercise must have elapsed before steady 
state gas exchange kinetics will have become established (Sietsema et al 1989). 
Pulmonary artery pressures given are the mean pressures measured during the same 
period.
5.2.5.1 Protocol.
Exercise was performed on the electromagnetic, cycle ergometer and consisted of a
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steady state exercise test at a workload of 30 Watts for a maximum of 8  minutes. This 
relatively low workload was chosen as manageable, and likely to be below the 
anaerobic threshold, for this group of patients with expected limited exercise capacity. 
Constant work rate testing was performed because exercise of this type is particularly 
suitable for measuring cardiovascular, ventilatory and gas-exchange kinetics (Nery et 
al 1982). Baseline values were measured over 2 minutes with patients sitting at rest 
on the cycle, before pedalling at 30 watts for a maximum of 8  minutes.
5.2.5.2 Cardiopulmonary exercise testing data
In each case breath by breath measurements of gas exchange were made. These 
included ventilation, tidal volume, respiratory rate, end tidal oxygen and carbon 
dioxide concentrations, oxygen saturations, oxygen uptake (VO2) and carbon dioxide 
production (VCO2). From these measurements other variables were derived including 
oxygen pulse (oxygen uptake / heart rate), and the ventilatory equivalents for oxygen 
(VE/VO2) and carbon dioxide (VE/VCO2) i.e. the ratios of ventilation to oxygen 
uptake and carbon dioxide output respectively. During exercise PAP was recorded 
continuously with the micro-manometer tipped pulmonary artery catheter.
5.2.6 Data Recording, Handling and Analysis
Data was recorded and processed as described in Chapter 2.5.1.
5.2.7 Statistics
All data are expressed as mean (± SD), unless otherwise stated. The strength of the 
correlation between the means was assessed by the Pearson correlation test. A p value 
of < 0.05 was considered to be statistically significant. Statistical analyses were
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carried out using the OXSTAT package for personal computers (OXSTAT II, © 
1983,1985 Holman, Jones, Walter & Wiggins; © 1986 Walter; © Microsoft Corp., 
1982, 1983, 1984, 1985.).
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5.3 Results
5.3.1,Relationship of PAP to Non-invasive Variables Measured during 
Cardiopulmonary Exercise Testing
PAP measured with the micro-manometer tipped pulmonary arteiy catheter during the 
minute of steady state exercise at 30 watts correlated with VE/VO2 (i-0.78, 
p=0.008), and VE/VCO2 (r=0.80, p=0.005). Figures 5.1 and 5.2.
There was no correlation between exercise PAP and other exercise testing variables. 
These ineluded heart rate, oxygen pulse (O2 Pulse), oxygen uptake (VO2) and exercise 
time; nor did baseline line lung function (FEVi, FVC and carbon monoxide transfer 
factor [KCO], Table 5.1) correlate with PAP, either at rest or during exercise.
The values for PAP, at rest and on exercise, measured with both the fluid filled, and 
micro-manometer tipped, pulmonary arteiy catheters are shown in Table 5.2. Patient 2 
shows a considerable difference between resting and exercise measurements made 
with the two types of catheter. Patients 3 and 5 demonstrated a much higher 
pulmonary artery pressure on exercise measured with the micro-manometer tipped 
catheter than during straight leg raising measured with the fluid filled pulmonary 
artery catheter. Conversely patient 6  achieved a lower pulmonary artery pressure with 
the micro-manometer tipped catheter than fluid filled catheter. Table 5.3 shows the 
gas exchange variables recorded for each patient during steady state exercise testing.
5.3.2 Resting v Exercise Measurements made with the Fluid Filled, Pulmonary Arteiy 
Catheter
When patients were asked to perform three minutes of straight leg raising there was a 
correlation between resting and exercise values of mean PAP measured in the supine
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Figure 5.1 Ventilatory Equivalents for Oxygen
Ventilatory equivalents for oxygen measured during cardiopulmonary exercise testing (at a 
workload of 30 watts) from the onset of the 4^ ' minute of exercise, for one minute, are shown 
plotted against the mean PAP recorded simultaneously. There was a significant correlation 
between the mean PAP on exercise and the mean value for the ventilatory equivalents r = 0.78, p 
= 0.008.
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Figure 5.2 Ventilatory Equivalents for Carbon Dioxide
Ventilatory equivalents for carbon dioxide measured during cardiopulmonary exercise 
testing (at a workload of 30 watts), from the onset of the 4* minute of exercise, for 
one minute, are shown plotted against the mean PAP recorded simultaneously. There 
was a significant correlation between the mean PAP on exercise and the mean value 
for the ventilatory equivalents r=0.80, p=0.05.
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Table 5.2
Resting PAP (mmHg) 
[Cardiac outputs (L/min)]
Exercise PAP (mmHg) 
[Cardiac outputs (L/min)]
Patient No. Fluid filled MM tipped Fluid filled MM tipped
1 13 5.41 13 14 [7.0] 14
2 2 0 4.71 8 39 [7.01 14
3 40 3.41 29 56 [4.4] 48
4 33 5.01 33 43 [7.2] .... 55
5 47 5.2] 45 65 [5.4] 46
6 40 5.41 42 45 [8.9] 59
7 54 5.01 42 61 [&8 ] . _ 55
8 48 3.21 48 60 [3.31 82
9 55 3.81 73 70 [5.71 74
1 0 71 4.71 69 90 [6.21 89
Table 5.2 Mean PAP at Rest and on Exercise with the Conventional (Fluid 
Filled) and the Micro-Manometer Tipped (MM Tipped) Catheters
Fluid filled catheter: resting pressure and cardiac output measurements were made in 
supine subjects and are the mean of 6  beats, breath holding at functional residual 
capacity (PRC). Exercise pressure and cardiac output measurements were made 
during the last 30 seconds of 3 minutes of straight leg raising.
MM tipped catheter: resting pressure measurements in the sitting position on the 
exercise bike for 2 minutes immediately prior to the onset of exercise. Exercise values 
were measured from the onset of the 4^*^ minute of steady state exercise (at a workload 
of 30 Watts) for one minute.
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Table 5.3
Patient No. HR (bpm) VE/VO2 VE/VCO2 O2 Pulse VO2 (l/min)
1 1 1 2 45 40 14.8 1.65
2 143 32 32 5.8 0.83
3 83 54 47 2 . 8 0.23
4 1 2 0 59 48 4.8 0.58
5 140 62 61 6 . 8 0.95
6 107 65 57 11.7 1.26
7 116 57 51 7.4 0.85
8 179 56 51 5.2 0.93
9 1 0 1 67 63 12.3 1.24
1 0 105 62 54 7.7 0.81
Table 5.3 Cardiopulmonary Exercise Testing Data
The mean values of gas exchange variables recorded during the minute of steady 
state exercise at 30 watts
HR; Heart rate
VE/Voz: Ventilatory equivalents for oxygen
VE/Vcoz: Ventilatory equivalents for carbon dioxide
O2 pulse: Oxygen pulse
Vo2: Oxygen uptake
Ventilatoi*y equivalents are the ratios of ventilation to oxygen uptake and carbon 
dioxide output respectively. The oxygen pulse is defined as the oxygen uptake divided 
by the heart rate.
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position using the fluid filled catheter. (r=0.96, p<0.001). The mean increase in 
pressure was 12.2 (±6.3) mmHg.
5.3.3 Resting v Exercise Measurements made with the Micromanometer Tipped 
Pulmonary Artery Catheter
When patients exercised on the cycle ergometer at a steady state workload of 30 watts 
there was a correlation between resting (measured in the sitting position) and exercise 
values of mean PAP (r=0.90, p=<0.001). The mean increase in pressure due to 
exercise was 9.6(±10) mmHg.
Both resting and exercise measurements with the fluid filled catheter were made in 
the lying position, whereas with the micro-manometer tipped catheter both 
measurements were made in the sitting position. To determine whether this postural 
difference had influenced the results, PAP was also measured with the micro­
manometer tipped pulmonary artery catheter in the lying position and this was 
compared with exercise in the sitting position. PAP measured supine with the micro­
manometer tipped pulmonary artery catheter did correlate with the pressure measured 
on exercise in the sitting position with the same catheter (r=0.92, p<0.001). The mean 
increase in pressure was 7.3 (±11.9) mmHg.
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5.4 Discussion
5.4.1 Exercise: Non-Invasively Measured Variables Of Gas Exchange And 
Pulmonary Artery Pressure
This chapter has shown that PAP measured during steady state exercise with the 
micro-manometer tipped pulmonary artery catheter correlates with VE/VO2 and 
VE/VCO2 , but not with O2 Pulse, or VO2 .
The PAP values represent the mean of more than 60 values. VE/VO2 and VE/VCO2 
are also the mean of all the raw data for breath by breath values recorded for the same 
period of steady state exercise ( 1  minute) therefore the results are likely to be reliable. 
This is the first work to show that PAP on exercise correlates with simultaneously 
measured ventilatory equivalents for oxygen and carbon dioxide. The hypothesis is 
that these abnormal ventilatory equivalents on exercise are a result of increased 
physiological dead space ventilation, which is a consequence of the reduction in 
pulmonary capillary blood flow due to high pulmonary artery pressure.
These results are not surprising and have been predicted (Sietsema et al 1992, Manier 
and Castaing 1994) but it is surprising that no correlation between exercise PAP and 
VO2 or O2 pulse was seen. This may have been because the numbers of patients in this 
chapter was insufficient, or, more likely, because the chosen exercise protocol used 
too low a workload to allow these patients to demonstrate limitations in these 
variables and that we would have found a correlation between PAP and V0 2 max- 
Another explanation may be that the abnormally high levels of PAP seen on exercise 
in some patients with pulmonary vascular disease which limit increases in cardiac 
output, also mask the change in oxygen pulse with exercise.
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5.4.2 Pulmonaiy Haemodynamics During Exercise And Resting Pulmonary Function 
Resting lung function (FEVl, FVC and KCO) did not correlate with exercise PAP in 
this chapter. It has been shown previously that lung function tests are often normal in 
pulmonaiy hypertension of various aetiologies (Gazetopaulos 1974), suggesting that 
pulmonary artery pressure per se has no effect on lung function. The patients 
discussed here had no radiological or clinical evidence of underlying lung disease 
therefore it was not surprising that this group had virtually nonual spirometry. There 
was a reduction in the value of group mean KCO that would be explained on the basis 
of their pulmonary hypertension. This has also been described in pulmonary 
hypertension of a variety of causes (Romano et al 1993). It might therefore have been 
expected that this reduced KCO would have correlated with exercise levels of PAP 
but this was not the case. It would have been interesting to measure exercise KCO in 
this group of patients, but this was beyond the scope of this chapter.
5.4.3 Resting Vs. Exercise Pulmonary Haemodynamics.
This chapter shows that resting PAP measured in the supine or sitting position 
predicts PAP on exercise. Again this is not surprising and has been shown previously 
with fluid filled, pulmonary artery catheters (Lupi-Herra et al 1982) though this was 
not always the case in patients with milder degrees of pulmonary hypertension 
described in Chapter 3. Pulmonary artery occlusion pressure was not re-measured 
after exercise if the resting measurement was normal for the reasons previously 
discussed. It is likely that wedge pressure would have risen on exercise (Abdel Kafi et 
al 1998, Janicki 1985).
In this chapter the change in pressure on exercise was not predicted by the resting
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value of PAP. Furthermore there are discrepancies in some patients between the 
values of PAP measured with the two types of catheter, which are not consistent 
(Table 5.2). However in each case the micro-manometer tipped pulmonaiy artery 
catheter reading taken in the cardiac catheterisation laboratory was consistent with the 
measurement of PAP which had just been obtained with the conventional catheter. 
Patient 2 had results which were anomalous. This may have been because these 
measurements were not made simultaneously and it has been noted previously that 
there are significant intra-individual variations in pulmonary artery pressure measured 
at different times (Rich et al 1982). Alternatively it may be that the conventional 
cardiac catheterisation pressure measurement did not reflect the true resting state. 
However these differences seem too great to have been likely to have arisen 
physiologically and are more likely to have been due to technical error, probably with 
the zero levelling of the fluid filled pulmonary arteiy catheter.
Patients 3 and 5 had similar resting pressures measured with both types of catheter, 
but had much larger rises in pulmonaiy arteiy pressure on exercise when measured 
with the micro-manometer tipped catheter during the cardiopulmonary exercise test. 
These patients had moderate pulmonaiy hypertension and it is possible that the greater 
amount of work and greater pulmonary flow during the exercise test, when compared 
with simple straight leg raising, caused greater rises in pulmonary artery pressure. 
Patient 6  had severe rheumatoid arthritis and found cycling difficult. Consequently the 
rise in pulmonary arteiy pressure during the cardiopulmonary exercise test was less 
than that measured during straight leg raising.
Resting PAP measured with either fluid filled or micro-manometer tipped, pulmonary 
artery catheters did not correlate with cardiac output measured by thermodilution with 
fluid filled, pulmonary artery catheters, either at rest or after three minutes of exercise
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(straight leg raising). Nor was there any correlation between exercise PAP (measured 
with the micro-manometer tipped pulmonary artery catheter) and the change in 
cardiac output from rest to exercise when measured with the fluid filled pulmonary 
artery catheter. However a trend was observed in that patients with higher levels of 
PAP tended to have lower resting values of cardiac output. The small numbers of 
patients in this chapter and the low level of exercise achieved make the interpretation 
of these observations difficult.
This chapter has shown that pulmonary haemodynamics on exercise can be measured 
by micro-manometer tipped pulmonaiy artery catheters, and that these 
haemodynamics correlate with ventilatory equivalents for oxygen and carbon dioxide 
measured non-invasively during a simultaneous cardiopulmonary exercise test. 
Accurate measurements of PAP on exercise in patients with mild resting pulmonary 
hypertension, or normal PAP who are symptomatic on exercise, may be useful in 
identifying individuals at risk of developing pulmonary hypertension.
Ventilatory equivalents merit further study as potential non-invasive surrogates of 
PAP on exercise.
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Chapter 6
Oral Vasodilators in Patients with Pulmonary Hypertension Associated 
with Connective Tissue Disease: Assessment by Cardiopulmonary
Exercise Testing
6.1 Introduction
In Chapter 3 the importance of background physiological variation in PAP was 
studied using the micro-manometer tipped pulmonary artery catheter; in Chapter 4 
this method was used to study changes in PAP during sleep and exercise in a group of 
patients with COPD. In these situations such measurements could not have been made 
using conventional cardiac catheterisation. A perception of the growing need for 
repeated assessment of the pulmonary circulation led to work which attempted to 
identify surrogates of PAP measured non-invasively during cardiopulmonary exercise 
testing (Chapter 5).
Pulmonaiy hypertension is a life threatening complication of connective tissue disease 
(Hoeper et al 2002) and decisions about when to initiate specific therapy and how to 
evaluate responses remain difficult. In particular the point at which a patient may be 
deemed to have “failed” oral therapy and has become a potential candidate for 
parenteral treatment is controversial. The cost of such a decision, both to society and 
in terms of the impact on an individual patient’s life, is considerable and therefore 
requires to be made in light of the best available evidence.
Chapter 5 described invasive measurement of PAP during exercise using a micro 
manometer tipped pulmonary artery catheter simultaneously with gas exchange 
variables, measured non-invasively during cardiopulmonary exercise testing. Some of 
these variables were shown to correlate with exercise PAP and may constitute a non- 
invasive surrogate of pulmonary haemodynamics on exercise (Raeside et al 1998). In 
this chapter the effects of treatment with oral vasodilators on these variables was 
measured by cardiopulmonaiy exercise testing.
Patients with comiective tissue disease have been studied in Chapters 3 and 5 because 
they are analogous to PPH patients. The genesis of pulmonary hypertension in
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connective tissue disease includes pulmonary vasospasm as one component and 
administration of intravenous vasodilators such as prostacyclin improves 
haemodynamic variables (Alpert et al 1991, Jolliet et al 1995, Menon et al 1998). 
Oral vasodilators have been used in PPH but the effect of these dmgs on exercise 
variables in pulmonary hypertension associated with connective tissue disease is not 
known (Sanchez et al 1999).
PAP response to exercise has been shown to be abnormal in patients with connective 
tissue disease (Winslow et al 1993). Objective measurement of response to treatment 
with oral vasodilators using haemodynamic assessment may help in treatment 
decisions. Conventional cardiac catheterisation is an alternative but is invasive and 
can be used to measure haemodynamics on only very limited exercise.
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6.2 Patients and Methods
6.2.1 Patient group
10 consecutive patients were studied. These patients had pulmonary hypertension 
secondary to connective tissue disease and had been commenced on treatment with 
diltiazem. The connective tissue disease diagnoses were as follows. 7 patients had 
CREST syndrome patients, 2 had SEE and 1 patient had Sjogren’s syndrome (as 
defined by the American Rheumatology Association). All were female, mean age 63 
years (range 33-75).
All patients were considered capable of exercising on the cycle ergometer without 
limitation from connective tissue disease.
All patients were treated with diltiazem, initiated in hospital and titrated to the 
maximum tolerated dose. Diltiazem was chosen because of previous experience with 
this drug in the treatment of PPH (Rieh et al 1992). 6  of the 10 patients tolerated high 
dose diltiazem considered therapeutic for this indication. The mean, daily dose was 
625 milligrams (range 480-750), (Table 6.1). Data is presented for these patients, 4 of 
whom had CREST syndrome and 2 who had SEE. The mean age of this group was 57 
years (range 33-75).
All patients gave written informed consent. The study was approved by the West 
Glasgow Hospitals University NHS Trust Ethics Committee.
6.2.2 Measurements
All patients were referred for further investigation of pulmonary hypertension and had 
had pre-catheterisation investigations as described in Chapter 2.1.2. All patients 
underwent CT scanning to exclude interstitial lung disease. Echocardiography was
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performed to assess systolic PAP and to exclude significant left ventricular 
impairment. Serial measurements of PAP were made by echocardiography, by the 
same technician and at the same time of day ( ± 2  hours).
6.2.3 Cardiac Catheterisation
All patients had previously undergone conventional cardiac catheterisation as 
described in Chapter 2.2. Supine PAP was measured at functional residual capacity 
with the catheter tip placed in the right, proximal pulmonary arteiy. Response to an 
acute intravenous vasodilator (Adenosine) was measured and all patients reported 
were “responders”. A responder was defined as a patient in whom the administration 
of an intravenous vasodilator caused a reduction in pulmonary vascular resistance of 
>20% without a rise in PAP or a reduction in cardiac output. These patients did not go 
on to have ambulatory pulmonary artery pressure monitoring.
6.2.4 Cardiopulmonary Exercise Testing
All patients were exercised tested as described in Chapter 2.1.2.
Patients exercised at a steady state workload (30 watts) to a maximum of 8  minutes 
according to a standard protocol. The relatively low workload was considered 
appropriate for patients with presumed functional impairment both from their 
moderately severe pulmonary hypertension and underlying connective tissue disorder.
6.2.4.1 Measurements
A number of non-invasive variables of gas exchange were measured and derived. 
Ventilatory equivalents indicate ventilatory requirement for a given metabolic rate 
and oxygen pulse is the amount of oxygen extracted by the body from the oxygen
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carried in each stroke volume. These variables were recorded from the onset of the 
fourth minute of steady state exercise for one minute.
• Ventilatory equivalent for oxygen (VE/VO2) is calculated as the ventilation 
divided by the oxygen uptake.
• Ventilatory equivalent for carbon dioxide (VE/VCO2) is calculated as the 
ventilation divided by the carbon dioxide output.
• Oxygen pulse (O2 Pulse) is calculated by dividing the oxygen uptake by the heart 
rate
• Exercise time in minutes was measured from the onset of cycling at a constant 
workload of 30 watts up to a maximum of eight minutes.
6.2.5 Statistics
All data are expressed as mean (±SD) unless otherwise stated. The strength of the 
correlation between the means was assessed by the Pearson correlation test and a p 
value of < 0.05 was considered to be statistically significant.
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6.3 Results
6.3.1 Patient Tolerability
4 patients could not tolerate diltiazem at the doses indicated for pulmonary 
hypertension secondary to connective tissue disease. This was due to unacceptable 
ankle swelling for 3 patients and excessive tiredness attributed to the drug in 1.
6.3.2 Cardiac Catheterisation
The groups mean PAP was 40mmHg (range 23~53mmHg), (Table 6.1).
6.3.3 Cardiopulmonary Exercise Testing
The mean interval between initiation of diltiazem and repeat cardiopulmonary 
exercise testing was 5 months (range 2 - 8  months (Table 6.1).
• Exercise time; group mean exercise time measured before and during 
treatment with diltiazem showed no improvement, 5.6 minutes (±1.9) to 6.5 
minutes (±1.7), (Table 6.2 and Figure 6.1).
• VE/VO2: group mean VE/VO2 showed no change from baseline during 
diltiazem treatment, pre: 50.8 (±15.6) to post: 53.2 (±17.6). This change was 
not statistically significant (Table 6.2 and Figure 6.2).
• VE/VCO2; group mean VE/VCO2 showed a trend towards improvement from 
baseline during treatment with diltiazem, from 50.2 (±4.0) to 48.5 (±12.9), but 
this was not statistically significant (Table 6.2 and Figure 6.3).
• O2 pulse; group mean O2 pulse showed an improvement from baseline during 
treatment with diltiazem, from 5.5 (±1.9) to 8.2 (±1.7), (p=0.03), (Table 6.2).
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Figure 6.1 Exercise time
Steady state exercise times in minutes on the cycle ergometer (at 30 watts) are shown 
plotted before and during treatment with diltiazem for each of the six patients. There 
was no significant change in exercise time for the group (p=0.4).
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Figure 6.2 Ventilatory equivalents for oxygen
Ventilatory equivalents for oxygen (Vg/Voz) are shown plotted before and during 
treatment with diltiazem for each of the six patients. There was no significant change 
in Ve/Vo2 for the group (p=0 .8 ).
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Figure 6.3 Ventilatory equivalents for carbon dioxide
Ventilatory equivalents for oxygen (Ve/Vcoz) are shown plotted before and during 
treatment with diltiazem for each of the six patients. There was no significant change 
in VeA^co2 for the group (p=0 .8 ).
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6.4 Discussion
In this chapter it has been shown that patients with pulmonary hypertension secondary 
to connective tissue disease are able to perform cardiopulmonary exercise testing at a 
low workload and that this is repeatable. No complication from cardiopulmonary 
exercise testing or cardiac catheterisation arose in the patients studied. Diltiazem in 
doses similar to those used to treat PPH was not well tolerated and 4 of the 10 patients 
intended to treat had to stop taking the drug because of unacceptable side effects. 
While it would have strengthened the study to continue them at the highest dose they 
could tolerate, we felt that it would have been unethical to so because there is no 
evidence of benefit from diltiazem in pulmonary hypertension at lower doses. 
Furthermore these were troublesome side effects which required withdrawal of the 
drug to resolve. Finally it was felt that this aspect of the study mirrored clinical 
experience when many patients cannot tolerate calcium channel blockers at the doses 
indicated for pulmonary hypertension.
In those who tolerated treatment, no objective improvement in gas exchange variables 
measured non-invasively during cardiopulmonary exercise testing could be 
demonstrated, i.e. variables which conelate with PAP on steady state exercise.
There was a slight improvement in exercise time during treatment, but this was not 
significant. This could be explained by a learning effect though interpretation of these 
results is further complicated by the fact that subjects 3 and 6  exercised for the 
maximum exercise time on both occasions. Patient 3 had mild pulmonary 
hypertension and although patient 6  had the highest level of PAP she was also the 
youngest. 8  minutes was chosen as a maximum exercise time as it was considered 
unlikely that this patient group would exceed this and further it was assumed that 
steady state exercise conditions have been reached by the onset of the 4^ '^  minute of
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exercise. Neither subject 3 or 6  reported any subjective improvement in exercise 
tolerance during their treatment period.
Exercise testing may be subject to a learning effect and it would have been desirable 
to repeat the baseline cardiopulmonary exercise test to exclude this. However all of 
the patients included in this section had been subject to cardiopulmonary exercise 
testing within the previous 6  months in the context of other studies. While this 
timescale is longer than desirable to eliminate any baseline learning effect, it was felt 
that previous testing may have reduced its likelihood. Furthermore this possibility 
(and the undoubted desirability of repeating the baseline exercise test) had to be 
balanced against subjecting this particular patient group to the demands of possibly 
excessive cardiopulmonary exercise testing which may have adversely affected 
recruitment of an already small number of patients.
No improvement in VE/VO2 or VE/VCO2 during treatment was observed. These 
patients had abnormally high ventilatory equivalents, at rest and on exercise. This 
may reflect increased dead space ventilation due to poor perfusion of ventilated lung 
caused by vascular restriction of blood flow, which worsened during exercise as 
ventilation increased. Ventilatory equivalents normally reach a nadir during 
progressive cardiopulmonaiy exercise testing. When this value is elevated it reflects 
increased dead space ventilation (Wasserman et al 1994). Thus it would be expected 
that successful vasodilator treatment would reduce ventilatory equivalents during 
steady state exercise by improving lung blood flow. These patients did not show any 
improvement ventilatory equivalents because their pulmonary hypertension did not 
respond to this vasodilator, although they had all previously been shown to respond to 
an intravenous vasodilator.
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A significant change in O2 pulse was observed, although this was not one of the 
variables previously found to correlate with PAP (Chapter 5). This might have been 
explained by the limiting effect of diltiazem on exercising heart rate. Oxygen pulse 
was defined as the amount of oxygen extracted by the body tissues from the oxygen 
carried in each stroke volume, and was calculated by dividing the maximal oxygen 
uptake by the heart rate. Therefore a reduction in heart rate alone may have suggested 
an improvement in oxygen pulse even when maximal oxygen uptake fell. However 
the fact that the O2 pulse had not declined during treatment would also suggest a 
reduction in stroke volume did not occur, which might othei*wise have been 
responsible for the lack of improvement in ventilatory equivalents.
These results are disappointing but not surprising. Pulmonary vasospasm is only one 
component of the vascular changes seen in connective tissue disease complicated by 
pulmonary hypertension (Stupi et al 1986). Acute vasodilator studies are even less 
likely to be positive in patients with connective tissue disease than in those with PPH 
(Sanchez et al 1999). This would suggest that only a minority of patients would have 
had vasoconstriction as the predominant cause of their pulmonaiy hypertension and 
most patients would have had at least some element of irreversible pulmonary 
hypertension.
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6.5 Conclusion
In this chapter gas exchange variables were measured during cardiopulmonary 
exercise testing before and after treatment with oral vasodilator drugs in a group of 
patients with pulmonary hypertension secondary to connective tissue disease. These 
variables had previously been shown to coiTelate with steady state pulmonary artery 
pressure (Chapter 5). No improvement was demonstrated during treatment with 
diltiazem. These results suggest that there was no reduction in PAP on exercise in 
patients taking oral diltiazem who were known to be responders to intravenous 
vasodilators. Furthermore it was found that diltiazem in therapeutic doses for 
pulmonary hypertension was not well tolerated.
These results failed to demonstrate evidence for haemodynamic benefit from oral 
diltiazem in patients with pulmonary hypertension secondary to connective tissue 
disease. However the patient group was small (albeit due in part to side effects from 
diltiazem) and it is difficult to reach fmn conclusions from these data. This chapter 
has demonstrated that gas exchange variables measured during cardiopulmonary 
exercise testing and simultaneous ambulatory PAP monitoring, merit further study as 
possible surrogates for PAP in exercising patients.
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Chapter 7
General Discussion, Conclusions and Future Developments
7.1 Relevance of Secondary Pulmonary Hypertension to Mortality and 
Morbidity in Respiratory Disease and Connective Tissue Disease
The mortality of PPH is high with most patients dying within 10 years (Foster et al 
1984, D’Alonzo et al 1991). The importance of secondary pulmonary hypertension in 
the morbidity and mortality of respiratory disease is much less clear and the subject of 
debate (Weitzenblum et al 1996). Nonetheless if even the most conservative estimates 
of the incidence (Williams and Nicholl 1985) and progression (Weitzenblum1996) of 
pulmonary hypertension secondaiy to clironic lung disease are accepted then the size 
of the problem is considerable.
Many respiratory conditions can cause pulmonaiy hypertension, in particular COPD, 
interstitial lung disease, kyphoscoliosis and obstructive sleep apnoea. However 
although COPD constitutes more than 90% of pulmonaiy hypertension secondary to 
chronic hypoxic lung disease it is often misdiagnosed as other pathology such as 
congestive cardiac failure (Intersociety Commission for Heart Disease 1970); from 
the foregoing it is clear that the true incidence of pulmonary hypertension secondary 
to respiratory disease is unknown and possibly underestimated. What is clear from a 
number of studies in patients with COPD -whether receiving LTOT or not- is that the 
presence of pulmonary hypertension is a bad prognostic sign and that the higher the 
level of PAP the poorer the prognosis (Bishop and Cross 1984, Oswald-Manimoser et 
al 1995). These studies have shown that the 5 year survival rate in pulmonary 
hypertensive COPD patients is approximately 50%, rising to 62% in those on LTOT 
(Cooper et al 1987).
Pulmonary hypertension secondaiy to connective tissue disease is an easier problem 
to quantify, although the incidence varies considerably between different conditions.
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In some connective tissue diseases, in particular the CREST variant (calcinosis, 
Raynaud’s phenomenon, oesophageal dysmotility, sclerodactyly, telangectasias) of 
systemic sclerosis, the prevalence may approach 50% (Yousem 1990) and PAH is the 
most important cause of mortality and morbidity in this condition. The frequency of 
PAH varies in the other collagen vascular diseases (Chapter 1.2.3.6) however because 
the pathology of PAH associated with collagen vascular diseases is similar to that in 
PPH it is usually of significance. Thrombosis in situ also occurs in pulmonaiy 
hypertension associated with collagen vascular disease (Welsh et al 1996, Hoeper et 
al 1998) (Chapter 1.2.3.6) further complicating the management of systemic diseases.
In conclusion, whereas the presence of PAH in COPD is often considered an 
unremarkable finding whose presence extent and importance may be underestimated, 
in collagen vascular disease it is often sought and acknowledged as a serious 
complication which may prove difficult to control.
7.2 Limitations of Current Methods of Measurement in the Assessment of the 
Pulmonary Circulation
There is no easily applied sphygmomanometer for the pulmonary circulation and 
(until recently) no effective treatment for pulmonary hypertension has been available. 
The emergence of new treatments and a more rigorous approach to classification has 
renewed interest in making measurements in the pulmonary circulation and revealed 
deficiencies in many of the traditional methods of measurement. Non-invasive 
methods of measurement provide an indirect estimate of PAP (Chapter 1.3.1) but 
remain clinically very relevant and for most clinicians will be the only screening tools 
available to indicate individuals who should progress to invasive measurement of the
200
pulmonary circulation. The most widely used non-invasive method of measurement is 
Doppler-echocardiography. While this is an accurate and reliable tool in the 
assessment of PAP it is operator dependant and is not suitable for all patient groups, 
in particular those with COPD.
Cardiac catheterisation with fluid filled pulmonary arteiy catheters has long been 
considered the “gold standard” measurement in the pulmonary circulation. The 
principal limitations of such catheters are that they must be deployed in an 
unrepresentative enviromnent (i.e. the cardiac catheterisation laboratory) in an 
umepresentative position (i.e. supine) and in an unrepresentative state (i.e. resting). 
These are not usually the circumstances in which patients complain of symptoms. 
There are also technical considerations which limit the usefulness of data obtained by 
conventional cardiac catheterisation. These mainly relate to the generation of artefacts 
in the pressure trace (in particular damping of the trace) and the inability to measure 
instantaneous pressures(Chapter 1.3.3.3). These disadvantages may be of limited 
significance in routine haemodynamic monitoring, but in studies of a low pressure 
system -such as the pulmonary circulation- where an intervention may cause subtle 
changes in PAP they can be significant.
7.3 Relevance of the Patient Groups Chosen for Study by Diagnosis
7.3.1 Connective Tissue Disease
PPH is the purest model for the study of pulmonary hypertension however is an 
extremely rare condition and it would have been ideal to assess the ambulatory 
pulmonary artery pressure monitoring system in patients with PPH. Patients with 
connective tissue disease were chosen for study as they often have few symptoms
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(other than breathlessness) from their underlying lung disease (hence the symptoms 
experienced by patients with pulmonary hypertension secondary to connective tissue 
disease can be easier to identify) and because of increasing interest in the treatment of 
pulmonary hypertension associated with connective tissue disease. Finally, as 
connective tissue disease is commoner than PPH, they represent a suitable alternative 
group in which to identify the strengths and weaknesses of this measurement system. 
Previously treatment of such patients was aimed at the underlying connective tissue 
disease or consequent hypoxia (e.g. secondaiy to pulmonary fibrosis) and pulmonary 
hypertension, if recognised, was considered untreatable. However, because the 
pathology of PAH associated with collagen vascular diseases is similar to that in PPH 
(Chapter 1.2.3.6) and because thrombosis in situ is an important feature of pulmonary 
hypertension associated with collagen vascular disease -  as in PPH- (Welsh et al 
1996, Hoeper et al 1998) advances in the treatment of PPH in recent years, have led to 
the belief that similar treatment should be offered to patients with pulmonary 
hypertension secondary to connective tissue disease.
In PPH the demonstration of vasoreactivity of the pulmonary circulation in the cardiac 
catheterisation laboratory is accepted as in indication for treatment with oral 
vasodilator drugs (Rubin et al 1993). Administration of vasodilators in patients with 
pulmonary hypertension secondaiy to connective tissue disease has also been shown 
to produce beneficial haemodynamic results (Alpert et al 1991, Jolliet et al 1995, 
Menon et al 1998 and Badesch 2000) suggesting that these patients should also 
receive treatment with oral vasodilators. Consequently, as in PPH, when they cannot 
tolerate them, or do not experience sustained benefit from them, they should then be 
offered continuous, parenteral vasodilators (Sanchez et al 1999). This is an expensive 
and inconvenient treatment and therefore before it is considered, it is necessary to
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demonstrate objectively that treatment with oral vasodilators has failed. Pulmonary 
artery pressure is a physiological variable and hence subject to considerable variation. 
Stress testing would impose some uniformity of condition under which measurements 
might be made and when excessive elevations in PAP have been shown to be 
associated with diminished exercise tolerance in connective tissue disease (Winslow 
et al 1993).
Consequently we considered this patient group a suitable one to study with the 
micromanometer tipped pulmonary artery which allowed testing in a variety of 
situations including under controlled stress (exercise) and allowed us to assess the 
effects of posture and normal daily activity on the pulmonary circulation. Thus the 
ambulatory pulmonary artery pressure monitoring system offered significant 
advantages over conventional cardiac catheterisation. Furthermore we believed that 
this system might offer the opportunity to detect very early pulmonary hypertension 
(i.e. only present on exercise) with important treatment implications for a patient 
group at increased risk of pulmonary hypertension but with no clinical signs of it at 
rest.
7.3.2 Chronic Obstructive Pulmonary Disease
The commonest cause of secondary pulmonary hypertension by a large margin is 
chronic obstructive pulmonary disease (COPD); this patient group constitute a 
significant proportion (0.3%) of individuals in any industrialised community 
(Williams and Nicholl 1985) and constitute a major treatment challenge.
However there is considerable debate as to the importance of raised pulmonary artery 
pressure in this context as the actual increases in pulmonary artery pressure seen are 
small and progression is slow (Naeije 1992). While this is the case when these
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pulmonary artery pressures are measured conventionally, one hypothesis of this thesis 
is that ambulatory measurement systems reveal a number of situations (i.e. with 
postural changes, on exercise or during sleep) where pulmonary artery pressures can 
be transiently much higher. Consequently it may be the case that conventional 
methods of measurement in the pulmonary circulation underestimate the variations in 
pulmonary artery pressure experienced by patients in the course of normal daily 
activity. It remains unclear whether these variations are haemodynamically important; 
this has been the case in the systemic circulation where ambulatory blood pressure 
monitoring has become a routine and usefiil clinical tool and it is the case that patients 
with COPD seem to experience markedly differing exercise limitations for similar 
levels of lung function. This raises the possibility that differing responses in the 
pulmonary circulation may be one part of the explanation for this.
Should these suspicions be borne out, this would have implications for the treatment 
of COPD, particularly in patients with mild or early pulmonary hypertension and the 
ambulatory pulmonary artery pressure measurement has significant advantages over 
the other available methods of measurement in the further investigation of this area.
7.3.3 Others
Various other patient groups with pulmonary hypertension are included in this thesis, 
including those with chionic thromboembolic pulmonary hypertension, pulmonary 
hypertension secondary to drugs and patients with PPH. These patients presented with 
suspected pulmonary hypertension and were studied in accordance with standard 
protocols. Where appropriate they were then included in studies reported here. 
Patients described as normals were individuals in whom pulmonary hypertension had
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been wrongly suspected at rest and in whom ambulatory pulmonary artery pressure 
monitoring was carried out to exclude exercise related pulmonary hypertension.
7.4 Advantages of the Micromanometer Tipped Pulmonary Artery Catheter in 
the Assessment of the Pulmonary Circulation
In Chapter 1.3.3.5 the advantages and disadvantages of micromanometer tipped 
pulmonary artery catheters were described. The principal strength of such systems is 
the ability to make high fidelity pressure measurements in fully ambulant patients and 
to allow the correlation of symptoms and haemodynamic change in real time and 
with great accuracy. Chapters 3, 4 and 5 have shown that such solid state pulmonary 
artery catheters can be used safely (and are well tolerated) in patient groups with 
pulmonary hypertension of various aetiologies including frail patients with COPD on 
LTOT. Although the studies described previously never included periods of 
ambulatory pulmonaiy artery pressure monitoring greater than 24 hours there is no 
reason why this could not be done while accepting the increased risk of infection. 
Chapter 3 has demonstrated that variations in PAP can be measured (using the 
micromanometer tipped pulmonary artery catheter) during changes in posture and 
activity in a group of patients with pulmonary hypertension secondary to connective 
tissue disease. This allows a more realistic appraisal of the haemodynamic burden 
facing these patients than that obtained by conventional measurements and 
consequently may give better prognostic information. If the abnormal rises seen in 
these circumstances portend the future development of resting pulmonary 
hypertension ( and if early treatment is more likely to be beneficial) then this 
measurement system may also allow the identification of individuals who should be 
offered early treatment, or closely followed by conventional means.
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Chapter 4 has shown that ambulatory pulmonary artery pressure monitoring was well 
tolerated in a group of patients with severe lung disease. In such patients the 
phenomenon of increased PAP during sleep and exercise has been demonstrated 
(Riley et al 1948, Boysen et al 1979) however ambulatory measurement permitted the 
extent of these rises to be fully appreciated. The observation that abnormal rises in 
PAP during exercise in patients with lung disease predicts the future development of 
pulmonary hypertension also suggests that the technique of ambulatory pulmonary 
artery pressure monitoring could be used to identify individuals at risk. Furthermore 
observations made in Chapter 4 suggest that PAP variation during activities of daily 
living may be greater that previously appreciated; if these were to be borne out by 
further study then this might have implications for earlier treatment (e.g. oxygen 
therapy) in COPD.
While there are undoubted advantages to ambulatory pulmonary artery pressure 
monitoring it is an invasive teclmique involving an element of risk and discomfort for 
the patient. The ability to carry out formal cardiopulmonaiy exercise testing (CPET) 
while simultaneously measuring PAP led to the hypothesis that CPET might provide 
non-invasively measured surrogates for PAP. Chapter 5 identified such variables and 
demonstrated that CPET at low workload was well tolerated by patients with 
pulmonary hypertension secondary to connective tissue disease.
Chapter 6 utilised these correlates of PAP measured non-invasively during CPET to 
assess the response to treatment in a group of patients with pulmonary hypertension 
secondary to connective tissue disease. No benefit was demonstrated following 
treatment with oral vasodilators. While this may confirm anecdotal clinical 
impression, the previous observation that such treatment failure will now lead to the 
introduction of further therapies (with additional inconvenience and cost) suggests
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that a non-invasive, accurate and repeatable test of PAP under stress would be very 
useful. Such a test would allow clinical decision making to become more objective. 
The ambulatory pulmonary artery pressure monitoring is ideally suited to the study of 
the pulmonary circulation in such conditions and will pennit the necessary further 
studies to confirm or refute the usefulness of non-invasive sun’ogates of PAP 
measured during cardiopulmonary exercise testing.
7.5 Conclusions and Future Developments
This thesis has demonstrated that ambulatory pulmonaiy artery pressure monitoring is 
safe and well tolerated in a variety of patients groups including those with multi­
system disorders and in others with severe respiratory disease. Invasive 
haemodynamic assessment of patients with pulmonary hypertension and significant 
co-morbidity is challenging and it is difficult to conduct it on large numbers of 
patients. This leads to the possibility of type II errors where the study sample size has 
been too small to detect a difference between the two populations studied. While this 
is a very real concern it would not have been possible to recruit sufficient numbers of 
patients to power the studies reported in this thesis to exclude the possibility of type II 
errors arising. It is therefore necessary throughout this thesis to consider that such 
errors may have arisen.
This technique offers the opportunity to make very accurate measurements of PAP in 
patients carrying out their normal activities of daily living or in a variety of controlled 
circumstances including exercise. Such high fidelity measurements are likely to be 
very useful in making judgements about disease progression or the effectiveness of an 
intervention (and hence prognosis) in a low pressure system. Furthermore ambulatory 
pulmonary artery pressure monitoring permits the patient’s symptoms to be directly
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correlated with haemodynamic changes in the pulmonary circulation and 
consequently may allow us to achieve better insight into the total haemodynamic 
burden facing the right ventricle.
However even when safe and well tolerated, invasive procedures are time consuming, 
inconvenient for the patient and expensive for the investigator. An accurate, easily 
repeatable and hence non-invasive method of measurement in the pulmonary 
circulation remains an important goal, particularly as the options for the treatment of 
pulmonary hypertension increase. Chapter 5 described the simultaneous use of 
cardiopulmonaiy exercise testing and ambulatory pulmonary artery pressure 
monitoring in an attempt to define non-invasively measured surrogates for PAP. 
Further work is required to confirm the initial observation that cardiopulmonary 
exercise testing may provide these. An important strength of ambulatory pulmonary 
artery pressure monitoring is its ability to provide high fidelity PAP measured 
simultaneously with non-invasive methods of measurement.
If the burgeoning treatments for pulmonary hypertension lead to the anticipated 
increased diagnosis of this condition then resources and expertise are likely to become 
stretched. This possibility emphasises the need for new methods of measurement 
which have been proven to be reliable and accurate.
Furthermore if the emerging consensus that early treatment is more likely to be 
beneficial is proven, then screening susceptible individuals will be important. 
Ambulatory pulmonary artery pressure monitoring confers significant advantages 
over stress echo in the early identification of pulmonary hypertension in patients with 
normal resting pressure.
In this thesis ambulatory pulmonary artery pressure monitoring has been used to 
assess changes in PAP with posture and exercise patients with connective tissue
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disease and during exercise and sleep in a group with COPD compared with nonnal 
individuals. These studies have shown that PAP varies considerably in these 
circumstances and that resting pressure does not always predict these variations. 
Changes in PAP have also been correlated with symptoms. These results suggest that 
the contribution of secondary pulmonaiy hypertension to morbidity and mortality in 
patients with connective tissue disease and COPD is considerable and underestimated 
by conventional methods of assessment.
The technique of ambulatory, high fidelity pressure measurement obtains a more 
complete picture of the haemodynamic variations induced by normal daily activity 
and under stress and contributes to our appreciation of the morbidity of pulmonary 
hypertension.
While it is unlikely ever to become commonplace it nonetheless offers a unique 
opportunity to measure the pulmonary circulation under conditions of “stress” 
(exercise, hypoxia etc). It seems possible that such measurements might allow earlier 
detection of abnormal pulmonary vascular responses and hence the earlier initiation of 
treatment. If (as seems likely) earlier treatment is more likely to be associated with a 
better outcome then prompt diagnosis would be worthwhile. As newer and more 
complex (and expensive) treatments are available for pulmonary hypertension then 
the greater is the need for assessment of their efficacy. Ambulatory pulmonary artery 
pressure monitoring offers a unique opportunity to assess the response to treatment in 
the circumstances in which a patient experiences symptoms as well as under 
conditions of controlled stress. Finally this new method of measurement may enable 
us to identify non-invasive methods of measurement of the pulmonary circulation 
which might be an advance on those widely available.
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The pulmonary circulation is a stimulating and fast moving field; the emergence of 
effective treatments, improved understanding of the haemodynamics of raised PAP 
and the discovery of a possible genetic basis to abnormal responses in the pulmonary 
circulation demand improved pulmonary sphygmomanometers. Ambulatory 
pulmonary artery pressure monitoring is an important addition to this field.
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